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Abstract 
Blood vessels play a vital role in human disease including pathogen driven conditions such as 
septic shock and acute lung injury. In the innate immune system, host pattern recognition 
receptors (PRRs) recognise preserved pathogen associated molecular patterns (PAMPs) 
leading to cell activation. Previous work has shown that blood vessels respond to Gram 
negative bacteria via the PRRs Toll like receptor 4 (TLR4) and nucleotide oligomerisation 
domain 1 (NOD1). Indeed stimulation with a specific NOD1 agonist can induce vascular 
shock in rats (Cartwright, Murch et al. 2007). In humans however, the role of NOD1 in blood 
vessels is relatively unexplored. Accordingly, in this thesis I have sought to characterise the 
activity of NOD1 in rodent and human vascular tissue with comparison to TLR4 responses. 
I have shown that in rodents NOD1 is predominantly expressed and active in vascular cells 
and whole vessels. Crucially vessel organ culture suggests a predominant role for the 
endothelium in early responses to NOD1 and TLR4 agonists. I have then gone on to 
demonstrate induction of key inflammatory mediators by NOD1 agonists in human vessels 
and vascular cells, confirming the importance of the endothelium in this system. Finally I 
have used pharmacological tools to describe the signalling pathways downstream of NOD1 
and TLR4 in endothelial cells including use of highly novel NOD1 pathway inhibitors. 
In conclusion, NOD1 is identified as an important PRR mediating inflammatory responses in 
rodent and human vascular tissue. The endothelium emerges as a key site for NOD1 
mediated inflammation whilst the use of highly novel signalling inhibitors has enabled clear 
differentiation of NOD1 and TLR4 signalling. This suggests the possibility of selective 
targeting of NOD1 in human disease where disorders of the vasculature predominate. 
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Chapter 1 
Introduction 
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The immune system must guard against a myriad of pathogens, whilst preventing damage 
to the host’s own tissues through excessive inflammation. Until relatively recently it was 
thought that the very early responses to pathogens: the so-called ‘innate immune response’ 
was relatively non-specific, and of rather less importance than the highly evolved, 
lymphocyte dependent, adaptive immune system. The discovery of conserved host pattern 
recognition receptors (PRRs) that recognise invariant pathogen associated molecular 
patterns (PAMPs) has revolutionised our understanding of early pathogen recognition, and 
the interplay between innate and adaptive immunity. Whilst much of the seminal work in 
the characterisation of PRRs involved immune cells such as the macrophage, it is now clear 
that stromal cells express these receptors and play vital roles in health and disease. Previous 
work from our group and others has shown that vascular cells and whole vessels directly 
respond to pathogens via PRR pathways to initiate inflammation. Further study of these 
responses is therefore of potential importance in both acute and chronic diseases of the 
vasculature such as septic shock and atherosclerosis. This group has previously focussed on 
the PRR nucleotide oligomerisation domain 1 (NOD1), stimulation of which in rodent 
models, leads to profound vascular dysfunction both in vitro and in vivo. In my thesis I have 
extended work on NOD1 mediated inflammation in the rat vasculature whilst also 
translating the findings into human cells. My data suggests that the endothelium is a key site 
for NOD1 mediated vascular inflammation in both rodent and human systems. Accordingly I 
have focused further experiments on endothelial cells of the lung, pathology of which is felt 
to be crucial in sepsis and acute lung injury.  
1.1 Pathogens and human disease 
The history of human evolution is itself a history of our battle with the vast number of 
organisms to which we are constantly exposed. Despite the staggering diversity of human 
pathogens there are particular examples which had profound effects on society at large. 
Perhaps the best known example in European history is that of bubonic plague. The ‘black 
death’ of the 1300’s, was caused by the bacterium Yersinia pestis (Haensch, Bianucci et al. 
2010). It is estimated to have killed up to half the population of Europe, leaving social and 
political chaos behind it. Influenza remains another notorious pathogen responsible for 
periodic and deadly global pandemics. Indeed the infamous 1918 ‘Flu pandemic caused 
greater loss of life than the carnage of the Western Front. Yet we are not only defined by 
25 
 
these age old threats, as new organisms constantly emerge to challenge the complacency of 
the post-antibiotic age. Human Immunodeficiency Virus (HIV) provides a salutary example.  
The burden of pathogens on human health remains vast and exposes the striking inequality 
of our global society. The lowest income countries remain beset with infectious disease, 
exacerbated by poor nutrition, sanitation and health infrastructure. As examples, childhood 
pneumonia, infectious diarrhoea, and malaria kill millions each year (Liu, Johnson et al. 
2012). The pattern of infectious disease in advanced economies is different, but remains a 
vast cause of morbidity, mortality and health care expenditure. Sepsis is defined as a 
systemic inflammatory response to infection and remains the leading cause of admission to 
an intensive care unit in the developed world with mortality rates that may exceed 50% 
(Martin, Brunkhorst et al. 2009). The success and indeed excess of the modern world has 
provided its own problems. The emergence of ‘lifestyle’ diseases such as Type II diabetes 
and smoking related lung disease has impaired the body’s ability to fight pathogens leading 
to new patterns of chronic infectious disease. Meanwhile an over-reliance and possibly 
injudicious use of antibiotics has accelerated emergence of drug-resistant pathogens 
including multi-drug resistant Mycobacterium tuberculosis (TB) and Methicillin Resistant 
Staphylococcus aureus (MRSA) (Tacconelli, De Angelis et al. 2008). 
1.1.2 Pathogens and the lung 
My thesis explores the role of certain PRR’s on inflammatory pathways in blood vessels. A 
particular focus has been vascular tissue from the lung so I will give a brief overview of the 
importance and relevance of the pulmonary system in infectious disease.  Acute viral 
infection of the upper respiratory tract represents the most common infections in the 
developed world. However more serious infections of the lungs are themselves major 
causes of worldwide disease. TB is most commonly confined to the lungs. It is a disease that 
dates back to antiquity, with evidence of TB infection in Egyptian mummies dating to 3000-
2400 BC (Zink, Sola et al. 2003). Despite effective antibiotics, TB causes over one million 
deaths worldwide annually. Acute bacterial pneumonia remains a common cause of hospital 
admission and sepsis in the developed world. Common causal bacteria include both Gram 
positive (e.g. Streptococcus pneumonia) and Gram negative (e.g. Haemophilus influenzae) 
organisms. When considering the potential role of the pulmonary vasculature in disease it is 
particularly interesting to observe that the lung is frequently affected by infectious diseases 
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that begin in a remote site. For example, patients who develop severe intra-abdominal 
sepsis (e.g. from a perforated viscus) commonly proceed to develop respiratory failure. The 
underlying pathophysiology involves increased ‘leakiness’ of the pulmonary vascular 
endothelium and resultant shift of fluid and inflammatory cells into the alveolar spaces. This 
can be seen radiographically as diffuse air-space shadowing on the chest x-ray and is often 
termed acute lung injury (ALI) or adult respiratory distress syndrome (ARDS) in its most 
severe form. The diagnosis is determined by a mixture of clinical, radiographic and 
physiological features (Bernard, Artigas et al. 1994) . Although multiple aetiologies underlie 
ALI/ARDS, infection remains a very common cause. In addition, sepsis has been associated 
with acute pulmonary hypertension (increased blood pressure in the pulmonary circulation) 
(Sibbald, Paterson et al. 1978) whilst specific pathogens such as HIV have been implicated in 
more chronic forms of this disease (Sitbon, Lascoux-Combe et al. 2008).  Thus understanding 
the mechanisms by which pathogens interact with the pulmonary vasculature could 
generate important new insights into respiratory disease. This may also be relevant to other 
chronic lung diseases including chronic obstructive pulmonary disease (COPD), where there 
is increasing awareness of the role of endothelial pathology in early disease progression 
(Chandra, Sciurba et al. 2011). 
1.1.3 The immune response 
In order to combat the bewildering complexity of pathogens to which they are exposed, 
vertebrates including humans have evolved sophisticated immune defences. An important 
concept is that of multiple layers of immune defence. In man, the broad layers of defence 
include barrier systems (e.g. the skin or digestive tract), immediate or innate immune 
defences (e.g. phagocytic cells and the complement system), and finally adaptive immunity 
which provides the potential for immunological memory against previously encountered 
pathogens (Figure 1.1).  
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Figure 1.1: Simple overview of the vertebrate immune response to invading pathogens. 
Upon infection with a pathogen, innate immune responses generate inflammation. This 
response was first described by Celsus (30BC – 38 AD) in his text De Re Medicina in which he 
characterises the features of inflammation to include rubor (redness), calor (heat), tumor 
(swelling) and dolor (pain). This typical response is due to the action of inflammatory 
mediators (cytokines, chemokines and prostaglandins) that are released upon detection of 
the pathogen and act on host cells to initiate the immune response. Host cells that respond 
to pathogens include resident macrophages and dendritic cells as well as the endothelial 
cells that line blood vessel walls.   Activation of endothelial cells results in local vasodilation 
and increased blood flow to the area of inflammation, whilst also releasing mediators which 
encourage migration and extravasation of leukocytes, down a chemotactic gradient. The 
most abundant leucocyte is the neutrophil, and it is usually the first to arrive at the site of 
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infection. Neutrophils act as phagocytes, engulfing bacteria then killing them with digestive 
enzymes, or by release of free radicals (Langermans, Hazenbos et al. 1994). Other relevant 
leucocytes include monocytes which migrate from the blood then differentiate into 
macrophages which assume a more important role in the later stages of inflammation and 
its resolution. The action of the phagocytic cells is augmented by the complement system. 
This mechanism of humoral innate immunity involves a protein (and protease cascade) 
which attaches to antibody bound pathogens (or to preserved pathogen ligands) and marks 
the invading organism for leukocyte mediated destruction.  
Unique to vertebrates is the next layer of adaptive immune defence. This system relies on a 
type of leukocyte named lymphocytes. The two predominate lymphocytes are T cells and B 
cells. A key feature of lymphocytes is a high rate of somatic mutation and genetic 
recombination of specific antigen receptors. Thus vast numbers of lymphocytes are made 
with almost infinite randomness of antigen receptors which are ready to recognise their 
respective antigen on invading pathogens. Such antigens are presented to the lymphocytes 
either directly or by antigen presenting cells such as dendritic cells. Antigen presenting cells 
present antigen using specific host proteins, the major histocompatibility complex proteins I 
and II. T-cell recognition of its cognate antigen may lead to a direct killing response (e.g. 
Cytotoxic T-cells) or to further immune modulation (e.g. CD4+ ‘T helper cell’). This is known 
as the cell mediated adaptive immune response. Activation of B-cells by their specific 
antigen leads to the formation of antibody processing plasma cells. Antibodies are 
immunoglobulin proteins that are specific to the invading pathogen and opsonise immune 
defences to eradicate that pathogen. This is so called humoral immunity. Importantly B-cells 
and T-cells can go on to form long lived memory cells thus equipping the body with a library 
of specific responder cells for previously encountered pathogens. Should later re-infection 
occur these cells are rapidly re-activated preventing disease. This feature of adaptive 
immunity is exploited by the process of vaccination. 
1.2 Discovery of the Pattern Recognition Receptors 
Research into the immune system in the latter half of the 20th century had predominantly 
focussed on adaptive immunity. It was felt that the almost limitless variation of antigen 
receptors on T and B-Cells was sufficient to allow specific immune detection and removal of 
all invading pathogens. This orthodoxy was challenged by the Yale immunologist Charles 
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Janeway. He wanted to reconcile the fact that immunologists were unable to experimentally 
induce specific T cell responses to antigens without the addition of various other diverse 
factors including mineral oil, aluminium hydroxide and extracts of mycobacteria: so called 
adjuvants.  In a key essay, Janeway sought to explain why a co-stimulatory signal was 
required to activate adaptive immune cells (Janeway 1989). If T-and B-cell receptors were 
able to recognise an unlimited number of proteins, both host and non-host, and their 
activity was simply dependent on antigen-receptor binding then how could adaptive 
immune cells know how to proliferate and activate in response to ‘dangerous’ non-host 
antigens whilst remaining inactive for host derived antigens. He proposed that activation of 
the adaptive immune system must rely on another group of preserved receptors that had 
evolved to recognise pathogens therefore ensuring that adaptive responses were geared 
towards true threats to the host. This theory was supported by observations that 
invertebrates have effective defences against pathogens in the absence of a functional 
adaptive immune system. To provide evidence for his theory, Janeway demonstrated that T-
cell responses to a specific antigen were entirely dependent on co-stimulatory factors 
present or produced in the B-cell population from a non-antigen stimulated splenocyte cell 
mix (Liu and Janeway 1991). Crucially these co-stimulatory factors were not constitutive 
within the B-cells, but required induction by inflammatory factors such as lipopolysaccharide 
(LPS) from the cell wall of gram-negative bacteria. Thus it was demonstrated that T-cell 
responses to a specific antigen were modulated by a non-specific interaction with a PAMP, 
in this case LPS. 
But what was the host cell receptor or receptors responsible for the detection of PAMPs and 
the generation of subsequent co-stimulatory signals to adaptive immune cells? This was 
answered by work in the fruit fly Drosophila melanogaster. Work by Professor Jules A. 
Hoffmann demonstrated that the immune response of Drosophila to fungal and bacterial 
infection was dependent on a receptor called Toll (Lemaitre, Nicolas et al. 1996). Toll had 
previously been identified as an important factor in dorsal-ventral patterning during 
embryonic development in the fly (Nusslein-Volhard and Wieschaus 1980) and had also 
been demonstrated to have an intracellular domain homologous to the human interleukin-1 
(IL-1) receptor (Gay and Keith 1991). Hoffmann’s group demonstrated that loss-of-function 
mutations in Toll were associated with increased susceptibility to fungal infection and death 
(Figure 1.2). 
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Figure 1.2: Scanning electron 
micrograph of fatal fungal 
infection in Toll deficient 
Drosophila melanogaster. 
The fly is covered in 
germinating hyphae of 
Aspergillus fumigatus.   
 (Lemaitre, Nicolas et al. 
1996). 
 
 
 
In the same year, Ruslan Medhitov, a post-doctoral scientist in Janeway’s laboratory 
identified and cloned a human homologue of the Drosophila Toll receptor containing 
extracellular leucine rich repeat (LRR) domains and Toll/Interleukin-receptor (TIR) 
cytoplasmic signalling domains capable of activating the inflammatory transcription factor 
nuclear factor kappa B (NFκB) (Medzhitov, Preston-Hurlburt et al. 1997). Crucially activation 
of the human Toll homologue was able to induce the co-stimulatory signal to activate T-cells 
central to Janeway’s hypothesis. The human Toll homologue was eventually renamed as 
Toll-like receptor 4 (TLR4). In a later seminal paper by Bruce Beutler’s group, TLR4 was 
identified as the receptor for LPS (Poltorak, He et al. 1998). Thus the discovery of Toll 
demonstrated the presence of germ-line encoded PRRs capable of recognising conserved 
microbial patterns and of initiating and adapting the host immune response. 
Subsequently there has been an explosion of interest in innate immune research with the 
identification of multiple TLRs and other innate immune receptor families including the 
NOD-like receptors (NLRs) and the RIG like receptors (RLRs) as will be discussed in detail 
below. In recognition of their groundbreaking research and its subsequent influence on the 
field of innate immunity, the 2011 Nobel Prize for Physiology or Medicine was awarded to 
Jules Hoffmann and Bruce Beutler, together with Ralph M. Steinman for his work on the 
dendritic cell. 
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1.3 Toll-like receptor family 
The discovery of the LPS responsive human Toll homologue (now known as TLR4) allowed 
the identification and characterisation of multiple TLR family members based on shared 
sequence homology (Rock, Hardiman et al. 1998). Up to now, researchers have identified 10 
functional TLRs in human and 12 in mice. By virtue of the LRR regions on the extracellular 
domain, TLRs are able to recognise a wide variety of PAMPS, including lipids, lipoproteins, 
proteins and nucleic acids from pathogens including bacteria, viruses and fungi (Table 1.1).  
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TLR PAMP/synthetic 
ligand 
Pathogen Species  References 
2/1 
heterodimer 
 
Synthetic tri-acylated 
lipopeptide 
(Pam3CSK4) 
lipoteichoic acid (LTA) 
Gram positive 
bacteria 
Mouse/Human (Schwandner, Dziarski et al. 1999; 
Ozinsky, Underhill et al. 2000) 
 
2/6 
heterodimer 
Macrophage 
activating lipopeptide 
(MALP-2) 
Synthetic diacylated 
lipopeptide 
(Pam2CSK4) 
FSL-1 (synthetic) 
Zymosan 
Hyaluronan 
Mycoplasma 
fermentan 
Mycoplasma 
salivarium 
Yeast 
Mouse/Human (Takeuchi, Kawai et al. 2001; 
Okusawa, Fujita et al. 2004) 
(Sato, Sano et al. 2003) 
(Scheibner, Lutz et al. 2006) 
3 Poly I:C (synthetic 
analogue double-
stranded RNA). 
Viruses Mouse/Human (Fortier, Kent et al. 2004) 
4 Lipopolysaccharide 
(LPS) 
Ozone / Hyaluronan 
Gram negative 
bacteria 
Mouse/Human (Poltorak, He et al. 1998; Hoshino, 
Takeuchi et al. 1999) 
(Garantziotis, Li et al. 2010) 
5 Flagellin Motile bacteria Mouse/Human (Hayashi, Smith et al. 2001) 
7 Imiquimod 
(guanosine analogue) 
Single-stranded 
viral RNA 
Mouse/Human (Lee, Chuang et al. 2003) 
7/8 R848 (synthetic 
imidazoquinoline 
compound) 
unknown Mouse/Human (Hemmi, Kaisho et al. 2002; Jurk, 
Heil et al. 2002) 
8 ssRNA40 (R-1075) Single-stranded 
RNA viruses e.g. 
HIV-1, influenza. 
Mouse/Human (Heil, Hemmi et al. 2004) 
9 Unmethylated CpG 
sequences in DNA 
molecules  
e.g. ODN1585  
Bacteria 
Viruses 
Mouse/Human (Ballas, Krieg et al. 2001) 
10 Unknown Unknown Human 
 
 
11 Profilin Toxoplasma 
gondii 
Uropathogenic 
Escherichia coli 
Mouse 
(non-
functional in 
human) 
(Lauw, Caffrey et al. 2005; 
Yarovinsky, Hieny et al. 2008) 
 
13 Unknown Unknown Mouse (Tabeta, Georgel et al. 2004) 
 
Table 1.1: TLR family members.  
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TLRs are Type I transmembrane glycoproteins with an extracellular domain containing LRRs, 
a single transmembrane domain and an intracellular TIR signalling domain. The LRR domains 
are responsible for ligand binding and convey a classical horseshoe like structure to the 
extracellular domains. Upon ligand binding TLRs form either homo or heterodimers in order 
to activate and initiate downstream signalling (Jin, Kim et al. 2007; Kim, Park et al. 2007; Liu, 
Botos et al. 2008) (Figure 1.3). TLR2 forms heterodimers with either TLR1 or 6 (Ozinsky, 
Underhill et al. 2000), and TLR8 can also form dimers with TLR 7 or 9 (Wang, Shao et al. 
2006). TLRs 3, 4 and 5 form homodimers. TLRs can be clustered into those that are found in 
the cell membrane and those that are found intracellularly, on endosomes and other 
intracellular vesicles. The cell surface TLRs include TLR1, TLR2, TLR4, TLR 5, TLR6 and TLR 11 
and respond primarily to PAMPs from pathogen cell membranes. Intracellular TLRs include 
TLR 3, 7, 8, and 9 which respond to pathogen derived nucleic acids (Figure 1.4). 
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Figure 1.3: Illustration of TLR structure and dimerisation upon ligand binding. Ligand 
associates with the extracellular LRR domains and induces receptor dimerisation. The 
subsequent dimerisation of the intracellular Toll/IL-1 receptor (TIR) domains initiates 
downstream adapter protein binding and signalling events (adapted from 
http://www.rcsb.org/pdb/101/motm.do?momID=143). 
Downstream signalling from TLRs is not only determined by ligand binding but also by the 
recruitment of specific adaptor proteins to the intracellular domain dimers via TIR-TIR 
interaction (O'Neill and Bowie 2007). This interaction is specific to TLR biology and shows 
significant evolutionary conservation. For example genomic studies suggest that the sea 
urchin Strongylocentrotus purpuratus is likely to have 222 TLRs and 26 TIR containing 
adaptor proteins (Rast, Smith et al. 2006; Sodergren, Weinstock et al. 2006). Each adaptor 
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protein signalling pathway induces different inflammatory transcription factors thus 
influencing the overall inflammatory response to a particular pathogen. The 5 human TIR 
containing adaptor proteins are Myeloid differentiation primary response gene (88) 
(MyD88), MAL (MyD88 adaptor like, otherwise known as TIRAP), TRIF (TIR-containing 
adaptor protein inducing interferon (IFN)-β), TRAM (TRIF related adaptor molecule) and 
finally the sterile α- and armadillo-motif-containing protein (SARM) which acts as a negative 
regulator to TRIF signalling (O'Neill, Fitzgerald et al. 2003). All TLRs except TLR3 signal via 
MyD88 whereas TLR3 signals via the TRIF pathway. The MyD88 dependent TLRs tend to 
produce pro-inflammatory cytokines whilst TLR3 generates both cytokine and Type I IFN 
responses. TLR4 can signal by both MyD88 and TRIF pathways and therefore mediate both 
inflammatory cytokine and IFN signalling (Figure 1.4). 
 
Figure 1.4: Cellular locations and adaptor proteins for the major TLRs. 
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MyD88/MAL pathway 
MyD88 was first identified as a differentiating factor in myeloid cells (Lord, Hoffman-
Liebermann et al. 1990). Subsequently MyD88 was shown to be crucial to downstream 
signalling from the IL-1 receptor and TLRs. This was convincingly demonstrated in MyD88 
knockout mice which are completely insensitive to ligands for TLR 2,4,5,7 and 9 (Kawai, 
Adachi et al. 1999; Takeuchi, Takeda et al. 2000). MyD88 is guided to the TLR intracellular 
domains by MAL and the resulting signalling complex recruits IL-1 receptor-associated 
kinase-4 (IRAK-4), IRAK-1 and TNF receptor associated factor-6 (TRAF-6) (Cao, Xiong et al. 
1996). Recruitment of TRAF-6 leads to physical linkage with transforming growth factor β 
activated kinase 1 (TAK1) and the TAK-binding proteins 1,2 and 3 (TAB1,2,3) forming a larger 
signalling platform (Kanayama, Seth et al. 2004). Resulting phosphorylation of TAK1 leads to 
activation of the inhibitor to the IκB kinase (IKK) complex and in turn release and 
translocation of NFκB to the nucleus to initiate gene transcription (Wang, Deng et al. 2001) . 
In addition activation of the MyD88 dependent pathway can induce the upstream kinases to 
the mitogen activated protein kinase (MAPK) family including C-jun N-terminal kinase (JNK) 
(Ninomiya-Tsuji, Kishimoto et al. 1999; Wang, Deng et al. 2001). The MyD88 pathway can 
also induce inflammatory genes such as IL-6 and TNFα via a TRAF6 but TAK1 independent 
pathway. This involves recruitment of interferon regulatory factor 5 (IRF5) with subsequent 
nuclear translocation of IRF5 to initiate gene transcription (Takaoka, Yanai et al. 2005). The 
TIR containing adaptor MAL/TIRAP has been shown to be a crucial factor in MyD88 signalling 
by TLR2 and TLR4. Mice deficient in MAL show absent cytokine production from splenocytes 
after TLR2 stimulation and reduced and delayed activation after TLR4 stimulation. This 
deficiency is specific to the MyD88 pathway (Yamamoto, Sato et al. 2002). Further research 
suggests that MAL acts as a bridging protein to anchor MyD88 to the TLR2 or TLR4 
intracellular domain (Dunne, Ejdeback et al. 2003). 
TRIF/TRAM pathway 
TRIF is now established as the MyD88 independent pathway for TLR4 signalling and as the 
sole adaptor protein for TLR3. TRIF was initially identified by genome screening for TIR 
domain containing proteins and was found to induce the IFN-β promoter independently to 
MyD88 whilst a dominant negative form of TRIF impaired TLR3 signalling (Yamamoto, Sato 
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et al. 2002). Crucially murine macrophages deficient in both MyD88 and TRIF failed to 
upregulate any genes in response to challenge with LPS, confirming TRIF’s role in the TLR4 
MyD88 independent pathway (Hirotani, Yamamoto et al. 2005). In an independent 
experiment, mice with a frameshift mutation in TRIF were shown to be insensitive to the 
TLR3 agonist Poly I:C and were unable to mount IFN responses to cytomegalovirus infection 
(Hoebe, Du et al. 2003).  
Activation of the TRIF pathway results in induction of both NFκB and Type I IFN pathways. 
Activation of NFκB is thought to involve TRAF6 in a similar way to the MyD88 pathway as 
TRIF contains TRAF6 binding domains, mutations of which reduce TLR4 mediated NFκB 
activation but not IRF3 induction (Sato, Sugiyama et al. 2003). However there is also 
evidence that TRIF may activate NFκB via a receptor interacting protein (RIP) homotypic 
interaction motif which recruits RIP1. Mouse embryonic fibroblasts deficient in RIP1 fail to 
activate NFκB in response to Poly I:C, with unimpaired release of IFNβ (Meylan, Burns et al. 
2004). TRIF mediated induction of Type I IFN occurs through phosphorylation and 
subsequent nuclear translocation of IRF3. This is caused by interaction with tumour necrosis 
factor receptor associated factor (TRAF)-family member associated NF-κB-activator-binding 
kinase 1 (TBK-1), deficiency of which abrogates TLR3 or TLR4 induced IFN, RANTES or IP-10 
release in Mouse embryonic fibroblasts (McWhirter, Fitzgerald et al. 2004). There is further 
evidence that this process is regulated by TRAF3, and indeed that TRAF3 has a more general 
role in viral induced IFN responses by the innate immune system (Oganesyan, Saha et al. 
2006).  
TRIF is the sole adaptor protein for TLR3 but as already discussed initiates the MyD88 
independent pathway of TLR4 signalling. Recruitment of TRIF to TLR4 is dependent on 
another TIR containing adaptor protein TRAM. TRAM is specific to the TLR4 receptor and is 
required for TLR4 signalling via the MyD88 independent pathway (Fitzgerald, Rowe et al. 
2003; Yamamoto, Sato et al. 2003).  
The major MyD88/MAL and TRIF/TRAM signalling pathways (exemplified by TLR4 signalling) 
are illustrated in figure 1.5. 
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Figure 1.5: The MyD88/MAL and MyD88 independent (TRIF/TRAM) pathways downstream of 
TLR4. 
In my thesis I have focussed on the role of TLR4 in vascular inflammation. Therefore I will 
describe the biology of TLR4 in greater detail. 
1. 3.1 TLR4 function  
As previously described, TLR4 was the founder member of the TLR family and crucially was 
found to mediate LPS responsiveness (Poltorak, He et al. 1998). Accordingly a large body of 
research exists regarding the structure, activation and signalling of TLR4 in both infectious 
and sterile inflammatory disease. TLR4 is also of particular interest as it signals via two main 
pathways (MyD88/MAL and TRIF/TRAM) and thus may serve as a model signalling system 
for the TLRs. 
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1.3.2 TLR4 activation ligands, adaptor proteins and binding: 
Lipopolysaccharide (LPS) 
LPS has a long and distinguished history as an experimental pyrogen. As an evolutionary 
conserved crucial component of the cell wall of Gram negative bacteria, it is in many ways a 
prototypical PAMP. Structurally, LPS is composed of three domains, the lipid-A motif, core, 
and O-chain. The endotoxin activity of LPS is derived from the lipid-A motif and subtle 
structural differences in lipid-A alter the degree of this activity (Rietschel, Kirikae et al. 
1993). The O-chain region is highly variable and may be used to serotype Gram-negative 
bacteria e.g. E Coli.  
LPS sensing by TLR4 involves specific adaptor proteins, namely LPS binding protein (LBP), 
CD14 and MD2. LBP is a serum glycoprotein excreted as an acute phase protein mainly by 
hepatocytes. It acts to extract LPS monomers from bacterial membranes thus facilitating 
their delivery to membrane bound CD14. Although not essential for LPS-CD14 association, 
LBP catalyses the reaction by acting as a lipid transfer protein (Wright, Ramos et al. 1990; 
Hailman, Lichenstein et al. 1994). Interestingly high serum levels of LBP in the acute phase 
response may act to inhibit LPS association with CD14 which may act to limit downstream 
signalling via TLR4 and prevent an excessive pro-inflammatory response (Lamping, Dettmer 
et al. 1998). CD14 is a membrane bound glycosylphosphatidylinositol anchored or secreted 
protein that binds to LPS in association with LBP and facilitates the association with 
TLR4/MD2. This allows efficient signal transduction via TLR4 even with picomolar 
concentrations of LPS (Gioannini, Teghanemt et al. 2004). In support of this, CD14 deficient 
mice show resistance to endotoxin shock and CD14 deficient macrophages have markedly 
reduced responses to LPS (Haziot, Ferrero et al. 1996; Perera, Vogel et al. 1997). 
Determination of the crystal structure of CD14 has revealed that it is a dimer with a total 
number of LRR regions similar to that of TLR4 suggesting structural similarity (Kim, Lee et al. 
2005). Indeed the flexibility of binding sites offered by the LRR regions has allows CD14 to 
participate in the recognition of diverse PAMPs via TLRs 1,2,6 and 9 (Bas, Neff et al. 2008; 
Weber, Muller et al. 2012). MD2 differs from the above TLR4 associated proteins in that it is 
absolutely required for LPS signalling. Mice deficient in MD2 have an identical phenotype to 
TLR4 deficient mice, with complete LPS insensitivity (Nagai, Akashi et al. 2002). Recent work 
has characterised the crystal structure of the TLR4-LPS-MD2 complex, showing that a 
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symmetric multimer is formed composed of two TLR4-LPS-MD2 heterodimers (Park, Song et 
al. 2009). Thus the working model of LPS signalling via TLR4 includes binding of LPS to LPB, 
delivery of LPS/LBP to CD14, and subsequent association of LPS with TLR4-MD2 to form the 
signalling complex. 
The inflammatory response initiated by LPS/TLR4 interaction is biphasic. The early response 
occurs immediately after receptor dimerisation and recruitment of MAL and MyD88 to 
activate NFκB and AP-1 via the MyD88 dependent pathway discussed earlier. In addition 
there is a later response, 15-30 minutes after LPS binding, involving further signalling via the 
MyD88/MAL and TRIF/TRAM pathways. A key factor for this later response is dynamin 
dependent endocytosis of the LPS/TLR4/MD2/CD14 complex (Husebye, Halaas et al. 2006). 
The endosome bound TLR4 TIR domains may then preferentially bind to TRIF/TRAM to allow 
induction of Type I IFN by the MyD88 independent (TRIF) pathway. Subsequent 
endolysosomal degradation of TLR4 complex helps to limit the LPS induced inflammatory 
response (Chuang and Ulevitch 2004; Palsson-McDermott, Doyle et al. 2009). 
Alternative TLR4 ligands 
In addition to the well characterised binding of LPS, TLR4 is able to recognise and respond to 
a wide variety of ligands . These can be categorised as pathogen related ligands, host related 
ligands and host proteins released as a result of infection. Following on from the initial 
observation that TLR4 participated in fungal immunity in Drosophila, it has been observed 
that fungal mannan may be sensed in a CD14/TLR4 dependent fashion (Tada, Nemoto et al. 
2002; Roeder, Kirschning et al. 2004). Similarly responses to protozoal pathogens including 
Trypanosoma species have been shown to involve  TLR4, TLR2 and TLR9 and the MyD88 
dependent signalling pathway (Gazzinelli, Ropert et al. 2004). Although anti-viral responses 
are particularly associated with the intracellular TLRs, viral membrane glycoproteins have 
been implicated as ligands for TLR4, including for example the fusion protein from 
respiratory syncytial virus (Kurt-Jones, Popova et al. 2000) and the envelope protein of 
mouse mammary tumor virus (Burzyn, Rassa et al. 2004). 
The role of TLR4 in recognition of host associated proteins is of particular importance as it 
supports an involvement of the receptor in ‘sterile’ inflammatory disorders including, for 
example, ischaemia-reperfusion injury and atherosclerosis. These host proteins are usually 
released in the process of cell death or injury and are often termed ‘danger associated 
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molecular patterns’ (DAMPs). Constituents of the extracellular matrix, including biglycan 
and hyaluronic acid, have been shown to act in a TLR4 and TLR2 dependent fashion. Mice 
deficient in biglycan show resistance to zymozan and LPS induced shock (Schaefer, Babelova 
et al. 2005) whilst mice deficient in TLR2 and 4 show a reduced inflammatory response to 
hyaluran fragments in a murine model of non-infectious lung injury (Jiang, Liang et al. 2005). 
High-mobility group box 1 (HMGB1) proteins are released from necrotic cells and have been 
implicated as inflammatory mediators in sepsis and ischaemia-reperfusion injury (Yang and 
Tracey 2010). Macrophages from TLR4 deficient mice show markedly reduced cytokine 
release in response to HMGB1 (Yu, Wang et al. 2006) and TLR4 deficient mice are relatively 
protected in a HMGB1 ischaemia-reperfusion model (Tsung, Sahai et al. 2005). The heat-
shock proteins have also been implicated as TLR4 ligands to promote inflammation, but this 
data might well reflect contamination with LPS (Tsan and Gao 2009). Oxidised low density 
lipoprotein (LDL) is a key factor in the development of atherosclerosis and is thought to 
contribute to a chronic inflammatory response via activation of the innate immune system. 
Recent research has suggested oxidised LDL is recognized by a TLR4/6 heterodimer to 
initiate downstream signalling (Stewart, Stuart et al. 2010). 
Finally host proteins released after pathogen infection may further signal through TLR4 to 
modify the immune response. These include the anti-microbial protein β-defensin 2 
(Biragyn, Ruffini et al. 2002) and oxidised phospholipids relevant to acute lung injury (Imai, 
Kuba et al. 2008). 
1.3.3 Negative regulation of TLR4 responses 
The complexity of LPS-TLR4 signalling in terms of the interplay between numerous adaptor 
proteins is in keeping with its fundamental importance in host defence. For example this 
allows variation in signalling patterns dependent on subtle species differences in the LPS 
ligand, or for alternative TLR4 ligands. In addition negative regulation of the response is vital 
given the powerful inflammatory and potentially hazardous inflammatory response induced 
by LPS. Negative regulation can be appreciated in the phenomenon of endotoxin tolerance. 
This refers to relative hyporesponsiveness to LPS in inflammatory cells from septic patients  
(McCall, Grosso-Wilmoth et al. 1993) or cells previously stimulated in vitro by LPS 
(Mengozzi, Fantuzzi et al. 1993). Multiple negative regulators of TLR4 signalling have been 
identified at numerous points on the signalling axis. This may be straightforward such as the 
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production of the anti-inflammatory cytokine IP-10 via the TRIF pathway or via more 
complex interactions at the level of TLR adaptor proteins and signalling intermediates. Splice 
variants known to inhibit the MyD88 pathway include MyD88-s, the IRAK2c and the IRAK2c 
proteins (Janssens, Burns et al. 2002; Hardy and O'Neill 2004). Similarly a splice variant of 
TRAM named ‘Tram adaptor with GOLD domain’ (TAG), has been demonstrated to be a 
negative regulator of the TRIF pathway by displacing TRIF from TLR4 in the endosomal 
compartment (Palsson-McDermott, Doyle et al. 2009). Downstream signalling from TLR4 
may also be inhibited by ubiquitination, for example by degradation of TAB2, TAB3 (Shi, 
Deng et al. 2008) or the p65 subunit of NFκB (Tanaka, Grusby et al. 2007). In addition LPS 
may induce non-coding RNAs (so called microRNAs) which feed back to regulate the TLR4 
response. A recently described example would be the microRNA miR-20 which negatively 
regulates TLR4 function via inhibition of the pro-inflammatory tumour suppressor PCDC4 
(Sheedy, Palsson-McDermott et al. 2010).  
Despite the regulatory mechanisms described above it should be mentioned that animal 
models of endotoxin tolerance have suggested an important role for corticosteroids as both 
adrenelectomy (Evans and Zuckerman 1991) and a specific glucocorticoid receptor 
antagonist (Rearte, Landoni et al. 2010) can prevent the induction of tolerance. 
1.4 The Nucleotide-binding, leucine rich repeat protein (NLR) family 
The NLR family is a recently discovered group of intracellular proteins which behave as PRRs 
and contain preserved nucleotide-binding and LRR domains. NLR proteins share structural 
similarity to plant disease resistance proteins (van der Biezen and Jones 1998). Plants have 
no adaptive immune system and instead depend on transmembrane PRRs or intracellular 
nucleotide binding and LRR containing proteins. Pathogen recognition via these receptors 
leads to an exaggerated death response thus limiting the pathogen spread. Human proteins 
related to the plant nucleotide binding-LRR receptors, were identified using genomic 
screening techniques by several researchers in the last decade. These included caspase 
recruitment domain-4 (CARD4) / NOD1 (Bertin, Nir et al. 1999; Inohara, Koseki et al. 1999), 
CARD15/NOD2 (Ogura, Inohara et al. 2001) and the CATERPILLAR (CARD, transcription 
enhancer, R(purine)-binding, pyrin, lots of leucine repeats) gene family (Harton, Linhoff et 
al. 2002). In support of a potential role in innate immunity, overexpression of both NOD1 
and NOD2 led to activation of NFκB as well as caspase recruitment and cell apoptosis 
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(Bertin, Nir et al. 1999; Inohara, Koseki et al. 1999; Ogura, Inohara et al. 2001). The authors 
of these experiments also demonstrated that activation of NFκB was dependent on CARD-
CARD interactions with RICK (RIP-2/CARDIAC), a recently identified serine-threonine kinase 
(Inohara, del Peso et al. 1998). Following the discovery of these early NLRs, a large number 
of related receptors have been identified. 
1.4.1 Structure and nomenclature of the NLRs 
All NLRs share a core tri-partite structure (Figure 1.6). This comprises of a central nucleotide 
binding/NOD domain which facilitates self-oligomerisation, a C-terminal LRR domain and a 
variable N-terminal effector domain. The central binding domain has also been known as a 
NACHT domain  after the names of the proteins that define it (the neuronal apoptosis 
inhibitory protein (NAIP), MHC class II transcription activator (CIITA), incompatibility locus 
protein from Podospora anserina (HET-E), and telomerase-associated protein (TP1)) (Koonin 
and Aravind 2000). The LRR domains bear similarity to the ligand sensing regions of the TLRs 
and are putative sensing domains for NLR ligands. The N-terminal effector domains allow 
sub-classification of the NLRs depending on the specific structure. The four identified N-
terminal motifs that sub-divide the NLRs are the acid transactivation domain, the CARD 
domain, the pyrin domain (PYD) and the baculovirus inhibitor domain (BIR). A recent 
consensus group has agreed on the nomenclature to be used for the NLRs with receptors 
grouped according to the effector domain type i.e. NLRA (acid transactivation), NLRB (BIR), 
NLRC (CARD), and NLRP (PYD). In addition to this, an NLR sub-class localised to the 
mitochondria and capable of inducing NFκB and JNK has been identified and included in the 
NLR nomenclature as NLRX (Moore, Bergstralh et al. 2008; Tattoli, Carneiro et al. 2008). 
Within the sub-families individual names of well-studied NLRs have been kept e.g. NOD1, 
NOD2, CIITA (Ting, Lovering et al. 2008). Identified human NLRs, their murine orthologs and 
associated PAMPs are shown in the table (Table 1.2). 
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Figure 1.6: Structure of the NLRs. The sub-families of NLRs share a tri-partite structure 
comprised of a leucine rich repeat (LRR) domain, central nucleotide binding oligomerisation 
domain (NB-NOD) and a variable N-terminal effector domain. These include acidic 
transactivation (AD), baculoviral inhibitory repeat (BIR), caspase recruitment (CARD) and 
pyrin (PYD) domains. 
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Family Members Location Agonists Reference 
Human Mouse 
NLRA 
(AD 
domain) 
CIITA CIIta Cytosol (Mφ, 
Tφ, Bφ) 
IFNγ (Eisenbarth and Flavell 2009; Shaw, 
Lamkanfi et al. 2010) 
NLRB 
(BIR 
domain) 
NAIP  
Naip1                                                     
Naip2                                                   
Naip3                                                    
Naip4                                                    
Naip5                                                   
Naip6                                                   
Naip7 
Cytosol Legionella, Flagellin (Eisenbarth and Flavell 2009) 
NLRC 
(CARD 
domain) 
NOD1                                                               
NOD2                                                                    
NLR3 
NLR4 
NLR5 
 
Nod1
Nlrc3
Nlrc4 
Nlrc5 
 
Cytosol Meso-DAP 
(mesodiaminopimeli
c Acid from Gm-, 
Some Gm+, MTb), 
H.pylori. B.anthracis 
MDP (PGN from 
Gm+, Gm-, 
Mycobacterium), 
T.gondii, RSV 
Pseudomonas, 
Salmonella, 
Legionella, Shigella, 
flagellin 
(Chamaillard, Philpott et al. 2003; 
Eisenbarth and Flavell 2009; Ip, 
Takahashi et al. 2009; Shaw, 
Lamkanfi et al. 2010),   
(Viala, Chaput et al. 2004)            
(Loving, Osorio et al. 2009)                     
(Chamaillard, Philpott et al. 2003; 
Girardin, Boneca et al. 2003; Shaw, 
Lamkanfi et al. 2010),  
(Chamberlain, Francis et al. 2009; 
Sabbah, Chang et al. 2009) 
NLRP 
(PYD 
domain) 
NLR1 
NLR2                                 
NLR3 
NLR4                       
NLR5                                 
NLR6  
NLR7 
NLRP8                                  
NLRP9                            
NLRP10  
NLRP11  
NLRP12
NLRP13                                            
NLRP14 
Nlrp1a-c 
Nlrp2
Nlrp3 
Nlrp4a-g 
Nlrp5
Nlrp6 
Nlrp9a-c 
Nlrp10 
Nlrp12 
Nlrp14 
Cytosol Anthrax Lethal 
Toxina,MDP, 
B.anthracis 
Pore-forming toxins, 
extracellular ATP, 
Crystals, Chemical 
Sensitizers, Silica, 
asbestos, amyloid β, 
nonoparticles, 
Bleomycin, 
*L.monocytogens 
(LLO), S.aureus, 
aluminium 
adjuvants, uric acid 
Sterile 
Inflammation—
Hyaluronan, Biglycan 
(Eisenbarth and Flavell 2009; Shaw, 
Lamkanfi et al. 2010) 
 
(Amer, Franchi et al. 2006; 
Mariathasan, Weiss et al. 2006; 
Martinon, Petrilli et al. 2006; 
Eisenbarth, Colegio et al. 2008) 
 
(Lich, Williams et al. 2007; Shaw, 
Lamkanfi et al. 2010) 
NLRX NLRX1 Nlrx1 mitochondrial  (Shaw, Lamkanfi et al. 2010) 
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Table 1.2: NLR nomenclature. AD, acidic transactivation; BIR, baculovirus inhibitor of 
apoptosis repeat; CARD, caspase recruitment domain; PYD, pyrin domain; NOD, nucleotide 
oligomerisation domain.  
Multiple lines of evidence now point to the role of NLRs as intracellular receptors for 
pathogen and host associated proteins (PAMPs and DAMPs), in keeping with their homology 
to plant NB-LRR disease resistance proteins. Broadly the functional response upon activation 
of the NLRs can be divided into two pathways. The first pathway involves a direct pro-
inflammatory response via, for example, induction of NFκB and MAPK. This is typified by the 
activity of NOD1 and NOD2 and will be discussed in detail below. The second NLR induced 
inflammatory pathway involves participation in the formation of an inflammasome complex 
to enable processing and maturation of the inflammatory cytokines IL-1β and IL-18, via 
activation of caspase-1. The role of NLRs in inflammasome signalling is illustrated by NLRP3. 
The role of NLRP3 is particularly interesting as it is able to respond to a wide variety of 
stimuli including bacterial and viral nucleic acids (Kanneganti, Ozoren et al. 2006), urate 
crystals (Martinon, Petrilli et al. 2006), reactive oxygen species induced by asbestos and 
silica (Dostert, Petrilli et al. 2008) , and alterations in intracellular potassium concentrations 
(Mariathasan, Weiss et al. 2006). The ability of NLRP3 to sense these diverse stimuli may 
rely on the ATP-sensing P2X7 receptor. Activation of P2X7 leads to opening of the 
membrane channel pannexin-1 which allows bacterial PAMPs into the cytosol or an influx of 
potassium thus activating the NLRP3 inflammasome (Kanneganti, Lamkanfi et al. 2007). 
Thus the NLRP inflammasome may represent a general sensor of cell stress, making it an 
attractive target for a variety of inflammatory conditions. 
In my thesis I have focussed on NOD1 and to a lesser extent NOD2, therefore the known 
function and signalling of these prototypic NLRs is now discussed in more detail. 
1.4.2 Function of the NOD receptors 
As discussed earlier, the NOD receptors NOD1 and NOD2 were amongst the earliest 
identified NLRs although the nature of their specific ligands was unknown. In a key paper, 
Girardin and colleagues indentified NOD1 as an essential receptor for detection of 
peptidoglycan (PGN) from gram-negative bacteria (Girardin, Boneca et al. 2003). PGN is an 
essential component of the cell wall in both Gram-negative and Gram-positive bacteria. 
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Unique pro-karyotic structural motifs in the PGN sugar chains make ideal PAMPS for 
eukaryotic PRRs, examples of which can be found in diverse species including plants,  the 
fruit fly, and man (Sorbara and Philpott 2011). This study demonstrated that the apparent 
NOD1 stimulatory property of LPS was in fact due to PGN contamination. Purified PGN 
fractions from Gram-negative, but not Gram-positive bacteria were able to activate NFκB, 
dependent on an intact LRR domain of NOD1. Further analysis by reversed-phase high-
performance liquid chromatography identified the specific PGN motif capable of activating 
NOD1. This is a muropeptide with the tri-peptide substitution L-Ala-D-Glu-mesoDAP (where 
DAP is diamino-pimelate). This so-called PGN Tri-peptide structure is largely confined to 
Gram negative bacteria, whereas Gram positive bacteria possess a Muramyl Di-peptide 
(MDP) PGN motif which has been demonstrated to be the ligand for NOD2 (Girardin, Boneca 
et al. 2003; Inohara, Ogura et al. 2003). The various PGN structures implicated in NOD1 and 
NOD2 signalling are illustrated in the figure (Figure 1.7).  
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Figure 1.7: Structure of bacterial peptidoglycan, including the motifs capable of NOD1 
(green) and NOD2 (blue) stimulation. The section highlighted in red illustrates the structural 
differences between Gram negative and Gram positive bacteria with substitution of D-
isoGlutamine to D-glutamic acid and L-Lysine to mDiaminopimelic acid (mesoDAP). 
In keeping with the role of NOD1 and NOD2 as cytosolic PRRs, they have been implicated in 
host defence against intracellular pathogens including Shigella Flexneri (Girardin, Tournebize 
et al. 2001), Listeria Monocytogenes (Opitz, Puschel et al. 2006), Pseudomonas Aeruginosa 
(Travassos, Carneiro et al. 2005) and Mycobacterium tuberculosis (Brooks, Rajaram et al. 
2011). However it is also apparent that the NODs can respond to extracellular pathogens 
including Clostridium Difficile (Hasegawa, Yamazaki et al. 2011)  and Helicobacter Pylori 
(Allison, Kufer et al. 2009). To do this, the PGN ligands must enter the cell. Several 
mechanisms of PGN uptake have been suggested from the literature. In the case of H.Pylori, 
PGN ligands are delivered into epithelial cells via a Type IV secretion system (Viala, Chaput 
et al. 2004). Alternatively PGN may be transferred from pathogens within outer membrane 
vesicles. These are composed of bacterial membrane proteins and lipids, including PGN, and 
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outer membrane vesicles from pathogens including H.Pylori and P.Aeruginosa have been 
shown to induce NFκB in epithelial cells in a NOD1 dependent fashion (Kaparakis, Turnbull 
et al. 2010). In the case of free extracellular PGN, membrane co-receptors may facilitate 
uptake into the cytosol. PepT1 has been identified as one such receptor which has been 
demonstrated to participate in MDP delivery into the cell (Ismair, Vavricka et al. 2006). 
Finally, Lee and colleagues demonstrated uptake of PGN peptides by clathryn mediated 
endocytosis, followed by pH dependent endosomal processing to allow further NOD1 and 
NOD2 signalling (Lee, Tattoli et al. 2009). Once inside the cell, PGN motifs are free to initiate 
signalling via NOD1 or NOD2. The exact mechanism of interaction between ligand and NOD 
protein remains a matter of debate, however a recent paper has demonstrated direct 
binding of DAP PGN to NOD1 using surface plasmon resonance and atomic force 
microscopy. Truncation of the LRR region prevented this association and subsequent close 
binding of NOD1 to RIP2 (Laroui, Yan et al. 2011). 
Activation of NODs by their specific ligands induces signalling via NFκB and MAPK to 
upregulate inflammatory and host defence genes. Upon receptor oligomerisation, the next 
crucial step is a CARD-CARD domain association with receptor-interacting protein 2 (RIP2) 
(Inohara, Koseki et al. 1999). RIP2 is a CARD domain containing receptor originally identified 
as a protein involved in apoptosis and activation of NFκB (Inohara, del Peso et al. 1998; 
McCarthy, Ni et al. 1998). Subsequent studies have revealed that RIP2 is essential for 
signalling via NOD1 and NOD2 (Magalhaes, Lee et al. 2011) but not via the TLRs (Park, Kim et 
al. 2007). CARD-CARD association of NOD1 with RIP2 has been demonstrated to lead to K63-
linked poly-ubiquitination allowing recruitment of the TAK1/TAB1,2,3 complex (Hasegawa, 
Fujimoto et al. 2008). This signalling scaffold then permits recruitment of the IKK signalling 
regulator NEMO, with subsequent release of NFκB to the nucleus to initiate gene 
transcription. NOD signalling also leads to activation of the MAPK family including JNK and 
p38 MAPK (Windheim, Lang et al. 2007), whilst recent evidence suggests induction of Type 1 
IFN responses after stimulation of NOD1 (Watanabe, Asano et al. 2010). 
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Figure 1.8: Schematic of NOD signalling via RIP2. After ligand recognition, NOD1/2 
associates with RIP2 via CARD-CARD interaction. Subsequent K63-linked polyubiquitination 
and recruitment of the TAK1/TAB1,2,3 complex leads to interaction with NEMO and release 
of NFκB to initiate gene transcription. The mechanisms leading to MAPK activation are not 
well characterised. 
1.5 Target genes of NOD and TLR signalling 
Activation of PRRs by specific ligands results in the induction of multiple genes responsible 
for host defence. Apart from the heterogenicity of response offered by the varied ligand 
specificity of TLRs and NODs, the added complexity of downstream signalling pathways adds 
greater nuance. A good example of this is the divergent MyD88/MAL and TRIF/TRAM 
signalling downstream of TLR4 which has been described earlier. Stimulation of the MyD88 
pathway results in activation of the transcription factors NFκB and AP-1 as well as MAPK 
driven gene transcription. This predominantly results in expression of inflammatory 
chemokine/cytokine genes including TNFα, IL-1β , CXCL8 and CXCL6, and other immune 
proteins including the immunoglobulins, the major histocompatibilty complex receptors and 
cell adhesion molecules such as intracellular adhesion molecule (ICAM) and vascular cell 
adhesion molecule (VCAM). In addition there is upregulation of inflammatory enzymes, 
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most notably cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS). Signalling 
through the TRIF/TRAM pathway also activates NFκB as described earlier but also induces a 
different profile of gene induction via activation of IRF3. This induces Type 1 IFN such as 
IFNβ, in addition to chemokines including RANTES and IP-10. In keeping with their activation 
of NFκB, the NOD receptors also induce inflammatory genes including chemokines 
(Masumoto, Yang et al. 2006; Carneiro, Magalhaes et al. 2008) and inflammatory enzymes 
such as iNOS (Cartwright, Murch et al. 2007).  
1.6 NOD/TLR interaction 
As I have discussed, NLRs and TLRs can induce inflammatory genes by independent 
activation of NFκB and associated signalling pathways. However a body of evidence exists to 
suggest significant interaction between the different receptors in fashioning the innate 
immune response. Perhaps the best example of cooperation between the NLRs and TLRs lies 
with the processing of pro-IL-1β into mature IL-1β by activated caspase-1 in the 
inflammasome. In a key paper, Núñez and colleagues demonstrated that LPS and ATP 
induced activation of caspase-1 via the NLRP3 inflammasome was independent of TLR4 and 
MyD88 induced NFκB activation, but instead dependent on P2X7 mediated activity of the 
Pannexin-1 membrane channel. However release of mature IL-1β following LPS challenge 
required TLR4 (Kanneganti, Lamkanfi et al. 2007). Thus dual activation of TLR4 and NLRP3 is 
required for caspase-1 mediated IL-1β release which may act as a vital regulatory step for 
this potent inflammatory cytokine. Considering NOD and TLR responses, there is evidence of 
synergistic interaction in various cell systems. For example NOD1 and NOD2 significantly 
enhance TLR induced cytokine secretion in monocytic cells (Yang, Tamai et al. 2001; Uehara, 
Yang et al. 2005) and similarly promote TLR mediated IL-12 release in human dendritic cells 
(Tada, Aiba et al. 2005). The exact mechanism underlying NOD and TLR synergy is poorly 
understood but clearly there are common features in the signalling cascades from both 
types of receptor which might serve as amplification points, for example the activation of 
NFκB. Indeed alterations of the kinetics in NFκB activation has been suggested as a possible 
explanation for NOD mediated up-regulation of TLR responses (Underhill 2007). 
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1.7 Disease associations of TLR4 and NODs 
As I have discussed both TLRs and NLRs are able to respond to a variety of stimuli including 
pathogen and host-related proteins and are able to induce significant immune responses via 
the upregulation of inflammatory cytokine/chemokine genes and enzymes. As would be 
expected from these functions, these PRRs have been implicated in human inflammatory 
diseases and in aberrant host responses to infectious disease. Data on polymorphisms of 
human PRRs has been useful to suggest disease associations. In the case of TLR4 a well 
studied polymorphism is the Asp299Gly amino acid substitution. Asp299Gly has been 
associated with an increased risk of Gram-negative infection in septic patients (Agnese, 
Calvano et al. 2002; Lorenz, Mira et al. 2002) and with increased risk of severe respiratory 
syncytial virus (RSV) infection in infants (Tal, Mandelberg et al. 2004). In addition to 
infectious disease, the Asp299Gly polymorphism has been associated with inflammatory 
diseases including asthma (Hussein, Awad et al. 2012) and inflammatory bowel disease 
(Browning, Huebner et al. 2007). An interesting point to consider is that despite the disease 
associations described above there must be considerable functional redundancy in TLR 
responses. This is suggested by data from patients with autosomal recessive MyD88 
deficiency (and therefore significant deficiency in TLR signalling). Although these children 
have an increased frequency of serious pyogenic infection (for example to Strep 
pneumonia), they do not have a severe immunodeficient phenotype with normal immunity 
to other pathogens (von Bernuth, Picard et al. 2008).  
Polymorphism data has also implicated the NOD receptors in human inflammatory disease. 
The best characterised example is that of NOD2 and Crohn’s disease (Hugot, Chamaillard et 
al. 2001). The three most common NOD2 polymorphisms in Crohn’s disease are Arg702Trp, 
Gly908Arg and Leu1007fs. Homozygosity for these alleles confers a 40-fold increased risk for 
the development of the disease. Interestingly the polymorphisms generally confer a loss of 
function phenotype, which is somewhat contradictory to the observation of increased 
inflammatory cytokines and NFκB activity in Crohn’s disease (Carneiro, Magalhaes et al. 
2008). There is ongoing debate and research regarding the mechanisms by which NOD2 
influences Crohn’s pathophysiology. Other examples of NOD2 related inflammatory disease 
include early onset sarcoidosis (Kanazawa, Okafuji et al. 2005) and the rare but related 
Blau’s syndrome, characterised by granulomatous inflammation, arthritis, uveitis and skin 
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disease (Miceli-Richard, Lesage et al. 2001). NOD1 has also been implicated in human 
inflammatory disease including asthma. Nysi and colleagues reported association of an 
insertion-deletion polymorphism in NOD1 (ND(1)+32656) with IgE variation and with a >5-
fold increased risk of childhood asthma (Hysi, Kabesch et al. 2005). The same mutation was 
also implicated in the development of inflammatory bowel disease.  
1.8 Pattern recognition receptor biology and the vasculature 
The focus of my thesis is the role of Gram negative PRRs including TLR4 and the NOD 
receptors in vascular inflammation. Before discussing the relevant literature in more detail I 
will give an overview of the structure of healthy blood vessels and their functions which 
include transport of oxygen and essential nutrients to the tissues, regulation of tone and 
coagulation, and interaction with immune cells. 
1.8.1 Structure of the blood vessel 
In his prescient and controversial treatise of 1628 ‘Exercitatio Anatomica de Motu Cordis et 
Sanguinis in Animalibus’ (An Anatomical Exercise on the Motion of the Heart and Blood in 
Living Beings), the scientist and physician William Harvey (1578-1657) described an essential 
role of the vasculature as part of a circulation carrying oxygenated blood from the lungs to 
the tissues in the arterial system whilst returning deoxygenated blood to the heart and 
lungs via the venous system. What Harvey brilliantly theorised but was unable to 
demonstrate experimentally was the passage of blood from arterial to venous systems via 
minute capillaries (which also permit transfer of oxygen and other nutrients from blood to 
tissue). In keeping with these diverse functions there are structural differences between the 
three types of blood vessel (artery, capillary and vein). Arteries are composed of three main 
layers. The interface with the vessel lumen is known as the tunica intima and is composed of 
a thin layer of endothelial cells. Below the intima, there is a deeper layer called the tunica 
media, composed mainly of smooth muscle cells and elastic tissue whilst the outer layer of 
the artery, the tunica externa (formerly tunica adventitia) predominantly contains 
connective tissue. The intima/media and media/externa are separated by thin layers called 
the internal and external elastic laminas respectively. Veins have intimal and externa layers 
but lack a significantly muscularised media layer in comparison to arteries reflecting the lack 
of significant functional venous constriction. In contrast to arteries and veins, capillaries 
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consist of a single layer of endothelial cells and a thin epithelial membrane. This facilitates 
the capillary function of oxygen and nutrient transport. In my thesis I have focussed on the 
role of the endothelium in responses to PAMPs therefore the physiological role of the 
endothelium is now discussed in more detail.  
 
Figure 1.9: The cross-sectional structure of a blood vessel. Adapted from 
http://www.corbisimages.com/stock-photo/rights-managed/42-23598247/a-human-arteriole-
crosssection. 
1.8.2 Function of the endothelium 
A) Barrier function 
The endothelium performs crucial physiological functions in blood vessels. Perhaps the most 
fundamental role is that of a barrier at the interface between circulating blood and the 
vessel wall. To achieve this barrier function, adjacent cells associate to form so-called tight 
junctions and adherens junctions. This association is mediated by both cell-membrane and 
associated intracellular proteins including Vascular-endothelial-cadherin (Vittet, Buchou et 
al. 1997) and the claudin family (Furuse, Sasaki et al. 1998). Tight junctions and adherens 
junctions allow the close regulation of solute permeability as well as migration of immune 
cells. Tight junctions and adherens junctions are themselves regulated by proteins including 
the Rab family of small GTPases which affect endosome-membrane protein shuttling 
(Morimoto, Nishimura et al. 2005). In addition a variety of signalling proteins including Src 
family tyrosine kinases, receptor tyrosine kinases, and protein tyrosine phosphatases have 
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been implicated to influence adherens junctions (McLachlan and Yap 2007). Together these 
factors provide a potential mechanism for dynamic regulation of endothelial permeability.  
B) Regulation of vascular tone 
Another crucial physiological role of the endothelium is the regulation of vessel tone. This is 
fundamental to the responsiveness of the vasculature to local and systemic needs e.g. local 
splanchnic vasodilation during digestion and peripheral vasoconstriction in the case of blood 
loss to conserve blood flow to the major internal organs. Central to the role of the 
endothelium in the regulation of vascular tone is the activity of key vasoactive hormones, 
which may be either constitutively active or induced. These include vasodilators such as 
nitric oxide (NO) and prostacyclin (PGI2), and vasoconstrictors including endothelin 1 (ET-1). 
i) Nitric oxide 
The concept of an ‘endothelium derived relaxing factor’ (EDRF) emerged from 
work showing that the vasodilatory affect of acetyl choline was dependent on an 
intact endothelium in isolated rabbit thoracic aortic strips (Furchgott and 
Zawadzki 1980). Acetyl choline was postulated to act via muscurinic receptors on 
the endothelium to release a factor which induced relaxation in the underlying 
smooth muscle cells. Complementary research showed that EDRF increased 
levels of cyclic guanosine monophosphate in vascular smooth muscle (VSM) 
suggesting that EDRF acted via induction of guanylate cyclase (Rapoport and 
Murad 1983). The elusive EDRF was later found to be NO, based on the 
pharmacological similarities in terms of concentration dependent vasodilation 
(Palmer, Ferrige et al. 1987), and inhibition of platelet aggregation (Radomski, 
Palmer et al. 1987). NO formation was  shown to require L-arginine (Palmer, 
Ashton et al. 1988) and the nitric oxide synthase (NOS) enzyme was later 
characterised (Bredt and Snyder 1990). The discovery and characterisation of NO 
as a biological signalling molecule led to the award of the 1999 Nobel Prize in 
Physiology or Medicine to Robert F Furchgott, Louis J Ignarro, and Ferid Murad.  
It is now understood that NO formation from L-arginine occurs by the action of 
three different isoforms of NOS. Endothelial NOS (eNOS) is constitutively active 
in vessels and contributes to resting tone. Neuronal NOS (nNOS) is another 
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constitutive form of NOS and is so named as it was first characterised in neurons 
where NO is a neurotransmitter. Both eNOS and nNOS activity is 
calcium/calmodulin dependent. The third calcium independent isoform of NOS, 
iNOS, can be activated by a variety of inflammatory stimuli including LPS and 
IFNγ and is of particular significance when considering the effect of pathogen 
induced inflammation. Importantly early experiments confirmed that iNOS can 
be induced directly in vascular tissues including the endothelium (Radomski, 
Palmer et al. 1990) and smooth muscle layer (Knowles, Salter et al. 1990). Once 
formed, NO activates guanylate cyclase as described above to produce cyclic 
guanosine monophosphate (cGMP). cGMP acts via kinases including Protein 
kinase G to lower intracellular calcium stores and inhibit smooth muscle 
contraction via myosin dephosphorylation, thus leading to vasodilation. NO has 
an extremely short half-life and as such its biological effects are local.  
ii) Prostacyclin 
PGI2 is an eicosanoid derived from arachidonic acid by the activity of cyclo-
oxygenase (COX). It is part of the wider family of prostaglandins which have 
prominent roles in inflammation and various homeostatic mechanisms. PGI2 was 
first characterised as a vasodilatory mediator and potent inhibitor of platelet 
aggregation by Sir John Vane and his group (Moncada, Gryglewski et al. 1976). 
COX breaks down membrane phospholipid derived arachidonic acid into the 
metabolites PGH2 and PGG2. The subsequent fate of the metabolites depends on 
the relative abundance of particular PG synthase enzymes in the specific cell or 
tissue. In the case of the endothelium PGI2 synthase is abundant, hence PGI2 is 
the predominant prostaglandin released by the endothelium. Once released PGI2 
acts directly on VSM to induce vasodilation. In addition it inhibits VSM 
proliferation and opposes the platelet aggregatory action of thromboxane A2, 
another prostaglandin family member, released predominantly from platelets. 
PGI2 acts on VSM via the IP receptor, a membrane associated G-protein receptor. 
Activation of the receptor and release of GTP activates adenylate cyclase and 
increases intracellular levels of cyclic adenosine monophosphate (cAMP). cAMP 
inhibits myosin light-chain kinase and therefore causes vasodilation in addition to 
other anti-inflammatory and anti-aggregatory roles.  
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iii) Endothelin 
In addition to endothelium dependent relaxation, it had been observed that 
vasoconstriction to various stimuli including noradrenaline and hypoxia was also 
dependent on an intact endothelial layer. Search for a soluble ‘constrictor’ factor 
led to the discovery of endothelin (ET), as a purified peptide from the 
supernatants of porcine aortic endothelial cells (Yanagisawa, Kurihara et al. 
1988). There are three identified isoforms of ET: ET1, ET2 and ET3, with 
discernable structural differences, although all three are extremely potent 
vasoconstrictors. ETs are formed by the activity of endothelin converting 
enzymes in endothelial cells and act on two specific G-protein coupled ET 
receptors, ET-A and ET-B. ET-A receptors are located on VSM cells and induce 
contraction after ET binding. Activation of ET-B receptors also induce contraction 
in VSM but conversely on endothelial cells they induce NO release and 
vasodilation. 
The overall regulation of vessel tone depends on the balance of the various vasodilator and 
vasoconstrictor mediators including NO, PGI2 and ET, as well as systemic neurohumoural 
regulation with for example nor-adrenaline and vasopressin. Disruption of this fine balance 
in disease leads to vascular dysfunction. For example, in septic shock there is early 
downregulation of eNOS, with a loss of NO dependent vasodilatation (Zhou, Wang et al. 
1997), followed by iNOS dependent release of NO and potent vasodilation (MacMicking, 
Nathan et al. 1995; Wei, Charles et al. 1995). This is equally true in late haemorrhagic shock 
(Thiemermann, Szabo et al. 1993). In support of this, NOS antagonists such as L-NAME 
improve haemodynamic variables in patients with septic shock. Another well characterised 
example is that of ET predominance in Pulmonary Arterial Hypertension. These patients 
have higher levels of circulating ET-1 and have higher levels of ET-1 expression in their 
vessels. Accordingly effective therapies in Pulmonary Arterial Hypertension include PGI2 to 
oppose the effect of ET-1 and ET receptor antagonists such as Bosentan (Channick, 
Simonneau et al. 2001). 
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C) Regulation of coagulation 
In health, the endothelium plays a vital role in preventing the unwanted coagulation of 
blood within the vessel lumen. This is achieved by the release of anti-coagulant factors 
including anti-thrombin III, tissue-factor pathway inhibitor, and thrombomodulin. 
Thrombomodulin itself potentiates the anti-coagulant effect of Protein C (Rosenberg and 
Rosenberg 1984). When damaged the endothelium becomes pro-coagulant to aid 
haemostasis. This involves pro-coagulant factors such as Tissue factor and the aggregation 
of platelets to damaged endothelium to begin the formation of the early blood clot. 
Thrombin itself may directly interact with receptors on the endothelium such as protease-
activating receptor 1 to increase the formation of fibrin and accelerate the coagulation 
cascade.  
D) Interaction with leukocytes 
Another crucial function of the endothelium is the attraction, adhesion and trafficking of 
leukocytes to areas of tissue inflammation in order to facilitate the immune response. 
Endothelial cells express cell surface proteins which mediate a reproducible series of actions 
to achieve this. Early leukocyte-endothelial interaction is governed by the selectins (E and L 
selectin) (McEver, Moore et al. 1995), whereas later firm adhesion and rolling across the 
lumina, surface is governed by integrins and the intercellular adhesion molecule and 
vascular adhesion molecule immunoglobulin family members (Springer 1995). Endothelial 
cells also participate in adaptive immunity, for example by expressing major 
histocompatibility complex proteins and presenting antigen to circulating lymphocytes. 
Significant upregulation of the selectins, and other adhesion molecules are seen in 
pathological states including sepsis (Sessler, Windsor et al. 1995) and may contribute to 
leukocyte mediated tissue damage. 
1.8.3 Function of the vascular smooth muscle 
As described above the medial layer of the blood vessel is predominantly formed of VSM. 
The crucial function of the VSM layer is to provide variable vascular tone in order to ensure 
regulated blood flow to the major organs and extremities. As already discussed the 
endothelium exerts control over the smooth muscle layer via the release of vasoactive 
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mediators including NO and PGI2. In addition the smooth muscle layer is innervated by the 
sympathetic nervous system via the adrenergic receptors. α1 and α2 receptors mediate 
vasoconstriction in response to noradrenaline whilst β2 receptors have a vasodilatory effect. 
The predominant vasoconstrictive effect of noradrenaline (via α receptors) has long been 
used clinically in the treatment of septic shock (Desjars, Pinaud et al. 1987) whilst 
pharmacological antagonism of α receptors with for example clonidine and  doxazosin, is 
used to treat hypertension. However the VSM is not only a passive responder to vasoactive 
mediators released from other cells. Early work with rats demonstrated that LPS could 
induce vasodilation and  NO release in endothelium denuded aorta and VSM cells even 
though these cells do not constitutively release NO (Rees, Cellek et al. 1990; Fleming, Gray 
et al. 1991). Thus VSM is itself capable of responding to PAMPs and whole bacteria 
(Jimenez, Belcher et al. 2005; Cartwright, McMaster et al. 2007) and may therefore play a 
more active role in pathogen induced vascular inflammation. Equally, airway smooth muscle 
cells have been demonstrated to release inflammatory mediators including CXCL8, CXCL6 
and Eotaxin and are thought to play an important role in the pathogenesis of airway 
diseases including asthma and COPD (Howarth, Knox et al. 2004). 
1.8.4 Primary Inflammatory mediators measured in thesis  
Given the important roles described for both endothelium and VSM in vessel responses to 
PAMPs I have studied both cell types in this thesis. My choice of ‘readouts’ of vascular 
activation include important mediators of vessel function described above. These include 
NO and PGI2, which as I have described, are known to be induced by PAMPs including LPS 
and have profound effects on vessel tone. NO release appears less avid in human cells 
(Padgett and Pruett 1992; Albina 1995), so for human vascular cell lines the chemokine 
CXCL8 has been measured in addition to PGI2. Chemotaxis refers to the movement of 
immune effector cells, including neutrophils to sites of infection and injury, which as 
described earlier in this chapter is a key feature of the inflammatory response. Immune cells 
move down a chemokine concentration gradient to reach target tissues. CXCL8 (formerly 
interleukin-8) was the prototypic human chemokine and was discovered over 20 years ago 
(Yoshimura, Matsushima et al. 1987). CXCL8 is principally a neutrophil chemoattractant with 
additional actions including induced conformational change of neutrophils, expression of 
cell surface adhesion molecules to encourage neutrophil binding to the endothelium, and  
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promotion of the neutrophil respiratory burst (Baggiolini and Clark-Lewis 1992). Crucially, 
CXCL8 is a highly inducible gene. From undetectable basal levels, expression can be up-
regulated over 100-fold by stimulants including other inflammatory cytokines (e.g. TNF, IL-
1β) (Kasahara, Mukaida et al. 1991), bacteria (Aihara, Tsuchimoto et al. 1997; Hobbie, Chen 
et al. 1997) and viruses (Mastronarde, Monick et al. 1998). Thus CXCL8 is an ideal mediator 
to enable study of inflammatory responses in vascular cells, particularly as there is ample 
evidence in the literature for inducible CXCL8 release in both endothelial cells (Yoshida, Ono 
et al. 1997) and smooth muscle cells (Zhu, Bradbury et al. 2003). Moreover CXCL8 is 
implicated in human disease including sepsis (Kern, Heiss et al. 2001) and inflammatory lung 
disease (Ordonez, Shaughnessy et al. 2000).  
In terms of signalling, the induction of CXCL8 involves pathways common to the 
downstream events following TLR and NOD stimulation. A body of evidence suggests that 
NFκB is a key transcription factor mediating CXCL8 expression. NFκB binding elements are 
present in the CXCL8 gene promoter region have been shown to be essential for IL-1 
mediated CXCL8 release (Mukaida, Morita et al. 1994) and direct binding of NFκB to the 
CXCL8 promoter has been demonstrated by chromatin immunoprecipitation (Hoffmann, 
Dittrich-Breiholz et al. 2002). In addition the transcription factors AP-1 and CAAT/enhancer 
binding protein (C/EBP) also has a role in CXCL8 expression implicating MAPK members 
including ERK and JNK which signal upstream of AP-1 (Hoffmann, Dittrich-Breiholz et al. 
2002).  Post-translational modification of CXCL8 is also of potential importance and there is 
evidence for a role of p38MAPK in this regard (Winzen, Kracht et al. 1999). The schematic 
illustrates major signalling pathways involved in the release of key inflammatory mediators 
described in this thesis (Figure 1.10). 
61 
 
 
Figure 1.10: Overview of signalling events for induction of iNOS and CXCL8 by inflammatory 
stimuli (in this case LPS). 
To provide a broader overview of inflammatory activation in the human vasculature, results 
seen with CXCL8 have in certain experiments been supported by measurement of NFκB 
activity and induction of multiple inflammatory mediators both at the gene and protein 
level. 
1.8.5 Activity of PRRs in blood vessels 
TLR4 
Although it is more typical to consider pathogen-host interactions in the context of 
‘professional immune cells’ such as macrophages it is clear that vascular cells express PRRs 
and that these PRRs have a potentially important role in vascular inflammation. In the case 
of the TLRs much of the data in the literature concerns TLR4. It is well established that the 
TLR4 ligand LPS induces vasoactive enzymes in blood vessels including NO and COX-2 
(Knowles, Salter et al. 1990; Radomski, Palmer et al. 1990; Bishop-Bailey, Larkin et al. 1997). 
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In addition, given the long association between inflammation and the development of 
atherosclerosis, there has been considerable interest in TLRs, including TLR4, as possible 
mechanisms of early disease progression. This rationale was supported by studies revealing 
low grade endotoxaemia as an independent risk factor for atherosclerosis (Wiedermann, 
Kiechl et al. 1999) and by the demonstration that LPS could induce atherosclerosis in 
hypercholesterolaemic rabbits (Lehr, Sagban et al. 2001). In a wider context this research 
could potentially link to the observation that chronic infection itself was linked to 
atherosclerosis, particularly with bacteria such as Chlamydia Pneumoniae (Saikku, Leinonen 
et al. 1988; Kuo, Shor et al. 1993).  
Direct evidence for the role of TLRs in vascular inflammation and atherosclerosis has begun 
to emerge. Expression of TLR4, together with TLRs 1 and 2 is highly upregulated in 
atherosclerotic plaques (Xu, Shah et al. 2001; Edfeldt, Swedenborg et al. 2002), whilst 
several mediators implicated in atherogenesis utilise TLR4 signalling pathways including 
heat-shock protein 60 (HSP60) (Sasu, LaVerda et al. 2001) and inflammatory lipoproteins 
such as minimally-modified LDL (Walton, Hsieh et al. 2003). Supportive evidence has come 
from studies in TLR4 knock-out mice. Deficiency of the essential TLR adaptor molecule 
MyD88, but not the TLR4 co-receptor CD14,  markedly reduced early atherosclerotic plaque 
formation in non-infected, hyperlipidaemic mice, with reduction in macrophage recruitment 
to the vessel wall and reduced chemokine secretion (Bjorkbacka, Kunjathoor et al. 2004). 
Michelsen et al confirmed the effect of MyD88 deficiency on plaque formation whilst also 
demonstrating lack of atherogenesis in TLR4 deficient mice (Michelsen, Wong et al. 2004). 
The above in vitro and in vivo findings have to some extent been supported by 
epidemiological data in patients with TLR4 polymorphisms. The Asp299Gly mutation of TLR4 
has been described earlier in this text and confers hyporesponsiveness to LPS. Various 
studies have linked the Asp299Gly mutation to reduced risk of atherosclerosis, including 
that of the carotid artery, as well as a reduced rate of acute coronary events (Kiechl, Lorenz 
et al. 2002; Ameziane, Beillat et al. 2003). However there is contrasting evidence in studies 
where the Asp299Gly mutation either offered no reduction in atherosclerosis risk (Yang, 
Holloway et al. 2003) or a paradoxical increased risk of coronary events (Edfeldt, Bennet et 
al. 2004). More recent prospective studies have also failed to confirm the epidemiological 
association between TLR polymorphisms and the risk of atherogenesis (Morange, Tiret et al. 
63 
 
2004; Labrum, Bevan et al. 2007), thus the true role of TLR4 in chronic vascular 
inflammation remains elusive.  
Bacterial infection may also play a role in the development of cardiac failure. There is 
evidence that Gram negative bacteria such as E Coli may increase the population of non-
contractile cardiac myocytes via TLR4 (Patel, Belcher et al. 2007). Intriguingly work in human 
embryonic stem cell derived endothelial cells has suggested relative deficiency in TLR4 
signalling compared to primary human endothelial cells (Foldes, Liu et al. 2010). This may 
have therapeutic implications if these cells are used clinically. 
NLRs 
In contrast to TLR4, the role of the NLRs including NOD1/2 in vascular inflammation has 
been relatively unexplored. Evidence for a putative role of NODs in vascular inflammation 
has emerged from data concerning the response of human endothelial cells to the 
intracellular pathogens Chlamydia Pneumonia (implicated in atherogenesis as described 
above) and Listeria monocytogenes. In both cases inflammatory responses to the bacteria 
have been shown to be NOD1 dependent, as determined by small interfering RNA (siRNA) 
techniques (Opitz, Forster et al. 2005; Opitz, Puschel et al. 2006). Work in our own group 
focussed on the potential role of NOD1 in driving vascular inflammation and dysfunction 
both in vitro and in vivo. Administration of the specific NOD1 ligand FK565 was shown to 
induce iNOS in rat VSM cells and to promote vasodilation of rat aorta ex vivo, with 
resistance to vasopressors agents. In addition, when given in vivo, FK565 induced vasoplegic 
shock and end-organ injury (Cartwright, Murch et al. 2007). Intriguingly despite the 
profound induction of vascular shock seen with FK565, there was little impact on neutrophil 
ingress into the lung compared to LPS suggesting a predominant vascular effect of the NOD1 
ligand. Thus, NOD1 appears to be an important pathway for vascular inflammation (certainly 
in the rat), which provided the rationale for further characterisation of the mechanisms of 
NOD1 signalling in blood vessels in this study. During the course of my PhD further 
publications have highlighted the potential importance of NLR mediated vascular 
inflammation. Nishio and colleagues examined the role of FK565 in the induction of site 
specific vascular inflammation in mice. They found that oral administration of FK565 
induced specific inflammation in the aortic root, with evidence for significant up-regulation 
of inflammatory cytokine and matrix metallopeptidase genes (Nishio, Kanno et al. 2011). 
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Finally, in a key paper, the NLRP3 inflammasome has been implicated in the very earliest 
stages of atherogenesis, by detection of cholesterol microcrystals in the forming plaque. 
This raises the exciting possibility that NLR biology could lie at the heart of chronic, as well 
as acute pathogen driven vascular inflammation and therefore be a molecular target for 
new therapies.  
1.9 PRRs as therapeutic targets 
The discovery of PRRs as the sentinels of the innate immune system and regulators of 
adaptive immunity has presented the opportunity to develop new therapies to combat 
inflammatory and infectious disease. It is fair to say that this field is still very much in its 
infancy and that therapeutic advances may have to wait until the complex interplay 
between pathogen and PRR, PRR and PRR, and overlapping metabolic pathways is further 
unravelled. If we return to the thought experiment of Charles Janeway and ‘the 
immunologist’s dirty little secret’ it is clear that a major area of PRR related therapy is that 
of vaccine adjuvancy. Some former established adjuvants have now been demonstrated to 
contain PRR stimulating compounds. For example the NOD2 agonist MDP is the major 
immunogenic component of the potent Complete Freund’s Adjuvant (Lederer 1986). The 
use of PRR ligands as adjuvants in new vaccine design is ongoing. There are several 
examples of promising animal models with multiple PRR ligands including TLR2 (Latz, Franko 
et al. 2004), TLR5 (Huleatt, Jacobs et al. 2007), and TLR7/8 (Wille-Reece, Flynn et al. 2005). 
In a related fashion PRR ligands have been investigated as potential adjuvants in tumour 
vaccines as well as direct anti-cancer agents. This is a potentially exciting field as TLR ligands 
induce maturation of dendritic cells and other antigen presenting cells leading to the 
expansion of tumour suppressor T-cells (Iwasaki and Medzhitov 2004), although phase III 
trials of TLR ligand adjuvants against tumours are yet to show convincing results. As direct 
anti-tumour agents however, TLR ligands have entered clinical practise. A well known 
example is that of Bacillus Calmette-Guerin (BCG), the anti-tuberculous vaccine. This 
contains ligands for TLR2, 4 and 9 and is a licensed and highly effective therapy for intra-
vesical cancer, in which it is associated with production of multiple inflammatory cytokines 
(Jackson, Alexandroff et al. 1995). Another licensed TLR agonist is the TLR7 agonist 
Imiquimod. This is a highly effective topical therapy against superficial basal cell carcinomas 
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(Geisse, Caro et al. 2004) with evidence of some efficacy against melanoma (Bong, 
Bonnekoh et al. 2002).  
The approaches described above utilise the pro-inflammatory properties of the PRR ligands 
to either amplify vaccine responses of have direct cytotoxic effects. However it is appealing 
to postulate that inhibition of specific PRR responses could be beneficial in relevant 
inflammatory diseases. Given the potent inflammatory response induced by endotoxin, 
TLR4 remains an attractive target for anti-inflammatory therapy, particularly in the field of 
sepsis. TLR4 antagonists have indeed been developed and trialled in the arena of sepsis. 
Eritoran, a Lipid A analogue which competitively inhibits the TLR4 receptor, was suggested 
to reduce mortality in severely ill patients with sepsis in Phase II trials (Tidswell, Tillis et al. 
2010), however convincing clinical effect has not been demonstrated in later Phase III 
studies (Barochia, Solomon et al. 2011). It is clear that care must be taken with any drugs 
designed to inhibit PRR responses due to the potential risk of uncontrolled pathogen 
dissemination. 
1.10 Summary 
The preceding introduction has emphasised the burden of disease attributable to pathogens 
including acute illness such as pneumonia and septicaemia, together with influences on 
chronic diseases such as atherosclerosis. The discovery of the PRRs has opened up a new 
paradigm in which to understand the mechanisms by which pathogens interact with host 
tissues and modulate immune responses. Indeed research in this field is attractive for drug 
development and has already led to the development of specific therapies such as 
Imiquimod for the treatment of basal cell carcinoma. It is clear that blood vessels important 
sites of pathogen-host interaction and evidence has been discussed linking PRR biology to 
vascular inflammation. Whilst a good deal of research has addressed the role of TLR4 in 
blood vessels, much less is known about the role of the NLRs. However, previous work in our 
group has identified NOD1 as a potentially important inflammatory pathway in animal 
models of vascular inflammation. Therefore a more detailed understanding of NOD1 activity 
in vascular tissue, including translation into the human vasculature may improve our 
understanding of pathogen mediated vascular dysfunction, and may also reveal new 
therapeutic targets in related disease states. 
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Hypothesis: 
NOD1 represents an important receptor driving pathogen dependent vascular inflammation. 
Characterisation of NOD1 signalling in vascular cells and translation into human tissue may 
offer new therapeutic targets in human disease. 
Specific aims of thesis: 
A) Further characterisation of NOD1 ligand signalling in rodent vascular smooth muscle 
cells versus responses in macrophages, with comparison to TLR4 ligand responses. 
B) Exploration of NOD1 versus TLR4 ligand responses in whole vessel, including 
investigation of the role of the endothelium, and translation into human blood 
vessel. 
C) Translation of NOD1 responses to primary human cell lines, including comparison 
between endothelium, vascular smooth muscle and monocytic cells.  
D) Pharmacological investigation of NOD1 versus TLR4 signalling pathways in primary 
human cells to include profiling of novel specific inhibitors of the NOD pathway. 
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Chapter 2 
Methods 
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2.1 Reagents 
NOD1/2 receptor agonists and rationale for use 
The nucleotide oligomerisation domain-1 (NOD1) stimulatory acrylopeptide FK565 
(heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine) was obtained from 
Fujisawa Pharmaceutical (Japan). The NOD1 agonists iE-DAP (γ-D-glutamyl-meso-
diaminopimelyl-D-alanine), M-Tri-DAP (N-acetyl-muramyl-L-Ala-γ-D-Glu-meso-
diaminopimelyl-D-alanine) and C12-iE-DAP (Lauroyl-γ-D-glutamyl-meso- diaminopimelyl-D-
alanine) were from Invivogen (USA). The NOD2 agonist MDP (N-Acetylmuramyl-L-Alanyl-D-
Isoglutamine) was also from Invivogen (USA). 
FK565 represents an older immune stimulating peptide, the actions of which were later 
demonstrated to be mediated by NOD1 (Uehara, Yang et al. 2005). FK565 has previously 
been used in the group in order to study NOD1 responses (Cartwright, Murch et al. 2007) 
and was included in this thesis for proposes of comparison to newer commercial NOD1 
agonists. The commercial NOD1 agonist C12-iE-DAP has been reported to display increased 
cell membrane permeability and potency over that of iE-DAP (which itself represents the 
minimal structure which is able to stimulate NOD1) (Chamaillard, Hashimoto et al. 2003; 
Lee, Tattoli et al. 2009). This is by virtue of the addition of a lipophilic lauroyl group. 
Accordingly C12-iE-DAP was used in all organ culture experiments with the aim of achieving 
maximal NOD1 stimulation across the different cell layers. Similarly C12-iE-DAP was used in 
experiments studying nuclear translocation of nuclear factor kappa-B (NFκB) at an early 
time point, due to its relatively rapid onset of NOD1 stimulation. FK565, C12-iE-DAP and iE-
DAP were used to study cell signalling in rodent cells. As a pure, unmodified NOD1 agonist, 
iE-DAP was used in the majority of cell signalling work in human cells but comparisons were 
made to the action of C12-iE-DAP to ensure consistency.  
TLR agonists  
The Toll-like receptor 4 (TLR4) agonist lipopolysaccharide (LPS) was obtained from a culture 
of Escherichia Coli (E Coli) (Sigma Aldrich, UK). All other TLR agonists used were from 
Invivogen (USA), including the TLR 1/2 agonist Pam3CSK4 (Ozinsky, Underhill et al. 2000), 
the TLR2 agonist Heat Killed Listeria monocytogenes (HKLM) (Flo, Halaas et al. 2000), the 
TLR3 agonist Polyinosinic-polycytidylic acid (poly(I:C)) at both high molecular weight (Poly 
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(I:C) HMW) and low molecular weight (Poly (I:C) LMW) (Alexopoulou, Holt et al. 2001; 
Matsumoto, Kikkawa et al. 2002), the TLR4 agonist LPS-EK from E Coli K12 (standard purity 
therefore containing lipoproteins with some TLR2 activity), the TLR5 agonist flagellin (from 
Salmonella typhimurium) (Hayashi, Smith et al. 2001), the TLR2/6 agonist FSL-1 
(Pam2CGDPKHPKSF) (Takeuchi, Kawai et al. 2001), the TLR7 agonist Imiquimod (Lee, Chuang 
et al. 2003), the TLR8 agonist ssRNA40 (complexed with the cationic lipid LyoVec™) (Heil, 
Hemmi et al. 2004) and the TLR9 agonist ODN 2006 (Type B CpG oligonucleotide) (Bauer, 
Kirschning et al. 2001). 
Preparation of heat-killed bacteria 
Heat-killed E Coli was prepared as previously described (Cartwright, McMaster et al. 2007). 
Briefly E Coli 0111.B4 was obtained from a clinical blood culture isolate and stored frozen in 
15% glycerol. To culture, E Coli was streaked onto agar plates from which single colonies 
were isolated and inoculated into RPMI-1640 medium with 10% foetal calf serum (FCS) and 
glutamine. Cultures were incubated at 370C overnight before they were centrifuged at 800 x 
g to pellet the bacteria. The bacterial pellet was washed twice and then re-suspended in 
sterile non-pyrogenic saline (0.9% weight/volume). Aliquots of the bacterial suspension 
were serially diluted and plated onto agar in order to quantify the cell density. The bacterial 
suspensions were then heat treated for 4 min at 700C to kill all bacteria. Sterility was 
confirmed by plating of the resultant suspension. Suspensions were adjusted to 1010 – 1012 
colony forming units per ml (CFU/ml) and stored frozen at -200C in 0.9% saline containing 
15% glycerol. 
Drugs 
All drugs described in this thesis were dissolved in either culture medium or dimethyl 
sulfoxide (DMSO). In those drugs dissolved in DMSO a final concentration of 0.1% v/v was 
used and maintained for all subsequent drug dilutions. In addition in those protocols where 
DMSO was used as a solvent the non-treated (CTRL) wells were made up to 0.1% DMSO in 
medium. Drugs were added to cells or tissues 30 min prior to addition of bacterial ligands or 
cytokines as described in the individual results chapters. 
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The inhibitor of NFκB kinase subunit beta (IκBβ) inhibitor SC-514, transforming growth 
factor β activating kinase (TAK1) inhibitor 5Z-7-oxozeaonol and the pan-caspase inhibitor Z-
VAD-fmk were from Tocris Bioscience (UK) and the inducible nitric oxide synthase (iNOS) 
inhibitor 1400W from Cayman Chemical (USA). The cell-permeable JNK peptide inhibitor D-
JNKi was purchased from EnzoLifeSciences. The p38 mitogen activating kinase (p38 MAPK) / 
receptor interacting protein 2 (RIP2) inhibitor SB203580, the C-jun activating kinase (JNK) 
inhibitor VI, TI-JIP153-163, the Protein kinase C (PKC) inhibitor KbNB-142-70 and the receptor 
interacting protein 2 (RIP2) / Src kinase inhibitor PP2 were from Merck (Germany). The 
corticosteroid dexamethasone was from Sigma (UK) and the p38 MAPK inhibitor BIRB0796 
and the extracellular growth factor regulating kinase (ERK) inhibitor PD184352 from 
Axonmedchem (Netherlands). 
Novel inhibitors to RIP2 (GSK’214) and NOD1 (GSK’217) were a kind gift from Dr John Bertin, 
from the Pattern Recognition Receptor DPU, GlaxoSmithKline (USA). 
2.2 Cell culture 
2.2.1 Vascular Smooth Muscle Cells  
Clonal populations of rat vascular smooth muscle cells (VSM) grown from balloon injured 
carotid artery were kindly provided by Professor Timothy Warner, from the William Harvey 
Research Institute, London, UK). Briefly, mixed populations of VSM cells were grown by 
explantation from the hyperplastic region of a balloon injured carotid artery. Single cell-
derived individual colonies with uniform appearance were surrounded by cloning rings, 
released with trypsin and expanded. Cells were characterised by their phenotypic 
appearance. Two phenotypes emerged: a spindle-shaped ‘contractile’ cell type, consistent 
with healthy VSM, and an epithelioid-shaped ‘secretory’ cell type, consistent with 
proliferative, neo-intimal VSM. For this work, as described previously (Jimenez, Belcher et al. 
2005), VSM clones of the contractile phenotype were used.  Cell cultures were maintained 
in 175cm2 sterile cell culture flasks with Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 10% heat- inactivated foetal calf serum (FCS), L-glutamine (L-Glut) 
(2mM), streptomycin (Strep) (100μg/mL), penicillin (Pen) (100 U/mL), and 1% vol/vol 
100xMEM non-essential amino acids (NEAA) containing L-Alanine, L-Asparagine, L-Aspartic 
acid, L-Glutamic acid, Glycine, L-Proline and L-Serine) (GIBCO Life Technologies, UK).  Cells 
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were grown at 37oC in 5% CO2 and cells between passage 3 and 10 were used for 
experiments. Confluent cell monolayers were washed twice with phosphate buffered saline 
(PBS), without calcium or magnesium, followed by the addition of trypsin EDTA (0.5% 
trypsin, 0.2% EDTA) in PBS. Cells were returned to the incubator for approximately 5 min 
until the cells became free floating. The trypsin was then inactivated by the addition of an 
equal volume of DMEM supplemented with 10% FCS. The cell suspension was transferred to 
a 50ml falcon tube and centrifuged at 190 x g for 5 minutes at room temperature. The cell 
pellet was resuspended in 10mls of medium and cell density was calculated using a 
haemocytometer. For experimentation cells were plated into 6 or 96 well plates at a density 
of 500,000 and 25,000 cells per well respectively in DMEM with 10% FCS for 24 hours. At 
this point the media was replaced with fresh DMEM with 10% FCS containing treatments as 
per the selected experimental protocol.  
2.2.2 Human Pulmonary Artery Smooth Muscle Cells 
Human pulmonary artery smooth muscle cells (HPASM), from 4 donors, were obtained by 
outgrowth from donor tissue by collaborators within the NHLI using methods described 
previously (Wort, Woods et al. 2002; Wort, Ito et al. 2009). Human pulmonary artery 
specimens were previously obtained from healthy segments of lung from patients 
undergoing lung resection at the Royal Brompton and Harefield NHS Foundation Trust 
(Research Ethics Committee study number 02-081, sub-amendment 3). Briefly, under sterile 
conditions, the adventitia and endothelium were removed, and the specimens were cut into 
3-4mm2 segments and placed in sterile tissue culture flasks. Proliferating smooth muscle 
cells were subcultured in 75cm2 sterile flasks in DMEM supplemented with 15% FCS, L-glut, 
Pen-Strep and NEAA.  Confluent cell monolayers were washed twice with PBS, without 
calcium or magnesium, followed by the addition of trypsin EDTA (0.5% trypsin, 0.2% EDTA) 
in PBS. Cells were returned to the incubator for approximately 5 min until the cells became 
free floating. The trypsin was then inactivated by the addition of an equal volume of DMEM 
supplemented with 15% FCS. The cell suspension was transferred to a 50ml falcon tube and 
centrifuged at 190 x g for 5 minutes at room temperature. The cell pellet was resuspended 
in 10mls of medium and cell density was calculated using a haemocytometer. For 
experimentation cells between passage 4 and 9 were used. Cells were seeded in 6 or 96 well 
plates at a density of 1x105 and 8x103 cells/well respectively. 24 hours prior to treatment, 
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the medium was changed to serum free in order to synchronise growth phase. On the day of 
treatment the serum free medium was replaced with that containing 15% FCS and all other 
supplements as described above, along with relevant treatments to the specific 
experimental protocol. 
2.2.3 Human lung microvascular endothelial cells 
Microvascular endothelial cells from the human lung were purchased from 2 companies. 
Clonetics® ‘human lung microvascular endothelial cells’ (Lonza Walkersville, Inc. 
Walkersville, MD, USA) and ‘human pulmonary microvascular endothelial cells’ (PromoCell, 
Heidelberg, Germany). In each case these cells are defined as lung-derived endothelial cells 
from healthy donors. Two donor populations were used from each company (Table 2.1). No 
differences were observed between both sets of human lung microvascular endothelial cells 
and, therefore, they will be referred to as human lung microvascular endothelial cells 
(HMVEC) in this text. 
 
Donor Description 
1 (7F4273) (Lonza) 19 years old, male, non-smoker 
2 (6F3836) (Lonza) 41 years old, male, non-smoker 
3 (50401) (Promocell) 54 years old, male, non-smoker 
4 (0071604.9) (Promocell) 64 years old,  female, non-smoker  
 
 Table 2.1: Donor information for HMVEC purchased from Lonza (USA) or Promocell 
(Germany). 
 
In both cases cells were removed from cryogenic storage and defrosted in a water bath for 
less than 5 minutes. Cells were immediately transferred into a T-25 flask containing specific 
endothelial cell media provided by each company (Table 2.1). Upon reaching confluence 
cells were washed in HEPES buffered solution (200-400µl per cm2 flask area). Trypsin/EDTA 
(100µl per cm2 flask area) was then added to the cells for 2-5min. Once the cells had 
detached from the flask an equal volume of trypsin neutralising solution was added. The cell 
suspension was transferred to a 50ml falcon tube and centrifuged at 200 x g for 5 minutes. 
The cell pellet was resuspended in 1ml medium and cell density was calculated using a 
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haemocytometer. For continued growth, cells were transferred to fresh flasks at a density of 
6.25 x104 to 1.25x105 (T-25 flask), 1.875 x105 to 3.75 x105 (T-75 flask) and 4.375 x105 to 
8.75x105 (T-175 flask). For experimentation HMVEC between passage 4 and 9 were used. 
Cells were seeded in 6 or 96 well plates at a density of 1x105 and 7x103 cells/well 
respectively for 24 hours. No significant difference was seen to agonist responses if the cells 
were placed in steroid free medium 48 hours prior to experimentation so experiments used 
fully supplemented medium. On the day of treatment medium was replaced with fresh 
medium containing drugs/ligands as per the specific experimental protocol. 
2.2.4 Human aortic endothelial cells 
Human aortic endothelial cells were purchased from Lonza (USA). Cells from one donor 
were used (4F1523, 40 years old, female, non-smoker). Cells were removed from cryogenic 
storage and defrosted in a water bath for less than 5 minutes. Cells were immediately 
transferred into a T-25 flask containing specific endothelial cell media (Table 2.1). Upon 
reaching confluence cells were washed in HEPES buffered solution (200-400µl per cm2 flask 
area). Trypsin/EDTA (100µl per cm2 flask area) was then added to the cells for 2-5 minutes. 
Once the cells had detached from the flask, twice the volume of trypsin neutralising solution 
was added. The cell suspension was transferred to a 50ml falcon tube and centrifuged at 
220 x g for 5 minutes. The cell pellet was resuspended in 1ml medium and cell density was 
calculated using a haemocytometer. For continued growth, cells were transferred to fresh 
flasks at a density of 6.25 x104 to 1.25x105 (T-25 flask), 1.875 x105 to 3.75 x105 (T-75 flask) 
and 4.375 x105 to 8.75x105 (T-175 flask). For experimentation HAEC were used at passage 6. 
Cells were seeded in 96 well plates at a density of 7x103 cells/well for 24 hours. On the day 
of treatment medium was replaced with fresh medium containing drugs/ligands as per the 
specific experimental protocol.  
2.2.5 Human umbilical vein endothelial cells 
Human umbilical vein endothelial cells (HUVEC) were kindly provided by Dr Caroline 
Wheeler-Jones at the Royal Veterinary College, London. Cells were used from three donors. 
Cells were provided as a confluent monolayer in a T75 flask containing M199 media (Sigma) 
supplemented with 20% FCS, Pen/Strep, L-Glut, endothelial cell growth supplement (19 
µg/ml; Sigma) and heparin (46 µg/ml; Sigma). Cells were maintained in a humidified 
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incubator at 370C containing 5% CO2. Prior to passage or plating of these cells, flasks and 
plates were coated for 30 minutes with 1% gelatin (Sigma), and then washed twice in sterile 
PBS. Subsequently, confluent cell monolayers were washed twice with PBS, without calcium 
or magnesium, followed by the addition of trypsin EDTA (0.5% trypsin, 0.2% EDTA) in PBS. 
Cells were returned to the incubator for approximately 5 minutes until the cells became free 
floating. The trypsin was then inactivated by the addition of twice the volume of DMEM 
supplemented with 10% FCS. The cell suspension was transferred to a 50ml falcon tube and 
centrifuged at 190 x g for 5 minutes at room temperature. The cell pellet was resuspended 
in 10mls of medium and cell density was calculated using a haemocytometer. For 
experimentation HUVEC between passages 3 and 4 were used. Cells were plated into 96 
well plates at a density of 10,000 cells per well in M199 supplemented as described for 24 
hours. At this point the medium was replaced with fresh medium containing treatments as 
per the selected experimental protocol.  
Endothelial cell subtype Media Supplements 
HMVEC (Lonza) EBM-2 basal medium (Lonza) 
 
EGM-2 MV SingleQuots (Lonza) 
containing  25mls FBS (5%), 0.5ml 
hEGF, 2.0ml hFGF-B. 0.5ml VEGF, 
0.5ml ascorbic acid, 0.2ml 
hydrocortisone, 0.5ml Long R3-IGF-1, 
0.5ml heparin and 0.5ml 
gentamycin/amphotericin  
HMVEC (Promocell) Endothelial Cell Growth  
Medium-MV2  (Promocell) 
5%  FCS, EGF 5ng/ml, FGF 10ng/ml, 
Long R3 IGF-1 20ng/ml, VGEF 
0.5ng/ml, Ascorbic acid 1µg/ml and 
hydrocortisone 0.2 µg/ml 
HUVEC Medium 199 (Sigma) 20% FCS, EGF, Pen-Strep and heparin 
45µg/ml 
HAEC EBM-2 basal medium (Lonza) EGM-2 SingleQuots (Lonza). As for 
EGM-1 MV but only 10mls FBS (2%). 
 
Table 2.2: Cell culture media and supplements used for various endothelial cell subtypes. 
2.2.6 J774.2 murine macrophages 
J774.2, a murine macrophage cell line, was obtained from the European Collection of Cell 
Cultures (ECACC). Cells were removed from cryogenic storage and defrosted in a water bath 
for less than 5 min. Cells were immediately transferred into a T-75 flask containing DMEM 
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with 10% FCS, Pen/Strep, L-Glut and NEAA. Cells were maintained in a humidified incubator 
at 370C containing 5% CO2. Once confluent J774.2 cells were passaged as follows: as only 
lightly adherent the cells were gently detached from the flask using a cell scraper. The 
resulting cell suspension was transferred to a 50ml falcon tube and centrifuged at 190 x g 
for 5 min. The cell pellet was resuspended in 10ml medium and cell density calculated using 
a haemocytometer. For experimentation J774.2 cells were seeded in 6 or 96 well plates at a 
density of 1x106 and 1x105 cells/well respectively for 24 hours. On the day of treatment 
medium was replaced with fresh DMEM supplemented as above, containing drugs/ligands 
as per the specific experimental protocol. 
2.2.7 THP-1 monocytic cells 
The human acute monocytic leukemia (THP-1) cell line was obtained from the European 
Collection of Cell Cultures (ECACC). Cells were removed from cryogenic storage and 
defrosted in a water bath for less than 5 minutes. Cells were immediately transferred into a 
falcon tube containing 50mls of pre-warmed RPMI 1640 medium supplemented with 10% 
FCS, Pen/Strep and L-Glut. The tube was centrifuged at 190 x g for 5 minutes and the 
supernatant discarded. The cell pellet was resuspended in 25mls fresh medium and 
transferred to a T175 flask. Cells were maintained in a humidified incubator at 370C 
containing 5% CO2 and at a cell density of 3-9 x 10
5 cells per ml. As THP-1 cells are non-
adherent they were passaged as follows: the cell suspension was transferred to a 50ml 
Falcon tube and centrifuged at 190 x g for 5 minutes. The cell pellet was resuspended in 
10ml medium and cell density calculated using a haemocytometer. For experimentation 
THP-1 cells were seeded in 96 well plates at a density of 1x105 cells/well for 24 hours. On 
the day of treatment medium was replaced with fresh medium supplemented as above, 
containing drugs/ligands as per the specific experimental protocol. 
2.2.8 Peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMCs) were obtained from 14 healthy donors. Blood 
was collected from healthy male and female volunteers (South East London Research Ethics 
Committee reference 08/H0805/58) into sodium citrate (Sigma) in a ratio of 1:9 sodium 
citrate:blood, according to the manufacturer’s instructions. A second 10ml blood sample 
was taken from each patient and allowed to coagulate in a refrigerator so that autologous 
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serum could be obtained. Prior to blood collection, 3mls of Histopaque1077 (Sigma H8889) 
was added to separate 15 ml centrifuge tubes. The non-coagulated blood was diluted 1:1 
with RPMI 1640 medium (Sigma). 6 ml of the diluted blood was then layered on top of the 
prepared Histopaque and the tubes were centrifuged at 400 x g (with a very low brake) for 
30 minutes at 22ºC. Following centrifugation the PBMC layer, lying between the Histopaque 
and plasma layers (‘Buffy Coat’), was carefully aspirated with a Pasteur pipette. Up to 7mls 
of PBMC were transferred to new 15ml centrifuge tubes and made up to 14mls with fresh 
RPMI 1640 medium. The tubes were then centrifuged at 200 x g for 15 minutes to discard 
any remaining Histopaque, and the supernatants discarded. The cell pellets were pooled 
into a 50 ml falcon tube with 20 ml of fresh RPMI and centrifuged again at 200 x g for 15 
minutes at 22ºC for a final wash. Autologous serum was prepared by centrifuging the 
previously refrigerated blood at 1300 x g for 15 minutes at 40C. The layer of serum was then 
carefully removed from the top of the tube.  
The isolated PBMC were resuspended in RPMI 1640 media supplemented with 3% 
autologous serum, Pen/Strep, L-Glut and NEAA and cell density was assessed using a 
haemocytometer. In preparation for treatment, PBMCs were plated in 96 well plates at a 
density of 1x105 cells/well and incubated for 2 hours prior to addition of treatments. 
2.3 Organ Culture 
2.3.1 Rat aorta organ culture 
Rings from rat aortas were prepared as previously described (Bishop-Bailey, Larkin et al. 
1997). Briefly male Sprague-Dawley rats (250-450 g) were killed by cervical dislocation 
following isoflurane anaesthesia. The rats were maintained and killed in accordance with UK 
Home Office guidelines for the use of experimental animals. Aortas (thoracic and 
abdominal) were immediately removed and placed into sterile pots containing phosphate 
buffered saline (PBS) supplemented with penicillin (1000 U/ml) and streptomycin (1 mg/ml) 
(PBS; Pen-Strep). Vessels were stored at room temperature for less than 2 hours before 
preparation. For bioassay experiments vessels were dissected clean of connective tissue 
under sterile conditions then washed 3 times in PBS; Pen-Strep to remove any adherent 
blood clots. Vessels were then cut into rings of approximately 2-3 mm width. Depending on 
protocol some of the rings had the endothelium mechanically disrupted by gentle rolling on 
sterile forceps. Individual rings were then placed into wells of sterile 96-well plates 
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containing 300 µl DMEM, supplemented with 10% FCS, L-Glut, Pen/Strep, amphotericin B 
(2.5µg/ml) and NEAA. Vessels were maintained in a humidified incubator at 370C in an 
atmosphere of 5% CO2. Vessels were left to equilibrate for 1 hour prior to replacement with 
medium containing drugs or vehicle. In selected experiments vessels were pre-treated for 
30 minutes with specific cell signalling inhibitors prior to addition of agonists. 
Medium was removed at 24 hours for analysis (24 hour time point); fresh medium with 
treatments was then added for a further 24 hour period (48 hours time point). Replicates 
from each individual donor were averaged to give one value for subsequent analysis.   
 
 
 
Figure 2.1: Example of aortic rings in organ culture in a 96-well plate. 
2.3.2 Human pulmonary artery organ culture 
Small segments of pulmonary artery were obtained from lung tissue surplus to diagnostic 
requirements following thoracic surgery at the Royal Brompton and Harefield NHS 
Foundation Trust, London, UK (Royal Brompton and Harefield local ethics committee, 
number 09/H0708172). Tissue from 8 donors was used (Table 2.3). Full informed written 
consent was obtained from all participants. The segments were dissected clean of 
connective tissue and washed 3 times in sterile PBS: Pen-Strep. The segments were carefully 
dissected into small pieces each approximately 2mmx2mm in surface area. The arterial 
pieces were then placed in individual wells of a 96 well plate in 300µl DMEM supplemented 
with 10% FCS, L-Glut, Pen/Strep, amphotericin B and NEAA. Vessels were maintained in a 
humidified incubator at 370C in an atmosphere of 5% CO2.  Vessel segments were left to 
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equilibrate overnight prior to replacement with medium containing drugs or vehicle. Vessels 
were treated for a total of 48 hours. Replicates from each individual donor were averaged to 
give one value per donor for subsequent analysis.   
 
Donor Age Sex Smoking status 
1 60 Female Ex-smoker 
2 55 Male Current smoker 
3 64 Female Ex-smoker 
4 81 Male Ex-smoker 
5 75 Female Current smoker 
6 79 Male Current smoker 
7 52 Male Non-smoker 
8 65  Male Current smoker 
 
Table 2.3: Donor information for pulmonary artery segments obtained from thoracic surgery 
at the Royal Brompton and Harefield NHS Trust, London, UK. 
2.4 Griess Assay 
Nitric oxide (NO) release by cells or vessels NO was measured by the accumulation of its 
oxidation product, nitrite using the Griess reaction. The reaction allows detection of organic 
nitrite compounds upon addition of the Griess reagent. The Griess reagent is a mixture of 
sulphanilic acid (which converts the nitrite compound into a diazonium salt) and an azo dye 
agent (which produces a pink colour) (Figure 2.2). The colour change in the presence of 
organic nitrite can be measured spectrophotometrically and compared to standard dilutions 
of sodium nitrite. 
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Figure 2.2: Schematic of the Griess reaction. 
The two components of the Griess reagent were prepared at least 24 hours prior to 
measurement of accumulated nitrite. Griess reagent 1 was prepared by adding 10g of 
sulphanilamide to 950ml distilled water and 50ml of phosphoric acid (H3PO4). Griess reagent 
2 was prepared by adding 5g of napthylethyl-endiamide dihydrochloride to 1L distilled 
water. The reagents were stored in separate light protective bottles at 2-80C for up to 1 
month. On the day of measurement, the required amount of Griess reagent was prepared 
by adding an equal amount of reagent 1 to reagent 2. This was prepared at least 10 minutes 
prior to use and protected from light. To prepare the nitrite standard curve a 100mM stock 
solution of Sodium Nitrite was prepared in culture medium (DMEM with 10% FCS, L-Glut, 
Pen/Strep and NEAA). The 100mM stock was then serially diluted in 2ml eppendorfs to 
provide 12 standards: 1mM, 500µM, 250µM, 125µM, 62.5µM, 31.25µM, 15.63µM, 7.82µM, 
3.91µM,  1.96µM, 1µM and 0 (just media alone). To measure nitrite 50μl of sample medium 
or standard was incubated with 50μl of the combined Griess reagents 1 and 2 for 5 minutes 
in 96 well plates. The resulting colour change was then measured by a Titertek Multiscan 
MCC/340 MK.II plate reader at a wavelength of 550nm. Under these conditions the 
detection limit of the Griess reaction was 1 nmol per ml. Unknown nitrite values in the 
samples were calculated by linear regression of the standard curve using computer software 
(Graphpad Prism version 5.0). Values below the minimum standard (1μM) were substituted 
to 1μM. The presence of extreme outlying values on each experimental day was assessed 
using Grubb’s score (Iglewicz and Hoaglin 1993) and excluded from subsequent analysis. A 
typical nitrite standard curve is shown (Figure 2.3).  
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Figure 2.3: Typical nitrite standard curve for Griess assay. 
2.5 Western Blot 
Expression of NOD1, iNOS and COX-2 proteins in cultured VSM cells and J774.2 
macrophages was measured by western blot as described below (Moreno, McMaster et al. 
2010).  
Protein extraction 
Cells were cultured in 6-well plates in medium alone or in medium + PAMPs or heat-killed E 
Coli for 24 hours. In preparation for protein extraction, homogenising buffer was made as 
follows: T-wash buffer was prepared by adding 1.86g EDTA (Sigma, UK) and 5ml Triton-X 100 
(Sigma, UK) to 495ml PBS. 100μl of 100mM PMSF (Sigma, UK) in DMSO and 1.5ml complete 
protease inhibitor cocktail (Roche, Switzerland) was then added to the T-wash buffer. To 
extract protein the cells were first washed three times in ice cold PBS to remove any trace of 
culture medium. 3 wells per experimental condition were pooled together for the purposes 
of protein extraction. Accordingly 100μl of homogenising buffer per 3 wells was used. In 
detail, the 100μl of homogenising buffer was added to the first well on ice and cell lysis 
encouraged by agitation with a sterile cell scraper. After 2 minutes the lysate was collected 
by pipette and transferred to the second well for 2 minutes with further agitation, followed 
by the same procedure in the 3rd and final well. The remaining lysate was carefully extracted 
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by pipette and transferred to a 500μl eppendorf where the sample was homogenised by 
repeatedly passing at least 5 times through an 18G sterile needle. The homogenate was 
then centrifuged at 150xg for 5 minutes at 40C. The resulting supernatant was removed for 
measurement of protein concentration and subsequent storage at -800C.  
Bradford assay 
The concentrations of protein in the sample homogenates were measured using the 
Bradford assay (Bradford 1976). This is a calorimetric assay based on an absorbance shift of 
the dye Coomassie Brilliant Blue G-250 which converts to its bluer form when bound to the 
proteins being assayed. The degree of absorbance shift correlates to the concentration of 
the protein in the sample which can be specified by comparison to a standard curve 
prepared using bovine serum albumin (BSA). To perform the assay the samples were diluted 
to 1:10 and 1:50 in PBS. The standards were prepared by serial dilution in PBS from a stock 
of 1mg/ml BSA. All standards were prepared with 100μl (1:10 dilution) of homogenising 
buffer as this can interfere with the protein-dye binding. 10μl of each standard (in duplicate) 
and diluted sample (in triplicate) were then pipetted into individual wells of a 96-well plate. 
200μl of Bradford reagent (Bio-Rad, UK) at a 1:4 dilution with H20 was then added to each 
well. The absorbance of each well was then measured at 560nm in the spectrophotometer. 
The protein concentrations in the samples were calculated by linear extrapolation from the 
standard curve using computer software (Graphpad Prism version 5.0). The triplicate values 
for each sample were averaged to give the final protein concentration. An example of the 
Bradford standard curve is shown (Figure 2.4). 
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Figure 2.4: Typical standard curve for Bradford protein assay. 
 
Protein separation and isolation: 
On the day of the experiment the samples were defrosted on ice. An appropriate volume of 
sample to give 20µg of protein was mixed 1:1 with Laemmli buffer (62.5 mM Tris-HCl, pH 
6.8, 25% glycerol, 2% SDS, 0.01% Bromophenol Blue) (Bio-Rad, UK) and boiled for 10 
minutes. The samples were then loaded onto a 10% sodium dodecyl sulphate (SDS)-
polyacrylamide gel. Rainbow markers (12-225 kDa, Amersham Biosciences, UK) were used 
to determine molecular mass. Protein separation was performed by gel electrophoresis for 
1 hour at 100V using the Mini-Protean system (Bio-Rad, UK). 
Proteins were then transferred onto nitrocellulose membranes and blocked for 1 hour with 
5% milk in PBS/Tween 20 at room temperature. After blocking, membranes were washed 
with PBS/Tween 20 for 15 minutes, 3 times. The membranes were then probed with 
primary rabbit polyclonal antibodies to either iNOS ( 1:500; Santa Cruz Biotechnology, USA, 
catalogue number bs-2072r), NOD1 (1:1000, Cell Signalling, UK, catalogue number 3545) or 
COX-2 (1:1000; Cayman Chemical, Ann Arbor, MI, catalogue number 160126) overnight at 
40C on a rocking platform. Following another wash step the membranes were exposed to a 
goat anti-rabbit IgG-horseradish peroxidise (Amersham Biosciences, UK, catalogue number 
NA9340V) diluted 1:2000 in 5% PBS/Tween 20 for a further 1 hour at room temperature on 
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a rocking platform. Blots were visualised onto film using ECL reagents (Amersham 
Biotechnology, UK). 
2.6 RNA extraction and polymerase chain reaction +RT-PCR 
For measurement of gene expression, cells were cultured in 6 well plates.  Ribo-nucleic acid 
(RNA) was extracted from the cells using a commercial RNA extraction kit (Quiagen, USA), 
according to the manufacturer’s protocol, detailed below.  RNA was extracted from 
unstimulated cells the day after plating and from treated cells at a 4 hour time point.   
Media was removed from the cells which were then washed 3 times with sterile PBS. 3 wells 
per experimental condition were pooled together for the purposes of RNA extraction.  
Between the 3 wells, 350μl of buffer RLT (containing guanidine salt and supplemented with 
1:100 dilution of β-mercaptoethanol (β-ME)) was used to lyse the cells and inactivate 
RNases. In detail 350µl of buffer RLT was added to the first well on ice and cell lysis 
encouraged by agitation with a sterile cell scraper. After 2 minutes the lysate was collected 
by pipette and transferred to the second well for two minutes with further agitation, 
followed by the same procedure in the 3rd and final well. The remaining lysate was carefully 
extracted by pipette and transferred into a 500µl RNase free eppendorf where the sample 
was homogenised by passing through an 18-gauge needle and syringe 5-10 times. If RNA 
extraction was not immediate, homogenised lysates were frozen at -80oC.   
To begin extraction of purified RNA from the fresh or defrosted homogenised lysates, an 
equal volume of 70% ethanol was added and mixed well by pipetting. Up to 700µl of the 
sample was then transferred to an RNeasy® spin column (containing a silica membrane to 
which the RNA binds) and spun for 15 seconds at 8000xg in a microcentrifuge (BOECO, 
Germany). At this point a DNase treatment step was also performed to eliminate 
contamination of the RNA sample with genomic DNA. Following two further wash and 
centrifuge steps, RNA was finally eluted from the RNeasy® column in RNA-free H20.  The 
concentration and purity of RNA in each sample was assessed by UV spectrophotometery 
(Nanodrop ND 1000, Thermo). Pure RNA was regarded as that where the ratio of 
absorbance readings at 260nm and 280nm (A260:A280) was between 1.9 and 2.1. Eluted RNA 
was stored at -80oC prior to further analysis. 
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Measurement of NOD1 mRNA expression  
NOD1 mRNA expression was measured in VSM, J774.2 macrophages, HMVEC and HPASM. 
RNA was obtained from cultured cells as described above and converted to complimentary 
DNA (cDNA) by reverse transcription following the protocol of the manufacturer 
(Omniscript® Reverse Transcription kit, Qiagen). Briefly the volume of sample required to 
give 1µg RNA was transferred into a fresh RNase free eppendorf and made up to 13µl with 
RNase free H20. 7µl of master mix (containing random primers (Promega), deoxynucleotide 
triphosphates (dNTPs), reverse transcriptase enzyme and buffer) was added to the tube 
which was transferred to the Thermocycler and run to the following protocol: 1h at 370C→ 5 
minutes at 600C → 40C ∞. Following the reverse transcription step the cDNA sample was 
kept on ice or frozen at -200C if not proceeding directly with polymerase chain reaction 
(PCR).  
Primers for the PCR in VSM and J774.2 macrophages were selected from the regions of the 
NOD1 mRNA sequence with the highest degree of homology in rat (NM_001109236.1, 
GenBank) and mouse (NM_172729.2, GenBank). Both sequences were compared with 
GenBank using the Blast software (National Center for Biotechnology Information website). 
The following primers, synthesized on request by Invitrogen (UK), were used for the 
amplification of NOD1; sense: 5'- GTC CTC AAC GAG CAT GGC GAG ACT -3' and antisense: 5'- 
TGC AGC TCA TCC AGG CCG TCA A -3' resulting in a product of 302 bp; and for β-actin, 
sense: 5'- GAT CAT GTT TGA GAC CTT CAA CAC C-3' and antisense: 5'-GTT TCA TGG ATG CC 
ACA GGA TTC-3', which yielded a product of 467 bp. For HMVEC and HPASM cells 
commercial primers for human NOD1 (Invivogen, USA) and human GAPDH (R&D systems, 
UK) were purchased.  
PCR of NOD1 in VSM and J774.2 macrophages was performed using a MyCycler Thermal 
cycler (Bio-Rad) by using Taq PCR Master Mix Kit (Qiagen) for 30 cycles (94°C for 45 seconds, 
64.7°C for 45 seconds, and 72°C for 45 seconds) followed by a final extension step at 72°C 
for 10 minutes. The same protocol was used for β-actin except for the annealing 
temperature, which was 60.4°C. For PCR of NOD1 in the HMVEC and HPASM, the Taq PCR 
Master Mix Kit was again used for 25 cycles (95°C for 30 seconds, 60°C for 30 seconds, and 
72°C for 1 minute) followed by a final extension step at 72°C for 5 minutes. A different 
protocol was used for the GAPDH with 30 cycles (940C for 45 seconds, 550C for 45 seconds, 
and 720C for 45 seconds) followed by a final extension step at 720C for 2 minutes. 
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The products of the PCR were separated in 2% agarose gels stained with ethidium bromide, 
and bands were quantified in the case of VSM and J774.2 macrophages using image analysis 
software (Quantity One, Bio-Rad). Results were normalized to the bands of β-actin from the 
same samples. 
Pro-inflammatory gene transcription array 
The gene expression patterns in cultured HMVEC following stimulation of NOD1 or TLR4 
were analysed using a focussed 84 gene Human Inflammatory Cytokines & Receptors RT2 
Profile PCR Array (SABiosciences™, UK). The array kit consists of a 96 well plate containing 
pre-dispensed gene specific primer sets for 84 common inflammatory genes. 7 genes in 
each plate related to PCR quality and DNA contamination controls and 5 genes in the array 
were housekeeping genes. RNA was collected as previously described and a quantity of 
243ng was converted to cDNA using the kit’s First Strand Kit.  The cDNA synthesis reaction 
was carried out at 42oC for 15 minutes.  The resulting cDNA was mixed with the kit’s 
mastermix, which contains a DNA polymerase enzyme.  25µl of this mixture was then 
aliquoted into each well of the 96 well plate and real time PCR was carried out using an 
Applied Bioscience 7500 machine with the following programme: 10 minutes at 95oC, 
followed by 40 cycles (95oC for 15 seconds, and 600C for 1 minute). Cycle threshold (CT) 
values were obtained for each gene of interest.  Fold changes in gene expression were 
calculated using the ΔΔCT method. Array data was visualised using the matrix2png program 
(Pavlidis and Noble 2003). 
2.7 Measurement of prostacyclin release 
In this thesis prostacyclin (PGI2) release was used as a measure of cyclooxygenase activity. 
PGI2 was measured by accumulation of its breakdown product 6-keto prostaglandin F1α (6-
ketoPGF1α). For Chapter 3 6-ketoPGF1α release was measured using the group’s in-house 
radio immunoassay by Ms Ivana Vojnovic at William Harvey Research Institute. For 
subsequent experiments described in Chapter’s 4 and 5, 6-ketoPGF1α was measured using a 
commercial Enzyme Immunoassay (EIA) kit (Cayman Chemical, USA). This is a competitive  
assay based on competition for a limited number of 6-keto PGF1α specific rabbit antibody 
binding sites, between free 6-keto PGF1α in the sample and Acetylcholinesterase (AChE) 
conjugated 6-keto PGF1α provided in the kit as tracer. Accordingly the higher the 6-keto 
PGF1α concentration in the sample, the less tracer will be able to bind resulting in a reduced 
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yellow colour change when the Ellman’s reagent (which is the substrate for the AChE) is 
added. The differences in colour change can be quantified in a spectrophotometer (at 
412nm) with comparison to a standard curve provided with the kit. Analysis of 6-keto PGF1α 
release in defrosted cell and organ culture supernatants was carried out at dilutions 
between 1:150 and 1:200. An example of the 6-keto PGF1α EIA standard curve is shown 
below (Figure 2.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Typical standard curve for 6-keto PGF1α EIA.  
2.8 ELISA CXCL8 
CXCL8 release from cultured cells and vessels was measured by enzyme-linked 
immunosorbent assay (ELISA) using a commercially available duoset kit (R&D systems, UK). 
A 96 well microplate (R&D systems) was coated with mouse anti-human CXCL8 antibody 
(720μg/ml in PBS) and incubated overnight at room temperature. The following day, 
supernatants for analysis that had been stored at -200C were thawed to room temperature.  
The ELISA microplate was then washed 3 times with 300μl wash buffer (0.05% Tween® 20 in 
PBS) (Sigma), and then blocked for a minimum of one hour using 150μl of 1% BSA in PBS.  
Reagent diluent (0.1% BSA, 0.05% Tween® 20 in Tris-buffered Saline (20 mM Trizma base, 
150 mM NaCl) was corrected to pH 7.2 – 7.4 and passed through a 0.2 µm filter prior to use. 
A seven point standard curve was prepared using recombinant human CXCL8 diluted in 
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reagent diluent, using 2-fold serial dilutions and a highest standard of 2000 pg/ml.  Thawed 
supernatants were pre-diluted to the required degree (10 to 200 times) in reagent diluents. 
After one hour, the ELISA plate was washed again and 50µl of neat or diluted cell 
supernatants and standards were added to the plate and incubated for two hours.  After 
another wash step, the plate was incubated for a further two hours with 50µl per well of 
biotinylated goat anti-human CXCL8 antibody (3.6μg/ml in reagent diluents); the detection 
antibody.  Following another wash step, 50µl of streptavidin conjugated to horseradish 
peroxidise (1:200 in reagent diluent) was added to each well and the plate incubated for 20 
minutes away from direct light.  After a last wash step, 50µl of substrate solution (a 1:1 mix 
of H2O2 and tetramethylbenzidine (BD Biosciences, UK)) was added to each well, and again 
the plate was incubated away from direct light for 20 minutes.  Wells containing CXCL8 
resulted in a colour change in substrate from colourless to blue.  Finally, the colour reaction 
was stopped after 20 minutes using 25µl of stop solution (2N sulphuric acid) per well, with a 
colour change in substrate from blue to yellow.  The optical density of each well was then 
determined using a microplate reader (Dynex, Magellan Biosciences) set to 450nm with 
wavelength correction set to 570nm.  The concentration of CXCL8 in each sample was then 
calculated by four parameter logistic interpolation of the standard curve using computer 
software (Graphpad Prism version 5.0).   A representation of the ELISA process and an 
example of the CXCL8 ELISA standard curve are shown below (Figures 2.6 and 2.7). 
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Figure 2.6: Illustration of the sandwich ELISA process as used to measure CXCL8 release from 
cultured cells and vessels. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Typical standard curve for CXCL8 ELISA (R&D systems, UK). 
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2.9 Measurement of multiple inflammatory chemokines / cytokines 
Release of interferon gamma (IFN-γ), interleukin 2 (IL-2), tumour necrosis factor alpha (TNF-
α), interleukin 1-beta (IL-1β), granulocyte-macrophage colony-stimulating factor (GM-CSF), 
Interferon gamma-induced protein 10 (IP-10), Interleukin 12 p70 subunit (IL-12p70), 
interleukin 6 (IL-6) and CXCL8 was measured in supernatants from cultured HMVEC using 
the Meso Scale Discovery® (MSD) human proinflammatory 9-plex base kit (Meso Scale 
Discovery, Gaithersburg, MD, USA).  This assay uses a sandwich immunoassay format where 
the specific capture antibodies are coated on single spots (electrodes) at the bottom of the 
multi-array well (Figure 2.8).  
 
 
 
 
Figure 2.8: Layout of MSD multi-array well. Individual capture antibodies for selected 
cytokines are coated on each spot (electrode) at the bottom of the well. 
 
All reagents were provided with the MSD kit. Each 96-well plate had 10-carbon electrodes in 
the bottom of each well, 9 of which were pre-coated with one of the 9-anti-cytokine 
antibodies of interest. The remaining electrode was coated in BSA to minimise non-specific 
binding. The standards were reconstituted in the assay diluent provided. Assay diluent 
(25 µl) was added to all wells and the plate sealed and incubated for 30 seconds at room 
temperature on an orbital shaker (600 rpm). Samples (diluted 1 in 10), standards and 
controls were added at 25 µl per well. The plate was sealed and incubated for 2 hours at 
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room temperature on an orbital shaker (600 rpm). At the end of the incubation the wells 
were washed three times using 200 µl PBS + 0.05%Tween 20, soaking for 30 seconds and 
then discarding. Detection antibody was added at 25 µl per well, and the plate sealed and 
incubated for 1 hour at room temperature on an orbital shaker (600 rpm). At the end of the 
incubation the plate was washed three times as before. 150 µl of the MSD Read Buffer was 
added to each well and the MSD plates were measured on the MSD Sector Imager 2400 
plate reader. The raw data was measured as electrochemiluminescence signal (light) 
detected by photodetectors and analysed using the Discovery Workbench 3.0 software 
(MSD). A 4-parameter logistic fit curve was generated for each analyte using the standards 
and the concentration of each sample calculated. Examples of standard curves generated by 
the MSD assay software are shown in Figure 2.9. 
 
 
Figure 2.9: Examples of standard curves generated by the MSD assay. 
2.10 Immunohistochemistry for NFκB 
Demonstration of NFκB translocation in rat aorta 
Fresh rat aorta was obtained as previously described. Connective tissue and adherent blood 
clots were removed and the vessels were divided into equal segments approx 2-4mm in 
length whereupon they were stored for a maximum of 30 minutes in PBS;Pen/Strep. The 
vessel segments were then placed into individual wells of a 96 well plate containing 300µl 
DMEM supplemented with 10% FCS, L-Glut, Pen/Strep, and NEAA, and containing drugs or 
vehicle. After 60 minutes incubation at 370C, 5% C02 the media was removed and the 
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segments washed twice with PBS;Pen-Strep. The segments were then fixed by the addition 
of 200µl 2% formaldehyde (from 10% buffered formalin solution, naturally contains ≈4% 
formaldehyde) for 15 minutes. After an additional wash step vessels were stored in PBS 
supplemented with 0.02% sodium azide (as a preservative) for up to one week before 
staining. 
Staining, mounting, and imaging of the rat aorta was performed in collaboration with Dr 
Martina Lundberg (post-doctoral scientist, Imperial College). The fixed vessels were first put 
through a permeabilisation and blocking step by the addition to the well of 0.1% Triton X 
(Sigma, UK) and 20% normal goat serum (in PBS) overnight at room temperature. Following 
2-3, 5 minute washes with 200μl PBS, primary antibody was added to the wells (anti-
p65/NF-κB antibody raised in rabbit (Santa Cruz, SC-372), 1:500 dilution in PBS) at 40C   
overnight.   After a further wash step, goat anti-rabbit secondary antibody conjugated to an 
Alexa Fluor 568 fluorophore (Invitrogen, A11026) was added for 2 hours at room 
temperature. The plate was protected from light from this point since fluorophores are light 
sensitive. Following another wash step, the wells were incubated with primary antibody 
against the endothelial cell marker CD31, directly conjugated to Alexa Fluor 488, overnight 
at room temperature. Another wash step was performed followed by the addition of 
25μg/ml 4’,6’-diamidino-2-phenylindole (DAPI) nuclear stain (Invitrogen, USA) for 5 minutes 
at room temperature in distilled water (dH20) since it falls out of solution in PBS. A final 
wash step with dH20 was then performed. 
After the staining protocol was complete the rat aorta was mounted on a coverslip slide 
with a drop of hard set mounting medium and was subject to the following mounting 
procedure. The slide was visualised under a light dissection microscope and the aortic rings 
were cut longitudinally then carefully flipped over with the luminal surface facing down 
against the coverslip glass. More mounting medium was then added to ensure even spread 
without air bubbles and a cover glass slide with clear nail varnish coated sides was slowly 
folded on top of the coverslip with the tissue, allowing the mounting medium to spread 
evenly. The labelled slide was then placed under 3 boxes of gloves (~7lb) and left at room 
temperature overnight to ensure that the tissues were sufficiently flattened.  
Slides were imaged using confocal microscopy. This offers greater optical resolution than 
conventional wide-field fluorescence microscopy and allows penetration to a greater depth 
of tissue. The confocal microscope used in this study was the Leica SP5 inverted confocal 
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microscope, located at the Imperial Facility for Imaging by Light Microscopy (FILM) facility in 
Sir Alexander Fleming Building at the South Kensington campus. This microscope is 
equipped with a diode laser for excitation at 405nm (and a UV light for visualisation in the 
microscope eye piece), an argon laser for excitation at 488nm and a helium neon laser for 
excitation at 543 nm.  
Images were selected blinded from target protein by observing only DAPI and CD31 staining 
down the eyepiece of the confocal microscope, with the red channel showing NF-κB 
immunoreactivity switched off. A clear CD31 signal reflected areas of minimal endothelial 
damage from the fixing, staining, and mounting procedure. Only when the area to be 
imaged had been chosen was the red channel activated to view NFκB immunoreactivity. 2 
images were taken from separate areas for each piece of aorta. Quantification of NFκB was 
performed using Leica Application Suite Advanced Fluorescence Lite software program (LAS 
AF, no licence, Leica Microsystems). For each image the NFκB immunoreactivity was 
measured directly in the nucleus and adjacent cytoplasm in 5 different locations. Again the 
nuclei were chosen by imaging DAPI only on the blue channel (leaving the red channel 
turned off) to prevent selection bias. Data was presented as overall nuclear NFκB intensity 
and as nucleus/cytoplasm relative intensity. Due to technical problems relating to activation 
of control tissues, pilot data from only one animal is shown in Chapter 4. 
Demonstration of NFκB translocation in cultured HMVEC 
Following treatment for 1 hour cells were washed in PBS and fixed immediately in 4% 
formaldehyde for 10mins at room temperature. Plates were then washed three times with 
PBS at 5 minute intervals. Plates were permeabilized with 0.2% Triton X-100 for 10 minutes 
and blocked with 4% FCS in PBS for 1 hour at room temperature. For NFκB staining, cells 
were incubated with NFκB-p65 (human) primary antibodies raised in rabbit (Santa Cruz 
Biotechnology, UK) for 1 hour at room temperature followed by secondary staining with 
AlexaFluor 568 anti-rabbit antibodies raised in goat (Invitrogen, UK) for 45 minutes at room 
temperature. Cells were washed three times between incubations with PBS at 5 minute 
intervals. Cell nuclei were stained with DAPI. Some wells were treated with secondary 
antibody only in order to determine levels of non-specific background staining. Plates were 
then stored in PBS at -4oC prior to imaging using a Cellomics VTi HCS Arrayscanner (Thermo 
Fisher, Pittsburgh, US).  
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In these experiments the system was used to scan 1000 cells per well across up to 49 fields 
per well. Images were analysed using a Thermo Fisher compartment analysis bioapplication 
for cytosol to nucleus translocation (Ding, Fischer et al. 1998). Mean nuclear-cytosolic 
intensity differences were calculated for each well and normalised to 1000 cells. High 
nuclear–cytosolic intensity differences corresponded to high nuclear staining and these can 
be plotted relative to control well values. 
2.11 siRNA knockdown of NOD1. 
For NOD1 small interfering RNA (siRNA) knockdown, targeting NOD1 siRNA (Hs_CARD4_1 
Flexitube siRNA (NM_006092)) (Qiagen, Crawley, UK) (Figure 2.10) was used according to 
manufacturer’s instructions. Four oligonucleotide sequences were used: SI00084462 
(CAGCCTGACAAGGTCCGCA), SI00084462 (CAGCCTGACAAGGTCCGCA), SI03057110 
(CACCACCGGCATCCTCAAT), and SI00084476 (AAGGCTGAGTACCATGGGC). HMVEC were 
seeded in 96 well plates 24 hours before transfection. Final concentration of siRNA was 
25nM. Scrambled non-targeting siRNA (25nM; Qiagen, Crawley,UK) were used as negative 
controls. Cells were treated 48 hours after transfection. Supernatants were collected after 
24 hours for analysis and cells lysed with TriReagent buffer (Sigma-Aldrich, Abingdon, UK) 
for total RNA extraction using the commercial RNA extraction kit described above.  For 
quantifying mRNA levels of NOD1 and TLR4, real-time PCR analyses were performed with 
TaqMan Gene Expression Assays (Applied Biosystems, CA). GAPDH was used as a 
housekeeping control. Relative expression was determined by ΔΔCt method in which fold 
increase = 2−ΔΔCt. 
2.12 Assessment of cell respiration by MTT or alamarBlue® 
Cell respiration, a marker of viability, was assessed after all treatments by either of two 
methods. Firstly by measuring the reduction of 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) (Sigma, UK) to formazan. Secondly by the alamarBlue® 
assay (invitrogen, USA) which incorporates a fluorometric/colorimetric oxidation-reduction 
(REDOX) indicator. Unless otherwise stated in the text, no treatment had a significant effect 
on cell viability. 
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2.12 Statistical analysis 
For Cell culture experiments data are mean ± S.E.M for separate incubations and unless 
otherwise stated protocols were repeated on at least 3 separate experimental days with 
separately prepared cells and drugs. For organ culture experiments data are mean ± S.E.M 
for tissue from separate animals or individual donors. Non-normalised data was analysed 
using one or two-way analysis of variance (ANOVA), with Bonferroni post-tests. Normalised 
data (to control or vehicle) are presented as mean ± SEM and were analysed by one-sample 
T-test and in some cases by two-way ANOVA with Bonferroni correction. Values of P<0.05 
were considered significant.  
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CHAPTER 3: 
Activity and pharmacology of NOD1 versus TLR4 receptor ligands in 
rodent Vascular Smooth Muscle cells and Macrophages. 
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3.1 Rationale 
Whilst it is accepted that ‘professional immune cells’ such as macrophages can recognise 
and respond to invading pathogens there is also evidence that vascular cells including 
vascular smooth muscle cells (VSM) are able to directly and independently bind pathogen 
associated molecular patterns (PAMPs) on invading organisms via pattern recognition 
receptors (PRRs) such as Toll-like receptor (TLR)2 and TLR4 (Jimenez, Belcher et al. 2005; 
Cartwright, McMaster et al. 2007). VSM cells respond to the TLR4 agonist lipopolysaccharide 
(LPS) independently of the endothelium (Bishop-Bailey, Larkin et al. 1997; Jourdan, Mitchell 
et al. 1997). In addition VSM have been demonstrated to release nitric oxide (NO) after 
stimulation of nucleotide oligomerisation domain-1 (NOD1) but not NOD2, with a 
suggestion of predominant effects on the vasculature in vivo compared to LPS (Cartwright, 
Murch et al. 2007).   
The pharmacology of new commercially available NOD1 agonists in VSM has not been 
studied. Previous experiments described above used the NOD1 stimulating acrylopeptide 
FK565. The minimal motif recognised by NOD1 has now been identified as D-γ-Glutamyl-
meso-diaminopimelic acid (D-γ-Glu-mDAP), a fragment of diaminopimelic (DAP) containing 
peptidoglycan (Chamaillard, Hashimoto et al. 2003; Girardin, Boneca et al. 2003). This led to 
the commercial agonists iE-DAP (D-γ-Glu-mDAP) and C12-iE-DAP (Lauroyl-γ-D-glutamyl-
meso-diaminopimelic acid) which contains an additional lauroyl group to enhance cell 
membrane permeability and agonist potency (Masumoto, Yang et al. 2006). There may be 
subtle but important differences between the new commercial NOD1 agonists and FK565 
including the potential of species specific effects (Magalhaes, Philpott et al. 2005). 
 Accordingly in this chapter the aim was to explore the effects of different NOD1 agonists in 
both VSM and macrophages with comparison to TLR4, NOD2 and whole bacteria responses. 
Nitric oxide (NO) has been used as the primary read out of cell induction in this chapter. NO 
was measured as its oxidation product, nitrite, using the Griess assay and, in this system, a 
product of inducible nitric oxide synthase (iNOS). In selected parallel experiments cyclo-
oxygenase (COX)-2 induction and activity was measured.  
To further understand the differences in NOD1 activity between VSM and macrophages, 
NOD1 expression was measured at the gene and protein level. Finally I have used 
pharmacological inhibitors to further understand relevant signalling pathways downstream 
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of both NOD1 and TLR4 in order to gain insight into the differential activity between these 
two Gram-negative surveillance receptors.  
3.2 Methods 
Methods are described in Chapter 2 in detail with brief details given below. 
Cell culture: 
As described in detail in Chapter 2 clonal VSM cells from balloon injured rat carotid artery 
(generated by Professor Timothy Warner at the William Harvey research Institute, London, 
UK) and the murine macrophage cell line J774.2 (European Collection of Cell Cultures- 
ECACC) were cultured in sterile culture flasks containing DMEM supplemented with 10% 
foetal calf serum, L-glutamine, non-essential amino acids, penicillin and streptomycin. In 
addition wild type peritoneal macrophages were collected from C57BL/6 mice or Wistar-
Kyoto rats by peritoneal lavage.  Cells were plated in either 6 or 96 well sterile plates at a 
density of 0.5x106 or 2.5x104 cells per well (VSM) and 1x106 or 1x105cells per well 
(macrophages) depending on the experimental protocol. Cells were maintained at 37OC in 
5% CO2. Others in the group have previously shown that the clonal VSM cells used in this 
chapter are typical of primary cultures of rodent VSM because they respond avidly to Gram 
negative bacteria and to the NOD1 agonist FK565. However, they are atypical in that that 
they do not respond to the TLR4 agonist LPS. It should be noted, as discussed later and in 
more detail in chapter 4 that the lack of response of LPS in VSM cells is not part of a normal 
phenotype. However, these particular clonal VSM cells grow very well in culture and, 
because of their persistent NOD1 response, can be used as a reliable model to study this 
PRR. 
Treatments: 
Cell culture experiments data are mean ± S.E.M for separate incubations and unless 
otherwise stated protocols were repeated on at least 3 separate experimental days with 
separately prepared cells and drugs. Cells were treated for either 24 (VSM, J774.2 cells) or 
48 hours (peritoneal macrophages) with the NOD1 agonists FK565, iE-DAP or C12-iE-DAP, 
the NOD2 agonist MDP, the TLR4 agonist LPS or whole heat-killed E.Coli. In some 
experiments the cells were pre-treated for 30-60 minutes with various cell signalling 
inhibitors. Details of all agonists and signalling inhibitors used are given in Table 3.1.  
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Table 3.1: Agonists and drugs used for experiments described in Chapter 3. 
Cell viability: 
Cell viability was measured by the MTT or Alamar Blue assays as described in Chapter 2. 
Nitric oxide (NO) release: 
NO production by cultured cells was measured by the accumulation of its oxidation product, 
nitrite, using the Griess reaction.  
Prostacyclin (PGI2) release: 
Cyclooxygenase (COX) activity was measured by the accumulation of 6 keto-PGF1α, the 
stable hydrolysis product of prostacyclin (PGI2), by specific radioimmunoassay.  
NOD1 gene expression and NOD1 / iNOS / COX2 protein expression: 
RNA was extracted from cultured VSM and macrophages using the RNeasy Minikit (Qiagen) 
and converted to complementary DNA by reverse transcription (Omniscript® Reverse 
Transcription kit, Qiagen). Specific primers for NOD1 and β-actin were selected as described 
in Chapter 2 to yield PCR products of 302 and 467bp respectively. PCR was carried out using 
a MyCycler Thermal cycler (Bio-Rad) with Taq PCR Master Mix Kit (Qiagen). The products of 
the PCR were separated in 2% agarose gels stained with ethidium bromide, and bands were 
Agonist / Drug Mechanism of action Dose range Solvent 
FK565 NOD1 agonist 0.1-100nM H20 
iE-DAP NOD1 agonist 0.01-10μg/ml H20 
C12-iE-DAP NOD1 agonist 0.01-1μg/ml H20 
MDP NOD2 agonist 0.01-10μg/ml H20 
LPS TLR4 agonist 0.01-10μg/ml H20 
5Z-7-oxozeaonol  TAK1 inhibitor 0.001-1μM DMSO 
BIRB0796 P38 MAPK inhibitor 0.001-1μM DMSO 
PD184352 ERK inhibitor 0.001-1μM DMSO 
D-JNKi JNK inhibitor 0.1-30µM DMSO 
KbNB-142-70 PKC inhibitor 0.01-10μM DMSO 
PP2 RIP2/src kinase 
inhibitor 
0.01-1μM DMSO 
 
Table 3.1 Drugs used in VSM/macrophage experiments. 
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quantified using image analysis software (Quantity One, Bio-Rad). Results were normalized 
to the bands of actin from the same samples. 
Measurement of NOD1, iNOS and COX2 protein expression was performed by Western blot 
using specific antibodies to NOD1 (1:1000, Cell Signalling,UK), iNOS (1:500, Santa Cruz 
Biotechnology, USA) and COX2 (1:1000; Cayman Chemical, Ann Arbor, MI).  
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3.3 Results 
3.3.1 Activity of ligands to NOD1, NOD2 and TLR4 in VSM and macrophages 
The ability of NOD1 and TLR4 ligands to activate VSM and macrophages was investigated by 
measurement of released NO and by demonstration of iNOS expression. iNOS is known to 
be an NFκB responsive gene downstream of NOD and TLR signalling (Xie, Kashiwabara et al. 
1994; Park, Kim et al. 2007). Responses were compared to that of heat-killed E.Coli which 
would be expected to activate both receptors via the peptidoglycan and LPS constituents of 
its cell wall. In VSM the NOD1 ligand FK565 (10nM) and whole heat-killed E.Coli (3x107 
CFU/ml) induced NO release compared to control (Figure 3.1A). This was associated with 
marked expression of iNOS (Figure 3.1C). The TLR4 agonist LPS induced more modest NO 
release and iNOS expression (Figs 3.1A and 3.1C). In the J774.2 macrophage cell line E. Coli 
(3x107 CFU/ml) was again shown to induce NO release and iNOS expression. LPS induced NO 
release and robust iNOS expression but the NOD1 agonist FK565 (10nM) failed to induce 
either NO release or discernable iNOS expression (Figures 3.1B and 3.1D).  
To illustrate the wider pro-inflammatory response elicited by NOD1 stimulation in VSM, the 
activity of COX-2 was measured. Following stimulation of VSM with 0.1-100nM FK565 
(NOD1), COX-2 activity was determined by assessment of PGI2 release as measured by the 
breakdown product 6-keto PGF1α. FK565 led to a concentration dependent release of 6-
keto PGF1α (Figure 3.2A). Induction of COX-2 expression by 10nM FK565  was also 
demonstrated by western blot (Figure 3.2B). 
Investigation of a wider variety of NOD1 agonists in VSM and macrophages was then 
performed. In isolated VSM cells the NOD1 agonists FK565 (0.1-100nM), iE-DAP (0.01-10µM) 
and C12-iE-DAP (0.01-1µM) induced concentration dependent release of NO (Figure 3.3). As 
expected C12-iE-DAP induced NO release at a 10-fold lower concentration than iE-DAP 
reflecting enhanced cell membrane permeability afforded by the additional lauroyl group. 
The TLR4 agonist LPS (0.01-10µg/ml) failed to induce NO release in the VSM cells (Figure 
3.3). 
In the J774.2 macrophage cell line the NOD1 agonists FK565 (1-100nM) and C12-iE-DAP 
(0.01-1µg/ml) failed to induce NO release. In contrast the TLR4 agonist LPS (0.01-1µg/ml) 
induced a concentration dependent increase in NO release (Figure 3.4).  
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In other cell types synergy has been reported between TLR and NOD agonists. In order to 
investigate if a similar pathway exists in VSM in respect of iNOS activity, separate 
experiments were performed where cells were stimulated for 24 hours with the 3 NOD1 
agonists in the absence and presence of LPS (Figure 3.5). As seen previously FK565, C12-iE-
DAP and iE-DAP each activated VSM cells to release increased NO and again, LPS had 
negligible direct effect. When cells were co-stimulated with LPS and NOD1 agonists no 
additional effect was seen with FK565. A slight trend to additional increase was seen with 
C12-iE-DAP or iE-DAP in cells co-treated with LPS, although this did not reach statistical 
significance (Figure 3.5).  
In separate experiments, in both VSM and J774.2 macrophages the NOD2 agonist MDP 
failed to induce NO release (Figure 3.6). Responses to C12-iE-DAP (VSM) and LPS 
(macrophages) were used as positive controls (Figure 3.6). 
3.3.2 NOD1 expression in VSM and J774.2 macrophages 
NOD1 expression was then measured at the gene and protein level. In keeping with the 
observed differences in NOD1 activity in the two cell types, NOD1 gene expression was 
detected in VSM cells but not in J774.2 macrophages (Figure 3.7A and 3.7B). Accordingly 
VSM cells expressed clearly detectable levels of NOD1 protein compared to low or 
undetectable levels in J774.2 macrophages or rat peritoneal macrophages (Figure 3.7C and 
3.7D). Treatment with FK565 (10nM) for 24 hours did not alter levels of NOD1 gene 
expression in either VSM or macrophages (VSM cells: control 0.100±0.030, plus FK565 
0.147±0.033; J774.2 macrophages: 0.006±0.002, plus FK565 0.003±0.006) (Figure 3.7B). 
3.3.3 Role of NFκB, MAPK and related signalling pathways in NOD1 and TLR4 receptor 
mediated NO release in VSM and macrophages 
Previous work in the group, using FK565 as an agonist of NOD1, had shown that the 
corticosteroid dexamethasone and the IKK2 inhibitor SC-514 inhibited iNOS responses 
induced by either NOD1 or TLR4 receptor activation in rat VSM cells and in J774 
macrophages (Moreno, McMaster et al. 2010). Similarly Gö6983 (a selective inhibitor of the 
conventional (α, βI, βII,γ), some novel (δ) and atypical (ι/λ, ζ) PKC isoforms (Way, Chou et al. 
2000) and Gö6976 (inhibits conventional isoforms plus PKCµ (PKD)) (Way, Chou et al. 2000) 
were used to investigate the effects of PKC in TLR4/NOD1 responses in these cells. In VSM 
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cells stimulated with FK565 to activate NOD1 pre-treatment with 10 nM Gö6983 failed to 
inhibit NO release (Moreno et al., 2010). Gö6983 had no effect on LPS driven NO release in 
J774.2 macrophages (Moreno et al., 2010) and Gö6976 mirrored the effect of Gö6983 in 
VSM with no effect on FK565 driven NO release. Conversely 10nM Gö6976 significantly 
inhibited NO release in J774.2 macrophages stimulated with LPS 1µg/ml (Moreno et al., 
2010). In order to extend and clarify what was known about NOD1 and TLR4 signalling in 
iNOS activity in VSM and macrophages I performed follow on experiments using, in these 
protocols, the NOD1 agonist iE-DAP. 
Transforming growth factor β activating kinase 1 (TAK1) is a signalling protein implicated in 
NFκB activation that is driven by a variety of inflammatory stimuli (Wang, Deng et al. 2001). 
To investigate the role of TAK1 in NOD1 and TLR4 signalling in VSM and macrophages I 
utilised 5Z-7-oxozeaonol, a specific TAK1 inhibitor (Ninomiya-Tsuji, Kajino et al. 2003). NO 
release was stimulated in VSM cell by the NOD1 agonist iE-DAP (10µg/ml) and in 
macrophages by the TLR4 agonist LPS (1µg/ml). Pre-treatment for 30 minutes with 5Z-7-
oxozeaonol profoundly inhibited NO release in both VSM (Figure 3.8A) and macrophages 
(Figure 3.8B). 
Signalling pathways from multiple pro-inflammatory stimuli are known to converge at the 
level of mitogen activated protein kinase (MAPK) (Akira, Uematsu et al. 2006). This includes 
LPS (Weinstein, Sanghera et al. 1992) and NOD receptor ligands (Girardin, Tournebize et al. 
2001; Pauleau and Murray 2003). To investigate the role of the MAPK family on NOD1 
signalling in VSM and TLR4 signalling in macrophages, specific pharmacological inhibitors 
were used. BIRB0796 is a highly specific inhibitor of p38 MAPK. It acts by a novel mechanism 
to indirectly block ATP binding via transformation of the ATP binding site (Kuma, Sabio et al. 
2005). PD184352 is a specific inhibitor of MEK (MAPK/ERK kinase or MAPK kinase) and the 
closely related MKK2 and suppresses the extracellular-signal regulated kinase (ERK) MAPK 
family (Allen, Sebolt-Leopold et al. 2003). Finally D-JNKi is a selective inhibitor of c-Jun N-
terminal kinase (JNK), a MAPK activated by stress stimuli such as pro-inflammatory 
cytokines (Barr, Boehm et al. 2004).  
In VSM cells stimulated with iE-DAP 10µg/ml (NOD1), pre-treatment for 30 minutes with 
BIRB0796 (0.001-1µM) led to a significant concentration dependent reduction in NO release 
(Figure 3.9A). In J774.2 macrophages stimulated with LPS 1µg/ml (TLR4), BIRB0796 did not 
have a significant effect on NO release even at the highest concentration (Figure 3.9B). In 
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contrast pre-treatment for 30 minutes with the MEK/ERK inhibitor PD184352 (0.001-1µM) 
led to concentration dependent reductions in NO release from both VSM stimulated with iE-
DAP and macrophages stimulated with LPS (Figure 3.10A and 3.10B). Finally the JNK 
inhibitor D-JNKi (0.1-30µM) had only a modest effect on NO release from induced by NOD1 
activation in VSM (stimulated in this set of experiments with 10nM FK565).  Slight inhibition 
was only seen at the highest concentration used (Figure 3.11A). Conversely in J774.2 
macrophages D-JNKi appeared to enhance LPS stimulated NO release (Figure 3.11B). This 
modest effect was again only seen at the highest concentration of D-JNKi (30µM). 
To clarify the role of the PKD isoform in NOD1/TLR4 signalling in VSM and macrophages, a 
highly specific PKD inhibitor KbNB-142-70 (Lavalle, Bravo-Altamirano et al. 2010) was used. 
Intriguingly pre-treatment with KbNB-142-70 for 30 minutes in VSM cells and macrophages 
stimulated by 10µg/ml iE-DAP and 1µg/ml LPS respectively, produced directly contrasting 
results to that seen previously with Gö6976. NO release was inhibited in NOD1 stimulated 
VSM cells although this was only observed at the highest concentration of KbNB-142-70 
(10µM) (Figure 3.12A). Moreover, KbNB-142-70 had no effect on NO release from LPS 
stimulated J774.2 macrophages (Figure 3.12B). 
Receptor-interacting protein 2 (RIP2) has been identified as a signalling protein downstream 
of the NOD receptors (Park, Kim et al. 2007; Magalhaes, Lee et al. 2011). In this initial 
chapter of my thesis, the role of RIP2 in NOD1/TLR4 responses in VSM/J774.2 macrophages 
was studied using the Src kinase inhibitor PP2, which has also been demonstrated to inhibit 
RIP2 (Windheim, Lang et al. 2007). 
In VSM cells stimulated with 10µg/ml iE-DAP (NOD1), pre-treatment for 30 minutes with 
PP2 (0.001-1µM) inhibited NO release in a concentration dependent fashion (Figure 3.13A).  
Conversely, in J774.2 macrophages stimulated with 1µg/ml LPS, PP2 failed to significantly 
reduce NO release (Figure 3.13B). 
3.3.3.4 Cell viability 
On the whole, the drugs or treatments used in this chapter had little or no affect cell 
viability. However, it should be noted that in VSM, the RIP2/Src kinase inhibitor PP2 reduced 
cell viability in cells co-stimulated with iE-DAP (Table 3.6). In J774.2 macrophages, LPS (0.1 
and 1µg/ml) (Table 3.4) and the p38 MAPK inhibitor BIRB0796 (1µM) (Table 3.7) modestly 
reduced cell viability. 
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3.3.5 Summary of effects of signalling inhibitors on iNOS activity induced by NOD1 
activation in VSM versus TLR4 activation in macrophages 
 
Inhibitor Mechanism of action Effect on NO release 
by VSM 
Effect on NO release 
by  macrophages 
5Z-7-oxozeaonol  TAK1 inhibitor Significant inhibition Significant inhibition 
BIRB0796 P38 MAPK inhibitor Significant inhibition No effect 
PD184352 ERK inhibitor Significant inhibition Modest inhibition 
D-JNKi JNK inhibitor No effect* No effect 
KbNB-142-70 PKC inhibitor Significant inhibition No effect 
PP2 RIP2/src kinase 
inhibitor 
Significant inhibition No effect 
 
Table 3.2: Summary of the effects of various cell signalling inhibitors on NO release by VSM 
or J774.2 macrophages. *D-JNKi did induce a small but statistically significant reduction in 
NO release from VSM at the highest concentration used (30µM) but the overall data does 
not suggest a specific effect. 
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3.4 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Effects of Gram-negative PAMPs on NO release by VSM cells and macrophages. 
VSM (A) and J774.2 macrophages (B) were treated for 24 hours with E. coli (EC; 3x107 
CFU/ml), LPS (1 μg/ml) or FK565 (10nM). NO was measured by the oxidation product nitrite 
by Griess assay and compared to cells incubated in media alone (CTRL). Data are presented 
as the mean ± SEM from n=6 for J774.2 cells and n=18 for VSM cells.  Data were analysed 
using 1-way ANOVA with Dunnett’s post-test; *p<0.05. Representative Western blots of 
iNOS (≈ 130 kDa) and β-actin (≈ 47 kDa) are shown from VSM cells (C) and macrophages (D) 
treated with E. coli, LPS or FK565 for 24 h.  
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Figure 3.2: Effect of the NOD1 ligand FK565 on COX-2 activity in VSM. (A) Prostacyclin (PGI2) 
release was measured by the stable hydrolysis product 6-keto PGF1α after stimulation of 
VSM cells with media alone (CTRL) or by FK565 0.1-10nM. Data are presented as mean ± 
SEM for n=6. Data were analysed using 1-way ANOVA with Dunnett’s post-test; *p<0.05. (B) 
COX-2 expression in VSM cultured with media alone or after treatment with FK565 10nM. 
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Figure 3.3: Concentration dependent effects of NOD1 and TLR4 agonists on NO release from 
cultured VSM cells. Cells were treated for 24 hours with (A) FK565 0.1-100nM (NOD1), (B) 
C12-iE-DAP 0.01-1µg/ml, (C) iE-DAP 0.1-10µg/ml (NOD1) or (D) LPS 0.01-10µg/ml (TLR4).  
NO was measured by the oxidation product nitrite by Griess assay and compared to cells 
incubated in media alone (CTRL). Data are presented as mean ± SEM from n=9. Data were 
analysed using one-way ANOVA with Dunnett’s post-test; *p<0.05. 
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Figure 3.4: Concentration dependent effects of NOD1 and TLR4 agonists on NO release from 
cultured J774.2 macrophages. Cells were treated for 24 hours with (A) FK565 1-100nM 
(NOD1), (B) C12-iE-DAP 0.01-1µg/ml (NOD1), or (C) LPS 0.01-1µg/ml. NO was measured by 
the oxidation product nitrite by Griess assay and compared to cells incubated in media alone 
(CTRL). Data are presented as mean ± SEM for n=9. Data were analysed using 1-way ANOVA 
with Dunnett’s post-test; *p<0.05. 
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Figure 3.5: Effect of co-stimulation of VSM cells with NOD1 agonists and LPS on NO release. 
Cells were treated for 24 hours with LPS 1µg/ml in addition to (A) FK565 1-10nM, (B) C12-iE-
DAP 0.01-1µg/ml, or iE-DAP 1-10µg/ml. NO was measured by the oxidation product nitrite 
by Griess assay and compared to cells incubated in media alone (CTRL).  Data are presented 
as  mean ± SEM for n=3. ns; not significant by two-way ANOVA. 
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Figure 3.6: Effects of the NOD2 agonist MDP on NO release by VSM cells and J774.2 
macrophages. (A) VSM cells were treated for 24 hours with MDP 0.1-10µg/ml or C12-iE-DAP 
0.01-1µg/ml. (B) J774.2 macrophages were treated for 24 hours with MDP 0.1-10µg/ml or 
LPS 0.01-1µg/ml. NO was measured by the oxidation product nitrite by Griess assay and 
compared to cells incubated in media alone (CTRL). C12-iE-DAP and LPS were used as 
positive controls for VSM cells and J774.2 macrophages respectively. Data are presented as 
mean ± SEM from n=9. Data were analysed using one-way ANOVA with Dunnett’s post-test; 
*p<0.05. 
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Figure 3.7: Expression of NOD1 in VSM cells and macrophages. (A) Ethidium bromide-
stained agarose gels containing RT-PCR products of NOD1 (302 base pairs) and β-actin (467 
base pairs) in VSM cells and J774.2 macrophages. (B) Densitometric data analysis of NOD1 
mRNA normalized to β-actin levels and expressed as arbitrary units (AU). Data are presented 
as the mean ± SEM from n=3. (C) Representative Western blot of NOD1 protein (≈ 95 kDa) in 
VSM, J774.2 or freshly isolated peritoneal macrophages from C57 BL/6 mice. (D) 
Densitometric data analysis of NOD1 protein normalized to β-actin levels and expressed as 
arbitrary units (A.U.). Data are presented as the mean ± SEM from n=3.  
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Figure 3.8: Role of transforming growth factor β-activated kinase 1 (TAK1) on iE-DAP (NOD1) 
and LPS (TLR4) induced NO production in VSM and J774.2 macrophages. VSM cells (A) and 
J774.2 macrophages (B) were treated with increasing concentrations of the TAK1 inhibitor 
5Z-7-oxozeaenol (0.001-1µM). Data are presented as a percentage of the response induced 
by iE-DAP or LPS respectively (mean ± SEM) from n=4.  Data were analysed using one 
sample t-test for normalised data; *p<0.05.  
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Figure 3.9: Role of p38 mitogen activated protein kinase (p38 MAPK) on iE-DAP (NOD1) and 
LPS (TLR4) induced NO production in VSM and J774.2 macrophages. VSM cells (A) and 
J774.2 macrophages (B) were treated with increasing concentrations of the p38 MAPK 
inhibitor BIRB0796 (0.001-1µM). Data are presented as a percentage of the response 
induced by iE-DAP or LPS respectively (mean ± SEM) from n=4.  Data were analysed using 
one sample t-test for normalised data; *p<0.05.  
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Figure 3.10: Role of extracellular signal-regulated (ERK) mitogen-activated protein kinase on 
iE-DAP (NOD1) and LPS (TLR4) induced NO production in VSM and J774.2 macrophages. 
VSM cells (A) and J774.2 macrophages (B) were treated with increasing concentrations of 
the ERK inhibitor PD184352 (0.001-1µM). Data are presented as a percentage of the 
response induced by iE-DAP or LPS respectively (mean ± SEM) from n=4.  Data were 
analysed using one sample t-test for normalised data; *p<0.05.  
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Figure 3.11: Role of c-Jun N-terminal kinase (JNK) on iE-DAP (NOD1) and LPS (TLR4) induced 
NO production in VSM and J774.2 macrophages. VSM cells (A) and J774.2 macrophages (B) 
were treated with increasing concentrations of the JNK inhibitor D-JNKi (0.1-30µM). Data 
are presented as a percentage of the response induced by iE-DAP or LPS respectively (mean 
± SEM) from n=5.  Data were analysed using one sample t-test for normalised data; *p<0.05.  
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Figure 3.12: Role of the specific protein kinase C µ (PKCµ or PKD) inhibitor KbNB-142-70 on 
iE-DAP (NOD1) and LPS (TLR4) induced NO production in VSM and J774.2 macrophages. 
VSM cells (A) and J774.2 macrophages (B) were treated with increasing concentrations of 
the PKC inhibitor KbNB-142-70 (0.001-1µM). Data are presented as a percentage of the 
response induced by iE-DAP or LPS respectively (mean ± SEM) from n=4.  Data were 
analysed using one sample t-test for normalised data; *p<0.05. 
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Figure 3.13: Role of receptor interacting protein-2 (RIP2) on iE-DAP (NOD1) and LPS (TLR4) 
induced NO production in VSM and J774.2 macrophages.  VSM cells (A) and J774.2 
macrophages (B) were treated with increasing concentrations of the RIP2/src kinase 
inhibitor PP2 (0.01-1µM). Data are presented as a percentage of the response induced by iE-
DAP or LPS respectively (mean ± SEM) from n=6 (VSM) or n=9 (macrophages).  Data were 
analysed using one sample t-test for normalised data; *p<0.05.  
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3.5 Results tables 
 
VSM MTT assay. Results expressed as % viability of unstimulated cells. 
FK565 (M)  
10exp-10 100.7 ± 17.4 
10exp-9 109.52 ± 21.3 
10exp-8 122.5 ± 22.9 
10exp-7 119.4 ± 21.6 
C12-IE-DAP (µg/ml)  
0.01 122.2 ± 21.5 
0.1 134.4 ± 24.9 
0.5 125.7 ± 22.7 
1.0 125.3 ± 22.2 
IE-DAP (µg/ml)  
0.1 107.4 ± 17.5 
1 115.7 ± 20.0 
5 107.8 ± 17.3 
10 87.0 ± 10.7 
LPS (µg/ml)  
0.01 95.5 ± 16.4 
0.1 103.4 ± 18.4 
1 95.6 ± 15.7 
10 81.4 ± 11.7 
 
Table 3.3: The effect of NOD1 and TLR4 agonists on vascular smooth muscle cell viability at 
24 hours as measured by the MTT assay. Data from n=9. Results are expressed as a % of the 
cell viability of unstimulated cells and are presented as mean ± S.E.M. Data were analysed 
using one sample t-test for normalized data. 
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J774.2 macrophages MTT assay. Results expressed as % viability of unstimulated 
cells. 
FK565 (M)  
10exp-9 94.7 ± 7.9 
10exp-8 94.7 ± 6.2 
10exp-7 92.6 ± 4.0 
C12-IE-DAP (µg/ml)  
0.01 97.7 ± 1.7 
0.1 97.4 ± 1.9 
1.0 91.4 ± 2.3 
LPS (µg/ml)  
0.01 96.8 ± 4.2 
0.1 88.9 ± 3.2* 
1 66.3 ± 5.0* 
 
Table 3.4: The effect of NOD1 and TLR4 agonists on macrophage cell viability at 24 hours as 
measured by the MTT assay. Data from n=9. Results are expressed as a % of the cell viability 
of unstimulated cells and are presented as mean ± S.E.M. Data were analysed using one 
sample t-test for normalized data; *p<0.05. 
 
Agonist Vascular smooth muscle  
MTT assay. Results 
expressed as % viability of 
unstimulated cells. 
Macrophages 
MTT assay. Results expressed as 
% viability of unstimulated cells. 
MDP (10g/ml) 130.1 ± 11.3 122.1 ± 2.5 
 
Table 3.5: The effects of the the NOD2 agonist MDP on cell viability of cultured vascular 
smooth muscle cells (C15) and macrophages (J774) at 24 hours as measured by the MTT 
assay.. Results are expressed as a % of the cell viability of unstimulated cells and are 
presented as mean ± S.E.M for n=9. Data were analysed using one sample t-test for 
normalized data. 
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Inhibitor VSM cells. Alamar Blue assay. Results expressed as Results expressed as 
% viability of unstimulated cells. 
CTRL + NOD1 agonist (iE-DAP 10µg/ml) 
5Z-7-oxozeaonol 
(1µM) 
96.5 ±3.6 83.6 ± 7.0 
BIRB0796 (1µM) 100.6 ± 1.6 100.7 ± 2.6 
PD184352 (1µM) 105.5 ± 2.4 89.1 ± 6.7 
Kb-NB 142-70 
(1µM) 
120.2 ± 3.8 100.8 ± 7.7 
PP2 (10µM) 76.2 ± 12.4 55.4 ± 12.5* 
 
Table 3.6: The effects of various cell signalling inhibitors on cell viability in VSM as measured 
by the Alamar Blue test. Results are shown for the highest concentration of inhibitor used. 
Data from n=4. Results are expressed as a % of the cell viability of unstimulated cells and are 
presented as mean ± S.E.M. Data were analysed using one sample t-test for normalized 
data; *p<0.05. 
 
 
Inhibitor J774.2 macrophages. Alamar Blue assay. Results expressed as Results 
expressed as % viability of unstimulated cells. 
 CTRL  + TLR4 agonist (LPS 1µg/ml) 
5Z-7-oxozeaonol 
(1µM) 
94.0 ± 7.2 106 .0 ± 5.3 
BIRB0796 (1µM) 87.2 ± 2.6* 105.0 ± 8.5 
PD184352 (1µM) 95.2 ± 5.0 96.2 ± 3.4 
Kb-NB 142-70 
(1µM) 
107.8 ± 8.1 102.0 ± 5.4 
 
Table 3.7: The effects of various cell signalling inhibitors on cell viability in J774.2 
macrophages as measured by the Alamar Blue test. Results are shown for the highest 
concentration of inhibitor used. Data from n=4. Results are expressed as a % of the cell 
viability of unstimulated cells and are presented as mean ± S.E.M. Data were analysed using 
one sample t-test for normalized data; *p<0.05. 
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3.6 Summary 
In this first chapter of my thesis, I have confirmed and extended earlier work performed 
within the group. These previous experiments had demonstrated that the NOD1 agonist 
FK565 induced iNOS activity in rodent VSM and that this effect was inhibited by 
corticosteroids, inhibitors of NFκB or PKC inhibitors (Moreno, McMaster et al. 2010). In 
addition the group has demonstrated that NOD1 agonists appear to have a pre-dominant 
effect on the vasculature in vivo with less activation of immune cells (Cartwright, Murch et 
al. 2007). I have extended these studies by confirming that FK565 induces iNOS activity in 
VSM, without any effect on activity in mouse macrophages, supporting the previous in vivo 
observations. I also show that, in addition to NO, FK565 induces release of prostacyclin and 
induction of COX-2 in VSM cells. In order to further validate the idea that NOD1 activation 
leads to iNOS activity in VSM cells, I have compared responses of FK565 with two other 
NOD1 agonists. My data confirms that the commercial NOD1 agonists iE-DAP and C12-iE-
DAP are equally as efficacious as FK565 at inducing iNOS activity in VSM, whilst having no 
effect on activity in J774 macrophages. These observations are explained by the findings 
that the VSM cells used in this study, but not mouse macrophages, express the NOD1 gene 
and protein.  In contrast to observations made with NOD1 agonists, the NOD2 agonist MDP 
had no measurable activity on iNOS activity in either VSM or macrophage.  NOD1 and TLR4 
are known to signal via NFκB and MAPK pathways as has been discussed earlier. To 
characterise downstream signalling from NOD1 and TLR4 in the VSM and macrophages, I 
have used pharmacological inhibitors. In keeping with previous data using dexamethasone 
and SC-514 (Moreno et al., 2010), the TAK1 inhibitor 5Z-7-oxozeaonol strongly inhibited 
NOD1 and TLR4 agonist induced NO release, reinforcing the dominant role of NFκB and 
associated pathways in the activity of these receptors. Interestingly, the response to the 
NOD1 ligand in VSM was more sensitive to inhibition of MAPK activity than LPS in the 
macrophage, as evidenced by the effects of the p38 inhibitor BIRB0796, ERK inhibitor 
PD184352, and to a lesser extent the JNK inhibitor D-JNKi. Conflicting results do not give a 
firm answer to the role of PKC in signalling downstream of NOD1 or TLR4, however the 
specificity of RIP2 to the NOD1 pathway is supported in this cell model, as shown by the 
NOD1 ligand specific effect of the mixed RIP2/src kinase inhibitor PP2. An overview of the 
signalling events demonstrated in this Chapter is presented in the schematic (Figure 3.14).  
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Figure 3.14: Suggested signalling pathways downstream of NOD1 in VSM cells and TLR4 in 
macrophages with suggested sites of action for selected pharmacological inhibitors. 
So in conclusion, the activity of multiple NOD1 agonists via established signalling pathways 
(NFκB and MAPK) in VSM is confirmed, and the hypothesis that NOD1 signalling is 
predominant in the vasculature is supported.  
There are limitations to the data presented in this chapter. The majority of the experiments 
described have been carried out using clonal cells. Caution must be exercised in the 
interpretation of this data as clonal cells may suffer up-and down regulation of genes after 
repeated passage. The results obtained would be supported by more data from primary 
cells. To address this, the data presented in Chapter 4 uses whole vessels in organ culture 
and the data in Chapters 5 and 6 is derived from commercial and donated primary human 
cells. Pharmacological inhibitors have been used in this chapter with the release of NO used 
as a readout of inhibitor effect. This data would be strengthened by further evidence of 
relevant signalling events such as NFκB nuclear translocation or protein phosphorylation. 
This point has been addressed in part by data in human endothelial cells, presented in 
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Chapter 6. Another limitation is that NO has been used as the predominant read out for cell 
activation in response to NOD1 and TLR4 agonists without validation with other inducible 
gene products. Again this criticism is addressed at the mediator and gene level in human 
cells lines, described in Chapter 5. Finally the specific effects of the NOD1 and TLR4 agonists 
used in this chapter could have been validated by techniques including gene knockdown or 
specific receptor antagonism. Again I have addressed this point later in the thesis in primary 
human cells by the use of a novel specific NOD1 receptor antagonist and a small interfering 
RNA knockdown technique. 
Discussion 
The relevance of these observations is discussed in detail in Chapter 7. 
The response of whole blood vessels to NOD1 ligands along with translational data in 
human tissue is presented in the next chapter. 
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CHAPTER 4: 
NOD1 versus TLR4 responses in whole blood vessel 
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4.1 Rationale 
 
The results described in Chapter 3 have established that vascular cells constitutively express 
nucleotide oligomerisation domain-1 (NOD1) with induction of inflammatory genes 
including inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) in response to 
stimulation with NOD1 ligands. The clone of vascular smooth muscle cells used in Chapter 3 
shows little response to lipopolysaccharide (LPS) but this is not typical of the response in 
whole blood vessels from rats (Bishop-Bailey, Pepper et al. 1998). In this chapter, in order to 
better understand vascular sensing of NOD1 ligands compared to LPS, a whole vessel 
bioassay system was used. Here intact segments of blood vessel, in this case rat aorta, are 
dissected and incubated in culture over time. Using this technique mediator release from 
inducible genes can be measured (Bishop-Bailey, Larkin et al. 1997) and, importantly, this 
offers the advantage of experimenting on tissue from multiple donor animals as opposed to 
limiting data from one clonal population of cells. Another obvious advantage is the potential 
to investigate the relative importance of the endothelium versus smooth muscle layer in 
mediator release by vessels (Jourdan, Mitchell et al. 1997). In this chapter I have therefore 
performed experiments using whole vessels in organ culture prepared with and without an 
intact endothelial layer stimulated with NOD1 ligands. 
In keeping with the literature, results from the experiments described in Chapter 3 confirm 
the importance of nuclear factor kappa B (NFκB) signalling and receptor interacting protein 
2 (RIP2) in the inflammatory events downstream of NOD1. In this chapter, specific 
pharmacological inhibitors were again used to explore the role of these signalling proteins in 
the activation of whole vessels by NOD1 agonists. 
Finally it is clear that species differences between rodent and human can significantly 
weaken the reliability of experimental data from animal models alone. Of relevance in this 
research, iNOS appears to be more readily induced in rodent cells compared to human cells 
(Padgett and Pruett 1992; Albina 1995) which may in part explain the particularly 
pronounced effect of NOD signalling in the rat vasculature (Cartwright, Murch et al. 2007). 
Accordingly in this chapter I have performed organ culture experiments using NOD1 and 
Toll-like receptor (TLR)4 agonists in segments of human pulmonary artery. 
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4.2 Methods 
Methods are described in Chapter 2 in detail with brief details given below. 
Vessel culture: 
Rings from rat aortas were prepared as previously described (Bishop-Bailey, Larkin et al. 
1997). Briefly male Sprague-Dawley rats (250 - 450 g) were killed by cervical dislocation 
following isoflurane anaesthesia. Aortas (thoracic and abdominal) were immediately 
removed and placed into sterile pots containing phosphate buffered saline (PBS) 
supplemented with penicillin (1000 U/ml) and streptomycin (1 mg/ml) (PBS; Pen-Strep) and 
stored at room temperature for less than 2 h before preparation. Vessel was cleared of 
connective tissue and adherent blood clot then cut into rings 2mm in length. In some 
experiments the endothelium of isolated rings was mechanically disrupted by gentle rolling 
on the tip of sterile forceps. Rings were equilibrated for 1 hour in individual wells of a 96 
well plate containing 300µl DMEM supplemented with 10% foetal calf serum, L-glutamine, 
non-essential amino acids, Pen-Strep and amphotericin. Fresh media was then replaced with 
and without treatments and rings were incubated at 370C in an atmosphere of 5% CO2 for up to 
96 hours with further replacement of media and drugs every 24 hours. 
For human vessel experiments, small segments of pulmonary artery were obtained surplus 
to surgical requirements from thoracic surgery at the Royal Brompton and Harefield NHS 
Trust, London, UK (ethics number 09/H0708172). The segments were dissected clean of 
connective tissue and washed 3 times all in sterile PBS: Pen-Strep. The segments were 
carefully dissected into small pieces each 2mmx2mm surface area. The arterial pieces were 
then placed in individual wells of a 96 well plate in 300µl DMEM supplemented as described 
for the rat aorta organ culture experiments. Vessel segments were left to equilibrate 
overnight prior to replacement with media containing drugs or vehicle. Vessels were treated 
for a total of 48 hours with replacement of media and drugs at 24 hours. 
Treatments: 
Vessels were treated for up to 96 hours with various agonists including C12-iE-DAP (NOD1), 
MDP (NOD2) and LPS (TLR4). In some experiments the vessels were pre-treated for 30mins 
with various pharmacological inhibitors. Details of all agonists and inhibitors used are given 
in Table 4.1.  
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Nitric oxide (NO) release: 
NO production by cultured vessels was measured by the accumulation of its oxidation 
product, nitrite, using the Griess reaction.  
Prostacyclin (PGI2) release: 
PGI2 release from vessels was measured by the breakdown product, 6-keto Prostaglandin 
F1α (6-keto PGF1α), in the tissue culture media by specific ELISA (Cayman Chemical Company, 
Ann Arbor, USA). 
CXCL8 release: 
Release of the chemokine CXCL8 by human pulmonary artery was measured in the tissue 
culture media by specific ELISA. 
Immunohistochemistry: 
For the purposes of immunohistochemistry, vessels were treated for 1 hour after which the 
media was removed and the segments washed x2 with PBS; Pen-Strep. The segments were 
then fixed in 2% formaldehyde solution for 15 minutes. After an additional wash step 
vessels were stored in PBS supplemented with 0.02% sodium azide (as a preservative) for up 
to one week before staining. Following an overnight blocking and permeabilising step, 
vessels were incubated for 24 hours with a primary antibody to the p65 subunit of NFκB 
(Santa Cruz). After another wash step vessels were incubated with a secondary goat anti-
rabbit Alexa Fluor 568 antibody for 2 hours followed by the endothelial cell marker CD31. 
Stained vessel rings were carefully cut into two and mounted on slides for confocal 
microscopy as described in detail in the methods chapter. 
 
 
 
 
 
 
 
 
 
Agonist / Drug Mechanism of action Dose Solvent 
C12-iE-DAP NOD1 agonist 1μg/ml H20 
MDP NOD2 agonist 10μg/ml H20 
LPS TLR4 agonist 1μg/ml H20 
SC-514 IKK2 inhibitor 30μM DMSO 
1400W iNOS inhibitor 1µM DMSO 
GSK’214 RIP2 inhibitor 1µM DMSO 
 
Table 4.1: Drugs used in whole vessel organ culture experiments. 
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4.3 Results 
4.3.1 The effect of the NOD1 agonist C12-iE-DAP and the TLR4 agonist LPS on NO and PGI2 
release from aortic rings in organ culture model. 
To investigate the effect of NOD1 and TLR4 stimulation in intact blood vessels, a whole aorta 
organ culture model was used. Following on from the findings in Chapter 3 NO and PGI2 
release (reflecting induction of iNOS and COX-2) was used as a measure of vessel activation.  
In initial experiments NO and PGI2 release from aortic rings was measured in tissue 
stimulated with 1µg/ml C12-iE-DAP (NOD1) or 1µg/ml LPS (TLR4) for up to 96 hours (Figure 
4.1 and 4.2). Basal release of NO did not fluctuate dramatically over the course of the 
experiment (Figure 4.1). However, basal release of PGI2 from aortic rings declined over 
successive days in culture (Figure 4.2). Stimulation of NOD1 with C12-iE-DAP or TLR4 with 
LPS resulted in increased release of NO at 24 and 48 hours, which declined at 72 hours 
(Figure 4.1). Similarly, LPS induced PGI2 release in whole aorta (measured by the oxidation 
product 6-keto PGF1α). By contrast, C12-iDAP had little effect on PGI2 release (Figure 4.2). 
Based on these observations further experiments using vessels in organ culture were 
performed measuring NO as the read out at the 24 and 48 hours time points only. 
4.3.2 Effect of the NOD2 agonist, MDP on NO release from rat aorta in organ culture. 
Addition of 10µg/ml of the NOD2 agonist MDP failed to induce NO release compared to 
control at 24 or 48 hours (Table 4.2).  
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4.3.3 Role of the endothelium in responses of whole aorta to NOD1 and TLR4 ligands. 
The endothelium is the predominant source of PGI2 and NO in the healthy vessel (Mitchell, 
Ali et al. 2008) but vascular smooth muscle is able to release these mediators after 
inflammatory stimuli such as LPS (Busse and Mulsch 1990; Thorin-Trescases, Hamilton et al. 
1995). The earlier results in Chapter 3 confirm that NOD1 is active in VSM and evidence 
exists that NOD1 induces pro-inflammatory responses in endothelial cells (Opitz, Forster et 
al. 2005; Opitz, Puschel et al. 2006), however the relative role of the endothelium in NOD1 
signalling in whole vessels remains unknown. To investigate the role of the endothelium in 
NOD1 induced iNOS activity the whole aorta organ culture model was used where 
endothelium-intact vessels were treated in parallel with vessels where the endothelium had 
been mechanically disrupted. 
As previously described, stimulation of endothelium intact aortic rings for up to 48 hours 
with 1µg/ml C12-iE-DAP (NOD1) or 1µg/ml LPS (TLR4) induced NO release (figure 4.3A + 
4.3B). Endothelium denuded rings released significantly less NO in response to C12-iE-DAP 
or LPS at 24 hours (Figure 4.3A). This effect was considerably reduced and non-significant at 
48 hours (figure 4.3B). For further experiments using vessels in organ culture, endothelial 
intact tissue was used. 
4.3.4 Role of iNOS in NOD1 and TLR4 driven NO release in whole aorta. 
There are three isoforms of nitric oxide synthase (NOS), endothelial NOS (eNOS), neuronal 
NOS (nNOS) and inducible NOS (iNOS) (Stuehr 1999). Inflammatory stimuli drive NO release 
via induction of iNOS (Stuehr and Marletta 1987; Stuehr and Marletta 1987; Stuehr, Cho et 
al. 1991). To confirm the role of iNOS in the NO release secondary to NOD1 and TLR4 
stimulation in whole aorta, the specific iNOS inhibitor 1400W (Garvey, Oplinger et al. 1997) 
was used. 
Pre-incubation of aortic rings for 30 minutes with 1µM 1400W inhibited the NO release 
induced by 1µg/ml C12-iE-DAP (NOD1) and 1µg/ml LPS (TLR4), both at 24 hours (Figure 
4.4A) and 48 hours (Figure 4.4B). 
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4.3.5 Role of NFκB in NOD1 and TLR4 responses in whole aorta. 
The inflammatory transcription factor NFκB is implicated in downstream signalling from 
PRRs including the TLRs and NOD proteins (Medzhitov, Preston-Hurlburt et al. 1997; 
Hasegawa, Fujimoto et al. 2008). The results described in Chapter 3 support the role of NFκB 
in NOD1 mediated NO release in VSM. To investigate the role of NFκB in responses of whole 
vessel, the IKK2 inhibitor SC-514 was again used to study the effect of NFκB inhibition in the 
organ culture bioassay. In addition, a proof of concept pilot study was conducted using an 
immunohistochemical technique to explore nuclear/cytoplasmic localisation of NFκB in the 
endothelium following NOD1 or TLR4 stimulation with C12-iE-DAP and LPS respectively. 
Pre-incubation of aortic rings for 30 minutes with 30µM SC-514 inhibited the NO release 
induced by 1µg/ml C12-iE-DAP (NOD1) and 1µg/ml LPS (TLR4) at 24 hours (Figure 4.5A). In 
support of this, pilot data from the immunohistochemical analysis revealed trans-
localisation of the NFκB staining from cytoplasm to nucleus in aortic rings stimulated for 1 
hour by 1µg/ml C12-iE-DAP (NOD1) or 1µg/ml LPS (TLR4) (Figure 4.6). 
4.3.6 Role of RIP2 in NOD1 and TLR4 responses in whole aorta 
RIP2 has been characterised in the literature as a signalling protein specific to the NOD 
pathway (Park, Kim et al. 2007). The mixed RIP2/Src kinase inhibitor PP2 specifically 
inhibited NOD1 induced NO release from VSM as described in Chapter 3. However this 
inhibitor is not a pure RIP2 inhibitor, as is the case with alternative compounds such as 
SB203580, which is a potent RIP2 and p38 MAPK inhibitor (Godl, Wissing et al. 2003). 
Accordingly to investigate more specifically the role of RIP2 in whole vessel activation 
downstream of NOD1 and TLR4, a novel small molecule inhibitor of RIP2 named GSK’214 
was obtained in collaboration with Dr John Bertin of the Pattern Recognition Receptor DPU 
of GlaxoSmithKline Pharmaceuticals (Philadelphia, USA). See also Chapter 6 and Appendix I. 
Pre-incubation of aortic rings for 30 minutes with 1µM GSK’214 completely inhibited the NO 
release induced by 1µg/ml C12-iE-DAP (NOD1) at 24 hours with no effect on the response to 
1µg/ml LPS (TLR4) (Figure 4.7A). GSK’214 continued to inhibit NOD1 mediated NO release to 
a greater degree than TLR4 at 48 hours (Figure 4.7B).  
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4.3.7 Effect of NOD1 and TLR4 stimulation in Human Pulmonary Artery 
To investigate the activity of NOD1 and TLR4 in whole human vessels, a whole pulmonary 
artery bioassay model was used. iNOS is not such a dominant gene in human as in rodent 
tissue. However, CXCL8 is a chemokine released following most types of inflammatory 
stimuli including bacterial PAMPs. Accordingly CXCL8, rather than NO, was used as a marker 
of vessel activation following stimulation with NOD1 or TLR4 ligands. 
As the inflammatory effect of LPS on whole vessels is well described (Jourdan, Mitchell et al. 
1997), I used a positive response to LPS as an internal control for tissue from each donor. 
Tissue from donors which failed to respond to LPS were removed, analysed separately and 
excluded from the pooled data (Table 4.3). This approach revealed 2 donors of the 8 whose 
tissue did not respond in vitro to LPS (Table 4.3). As shown in Table 4.3, pulmonary artery 
from donor 2 showed high basal CXCL8 release compared to the mean release across all 
donors. This could suggest bacterial contamination of the vessel prior to treatment. 
Conversely pulmonary artery from Donor 8 showed very low levels of CXCL8 release in basal 
and treated segments compared to the group mean suggesting a donor specific lack of 
response or damage to the vessel in the experimental protocol.  
For the remaining 6 donors, incubation of human pulmonary artery segments for 48 hours 
with 1µg/ml C12-iE-DAP or 1µg/ml LPS resulted in enhanced CXCL8 release compared to 
segments incubated in media alone (Figure 4.8). 
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4.4 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Effect of the TLR4 agonist LPS (A) and the NOD1 agonist C12-iE-DAP (B) on NO 
release by whole rat aorta over 96 hours. NO release was induced in aortic rings by C12-iE-
DAP 1µg/ml (NOD1) or LPS (TLR4) 1µg/ml. NO was measured by the oxidation product 
nitrite by Griess assay. Results expressed as mean ± SEM for n=6 animals. Data were 
analysed using two-way ANOVA; #p<0.05. 
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Figure 4.2: Effect of the TLR4 agonist LPS (A) and the NOD1 agonist C12-iE-DAP (B) on PGI2 
release by whole rat aorta over 4 consecutive days. PGI2 release was induced in aortic rings 
by C12-iE-DAP 1µg/ml (NOD1) or LPS (TLR4) 1µg/ml. PGI2 release was measured using ELISA 
by the breakdown product 6-keto PGF1α. Results expressed as mean ± SEM for n=6 animals. 
Data were analysed using two-way ANOVA; #p<0.05. 
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Figure 4.3: Role of the endothelium in NOD1 or TLR4 stimulated whole rat aorta. NO release 
was induced in aortic rings with endothelium intact (+EC) and denuded (-EC), by C12-iE-DAP 
1µg/ml (NOD1) or LPS 1µg/ml (TLR4). NO was measured by the oxidation product nitrite by 
Griess assay and compared to rings incubated in media alone (CTRL). Results are shown at 
24 hours (A) and 48 hours (B). Results expressed as mean ± SEM for n=9 animals. Data was 
analysed by one-way ANOVA followed by Dunnett's Test comparing responses to respective 
controls; *p<0.05 or by two-way ANOVA followed by Bonferroni's post tests; +p<0.05. 
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Figure 4.4: Role of iNOS in NOD1 or TLR4 stimulated whole rat aorta. NO release was 
induced in aortic rings by C12-iE-DAP 1µg/ml (NOD1) or LPS 1µg/ml (TLR4) after 30 minutes 
pre-treatment with the specific iNOS inhibitor 1400W. NO was measured by the oxidation 
product nitrite by Griess assay and compared to rings incubated in media alone (CTRL). 
Results are shown at 24 hours (A) and 48 hours (B). Results expressed as mean ± SEM for 
n=4 animals. Data was analysed by one-way ANOVA followed by Dunnett's Test comparing 
responses to respective controls; *p<0.05, or by two-way ANOVA followed by Bonferroni's 
post tests; +p<0.05. 
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Figure 4.5: Role of NFκB in NOD1 or TLR4 stimulated whole rat aorta. NO release was 
induced in aortic rings by C12-iE-DAP 1µg/ml (NOD1) or LPS 1µg/ml (TLR4) after 30 minutes 
pre-treatment with the I-κB kinase (IKK) 2 inhibitor SC-514. NO was measured by the 
oxidation product nitrite by Griess assay and compared to rings incubated in media alone 
(CTRL). Results are shown at 24 hours. Results expressed as mean ± SEM for n=4 animals. 
Data was analysed by one-way ANOVA followed Dunnett's Test comparing responses to 
respective controls; *p<0.05,  or by two-way ANOVA followed by Bonferroni's post tests; 
+p<0.05. 
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Figure 4.6: Activation and nuclear localisation of NFκB in response to NOD1 or TLR4 
stimulation in whole rat aorta. Freshly dissected aortic rings were incubated with C12-iE-
DAP 1μg/ml (NOD1) or LPS 1μg/ml (TLR4) for 60 minutes followed by fixation in 2% 
formaldehyde, immunohistochemistry and en face confocal microscopy of the endothelial 
surface.  (A-D) Representative confocal images where green= endothelial specific marker 
CD31, blue= 4',6-diamidino-2-phenylindole (DAPI) stained nuclei and red= p65 subunit of 
NFκB. (A+B) CTRL vs NOD1 stimulated aortic rings (C+D) CTRL vs LPS stimulated aortic rings.  
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Figure 4.7: Role of receptor interacting protein-2 (RIP2) in NOD1 or TLR4 stimulated whole 
rat aorta. NO release was induced in aortic rings by C12-iE-DAP 1µg/ml (NOD1) or LPS 
1µg/ml (TLR4) after 30 minutes pre-treatment with the novel RIP2 inhibitor GSK’214. NO 
was measured by the oxidation product nitrite by Griess assay and compared to rings 
incubated in media alone (CTRL). Results are shown at 24 hours (A) and 48 hours (B). Results 
expressed as mean ± SEM for n=3 animals. Data was analysed by one-way ANOVA followed 
by Dunnett's Test comparing responses to respective controls; *p<0.05, or by two-way 
ANOVA followed by Bonferroni's post tests; +p<0.05. 
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Figure 4.8: Effects of NOD1 and TLR4 stimulation in human blood vessel. Whole human 
pulmonary artery segments were treated with C12-iE-DAP 1μg/ml (NOD1) or LPS 1μg/ml 
(TLR4) for 48 hours. CXCL8 was used as a marker of vessel activation and measured by ELISA. 
Results expressed as a percentage of the response to media alone (CTRL) for n=6 donors. 
Data were analysed using one sample t-test for normalized data; *p<0.05. 
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4.5 Tables 
 Nitrite release (µM) 
24 hours  
CTRL 5.9±4.6 
MDP 10µg/ml 7.0±1.4 
48 hours  
CTRL 10.1±1.9 
MDP 10µg/ml 11.7±1.2 
 
Table 4.2: Effect of stimulation with the NOD2 agonist MDP on NO release by whole aorta. 
NO release was measured via the breakdown product nitrite using the Griess assay. Results 
are expressed as mean ± SEM for n=9. Data was analysed by one-way ANOVA followed by 
Dunnett’s post test;*p<0.05. 
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 CXCL8 release (ng/ml) 
Donors 1-8 (n=8)  
CTRL 107.6 ± 41.0 
C12-iE-DAP 1µg/ml 152.2 ± 52.0 
LPS 1µg/ml 231.6 ± 71.3 
Donors 1, 3-7 (n=6 donors)  
CTRL 106.3 ± 20.5 
C12-iE-DAP 1µg/ml 160.0 ± 25.7 
LPS 1µg/ml 278.7 ± 35.0 
Donor 2 (n=3 replicates)  
CTRL 206.8 ± 20.7 
C12-iE-DAP 1µg/ml 253.2 ± 23.7 
LPS 1µg/ml 163.4 ± 14.4 
  
Donor 8 (n= 3 replicates)  
CTRL 16.3 ± 5.3 
C12-iE-DAP 1µg/ml 4.5 ± 0.7 
LPS 1µg/ml 17.0 ± 4.6 
 
Table 4.3: Raw values of CXCL8 release in pulmonary artery segments from 8 separate 
donors. For group data shown in the first two rows replicate incubates of tissue from each 
donor (2-3 pieces per donor) were averaged, resulting in data of mean± S.E.M for n=8 (first 
row) and n=6 (second row). For data shown for individual donor tissues that did not respond 
to LPS, and so were excluded, data is mean ± S.E.M for 3 replicate incubations per donor. 
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4.5 Summary 
In this chapter I have extended the work performed in rodent VSM cells in Chapter 3 into a 
whole vessel model. The results demonstrate that the TLR4 agonist LPS induces activity of 
vasoactive enzymes in whole aorta as evidenced by release of NO and PGI2. I also found that 
the NOD1 agonist C12-iE-DAP induced clear increases in iNOS activity, demonstrated by 
increased NO release. However, in contrast to results with LPS, C12-iE-DAP did not induce 
convincing increases in PGI2 release in this whole vessel culture model.  This could be due to 
the known decline in PGI2 synthase activity seen in this system (Bishop-Bailey 1997). The 
role of iNOS in NO release induced by either LPS or C12-iE-DAP was confirmed by the use of 
the specific inhibitor 1400W. The two main metabolically active cells within a vessel are the 
endothelium and smooth muscle. Intriguingly, I found in this chapter that mechanical 
disruption reveals the endothelium to be a key site for agonist mediated activation of NOD1 
and TLR4 within the first 24 hours of stimulation. In keeping with observations in VSM cells, 
there appears to be an important role for NFκB in whole vessel sensing of NOD1 and TLR4 
agonists as demonstrated by the inhibitory effect of the IKK2 inhibitor SC-514. The bioassay 
data that suggests a key role for the endothelium is further supported by 
immunohistochemical staining and imaging of NFκB, demonstrating clear nuclear 
translocation of NFκB in this cell layer after 1 hour of treatment with iE-DAP or LPS. 
Although this data suggests that NOD1 and TLR4 employ conserved signalling via NFκB and 
iNOS to induce NO release in whole aorta, it does not help to differentiate the signalling of 
the two receptors. Given the evidence that RIP2 is a point of divergence between NODs and 
TLRs (both from the literature and the results in Chapter 3), a novel RIP2 inhibitor, GSK’214 
was profiled in the vessel bioassay. This inhibitor was extremely effective in totally 
suppressing responses to the NOD1 agonist C12-iE-DAP at 24 hours whilst having no effect 
on TLR4 responses. 
Finally data presented in this chapter has begun to translate the findings of NOD1 mediated 
vascular inflammation in rodent vessels into human tissue. Freshly removed human 
pulmonary artery specimens, surplus to surgical requirements, in patients undergoing 
thoracic surgery were exposed to C12-iE-DAP or LPS for 48 hours. Release of the ubiquitous 
inflammatory chemokine CXCL8 was significantly enhanced by both agonists compared to 
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control tissue exposed to media alone. This data is the first to my knowledge to translate 
NOD1 agonist responses directly into human blood vessel.  
There are some limitations to the data presented in this chapter. As with Chapter 3, NO has 
been used as the principle read out for vessel activation by NOD1 and TLR4 agonists as well 
as for the relevant effects of the cell signalling inhibitors used. It would be desirable to 
extend these observations by measuring protein expression directly in the vessels. For 
example it would have been interesting to image iNOS expression in the endothelium and 
underlying smooth muscle. Unfortunately this was beyond the scope of this thesis but 
remains the subject of current investigation within the group. In addition it would be 
desirable to measure release of alternative inflammatory mediators from the rat aorta 
although the tools for measuring rat cytokines are limited. To address this, I have measured 
a range of inflammatory mediators released from human endothelial cells in Chapter 5. Data 
is presented in this chapter for the nuclear translocation of NFκB in the endothelium in 
response to NOD1 and TLR4 agonists.  Unfortunately this was done only as a pilot study and 
it would be important to repeat this experiment with more n values and to consider 
additional signalling pathway intermediates.  
The data presented from rat vessels in this chapter has revealed a critical role for the 
endothelium in the early sensing of NOD and TLR4 agonists and directed my experiments in 
human vascular cell lines in Chapters 5 and 6. Whilst I was able to translate the effect of 
NOD1 and TLR4 agonists into human vessel in this chapter I was not able to perform 
experiments in human vessel showing the relative role of the endothelium. The relative 
scarcity of human tissue and the variability of the data necessitated a focus on 
demonstrating a response to NOD1 agonist in human vessel. Having established this point it 
would be desirable to investigate the relative role of the endothelium in future experiments 
by mechanical disruption of the endothelial layer as described for the rat aorta. Finally 
whilst I have demonstrated that whole human vessel can sense and respond to NOD1 
agonists I have not investigated an effect on vessel function. This would be extremely 
important given the dramatic vascular dysfunction seen in the context of Gram-negative 
sepsis. This point is the subject of ongoing investigation in the group using classical organ 
bath myography techniques. 
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Discussion 
The relevance of these observations is discussed in detail in Chapter 7. 
In the following chapter, NOD1 versus TLR4 responses in human vascular cells are 
considered in more detail, and in Chapter 6 I will return to the use of specific 
pharmacological inhibitors to attempt to differentiate NOD1 and TLR4 pathways in human 
endothelial cells. 
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Chapter 5: 
NOD1 versus TLR4 responses in human vascular cells in culture 
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5.1 Rationale 
The results from Chapters 3 and 4 show that nucleotide oligomerisation domain-1 (NOD1) 
and Toll-like receptor (TLR)4 agonists are active in rodent vascular smooth muscle cells 
(VSM) and whole aorta in organ culture. A key observation from Chapter 4 is that 
endothelial cells in intact vessels are critical for the sensing of NOD1 agonists in the first 24 
hours. In addition, in Chapter 4, I show that NOD1 or TLR4 agonists induce inflammatory 
chemokine release in isolated human pulmonary artery. This last piece of data in Chapter 4 
is critical to my thesis and serves to make the transition step in my hypothesis from rodent 
to human vascular systems. The human vessel I used in Chapter 4 was pulmonary arteries, 
which like other vessels, is composed, principally of two main cell types, endothelium and 
VSM cells. 
Human VSM and endothelial cells are known to respond to inflammatory stimuli including 
lipopolysaccharide (LPS) (Colucci, Balconi et al. 1983; Miossec, Cavender et al. 1986; Bishop-
Bailey, Pepper et al. 1998). However, the relative response of VSM and endothelium to 
NOD1 agonists is unknown. The data in Chapter 3 focuses exclusively on macrophages and 
VSM cells with no consideration of the endothelium. However, the data described in 
Chapter 4 reveals an important early role for the endothelium in NOD1 and TLR4 sensing. It 
might therefore be supposed that stimulation of NOD1 would induce more potent 
inflammatory responses in cultured endothelial cells than human VSM. 
To test this hypothesis, in this chapter, cultured human pulmonary artery smooth muscle 
cells (HPASM) and various endothelial cells including human lung microvascular endothelial 
cells (HMVEC), human umbilical vein endothelial cells (HUVEC) and human aortic endothelial 
cells (HAEC) were treated with NOD1, NOD2 and TLR4 agonists to assess inflammatory 
responses at the gene and protein level. These responses were then compared to those in 
human monocytic cells. 
Previous investigators have identified synergistic interaction between NOD and TLR 
pathways (Tada, Aiba et al. 2005; van Heel, Ghosh et al. 2005; Masumoto, Yang et al. 2006). 
Accordingly interaction between NOD1, NOD2 and TLR4 pathways were studied in both 
HPASM and HMVEC. Finally HMVEC were treated with a variety of identified TLR agonists to 
put NOD1/TLR4 activity in a wider context of inflammatory responses induced by pattern 
recognition receptor (PRR) activation. 
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5.2 Methods 
Methods are described in Chapter 2 in detail with brief details given below 
Cell culture: 
HLMVECs were purchased from Clonetics® (Lonza Walkersville, Inc. Walkersville, MD, USA) 
and from PromoCell (Heidelberg, Germany) whilst HAEC were from (Lonza Walkersville); in 
each case cells were grown in suppliers media according to manufactures instructions (Table 
5.1; see Chapter 2). HUVECs were kindly donated from the Royal Veterinary College 
(London, UK) and cultured as described in Chapter 2. In all cases cells were cultured in 
75cm2 sterile culture flasks with appropriate cell culture medium (see Table 5.1). All 
endothelial cells were treated in either 6 or 96 well plates at a seeding density of 1x105 and 
8x103 cells/well respectively. For HUVEC plates were pre-coated in 1% gelatine prior to 
seeding to aid cell attachment. 
HPASM were obtained by outgrowth from donor tissue (Research Ethics Committee study 
number 02-081, sub-amendment 3) in DMEM (see Table 5.1) and were seeded in 6 or 96 
well plates at a density of 1x105 and 8x103 cells/well respectively. Cells were maintained in 
serum free media for 24 hours prior to treatment. 
THP-1 cells, from a human monocytic leukaemia cell line, were obtained from the European 
collection of cell cultures (ECACC). Cells were cultured in RPMI 1640 media (Table 5.1) and 
seeded in 96-well plates at a density of 1x105 cells/well. 
Peripheral blood mononuclear cells (PBMCs) were isolated from human donors (Research 
Ethics Committee number 08/H0805/58). Were isolated as described in Chapter 2 before 
being resuspended in RPMI (Table 5.1) for seeding onto 96 well plates at a density of 1x105 
cells/well. 
Treatments: 
Cell culture experiments data are mean ± S.E.M for separate incubations and unless 
otherwise stated protocols were repeated on at least 3 separate experimental days with 
separately prepared cells and drugs. Unless otherwise stated, all protocols using passaged 
cells were carried out on cells from at least 2 separate donors using cells at different 
passage ranging from passage 3-9. For experiments using PBMCs cells from 5 separate 
donors were used. See Table 5.2 for details of all agonists used. 
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Measurement of inflammatory cytokines/chemokines: 
CXCL8 release was measured in cell culture supernatants by specific enzyme-linked 
immunosorbent assay (ELISA) (R&D systems, UK). Release of IFN-γ, TNF-α, IL-1β, IL-10, IL-
12p70, IL-6 and CXCL8 was measured in supernatants from cultured HMVEC using the Meso 
Scale Discovery® human proinflammatory 9-plex base kit (Meso Scale Discovery, 
Gaithersburg, MD, USA).   
Measurement of prostacyclin release: 
Prostacyclin (PGI2) release from cells was measured by the breakdown product, 6-keto 
Prostaglandin F1α, in cell culture supernatants by specific ELISA (Cayman Chemical Company, 
Ann Arbor, USA). 
NOD1 expression in HMVEC and HPASM: 
Total ribonucleic acid (RNA) was extracted from unstimulated HMVEC and HPASM, and 
those stimulated for 4 hours with NOD1 or TLR4 agonists using the RNeasy Minikit (Qiagen). 
RNA was converted to complimentary deoxyribonucleic acid (DNA) by reverse transcription 
(Omniscript® Reverse Transcription kit, Qiagen).  Specific primers to human NOD1 
(Invivogen) and GAPDH (R&D systems) were purchased. Polymerase chain reaction (PCR) of 
NOD1 was performed using a MyCycler Thermal cycler (Bio-Rad) by using Taq PCR Master 
Mix Kit (Qiagen) for 35 cycles (94°C for 30s, 60°C for 30s, and 72°C for 2 minutes) followed 
by a final extension step at 72°C for 5 minutes. The protocol used for GAPDH was 35 cycles 
(94°C for 45s, 54°C for 45s, and 72°C for 45s) followed by a final extension step at 72°C for 
10 minutes. The products of the PCR were separated in 2% agarose gels stained with 
ethidium bromide. 
Inflammatory gene expression in HMVEC: 
Total RNA was extracted from cultured HMVEC after 4 hours treatment with NOD1 or TLR4 
agonists using the RNeasy Minikit (Qiagen). Gene expression patterns were then analysed 
using a focussed 84 gene Human Inflammatory Cytokines & Receptors RT2 Profile PCR Array 
(SABiosciences™, UK).  
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Endothelial cell subtype Media Supplements 
HMVEC (Lonza) EBM-2 basal medium (Lonza) 
 
EGM-2 MV SingleQuots (Lonza) 
containing  25mls FBS (5%), 0.5ml 
hEGF, 2.0ml hFGF-B. 0.5ml VEGF, 
0.5ml ascorbic acid, 0.2ml 
hydrocortisone, 0.5ml Long R3-IGF-1, 
0.5ml heparin and 0.5ml 
gentamycin/amphotericin  
HMVEC (Promocell) Endothelial Cell Growth  
Medium-MV2  (Promocell) 
5%  FCS, EGF 5ng/ml, FGF 10ng/ml, 
Long R3 IGF-1 20ng/ml, VGEF 
0.5ng/ml, Ascorbic acid 1µg/ml and 
hydrocortisone 0.2 µg/ml 
HUVEC Medium 199 (Sigma) 20% FCS, EGF, Pen-Strep and heparin 
45µg/ml 
HAEC EBM-2 basal medium (Lonza) EGM-2 SingleQuots (Lonza). As for 
EGM-1 MV but only 10mls FBS (2%). 
HPASMCs DMEM (Gibco) 15% FCS, NEAA, Pen-Strep, and L-
glutamine. 
PBMCs RPMI (Gibco) 3% autologous serum, NEAA, Pen-
Strep and L-glutamine. 
 
Table 5.1: Cell culture media and supplements used for various cell types. 
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Agonist / Drug Mechanism of action Dose range Solvent 
iE-DAP NOD1 agonist 0.01-10µg/ml H20 
C12-iE-DAP NOD1 agonist 0.001-1µg/ml H20 
FK565 NOD1 agonist 100nM H20 
M-Tri-DAP NOD1 agonist 10μg/ml H20 
MDP  NOD2 agonist 0.01-10µg/ml H20 
LPS TLR4 agonist 0.01-1µg/ml H20 
 
Table 5.2: Agonists used in human cell culture experiments. 
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5.3 Results 
5.3.1 NOD1 expression in cultured human vascular cells 
Prior to assessment of NOD1 ligand activity in cultured human vascular cells, NOD1 gene 
expression was measured in HMVEC and HPASMs both unstimulated, and after 4 hours 
treatment with C12-iE-DAP (1µg/ml) or LPS (1µg/ml). NOD1 was clearly expressed in both 
cell types under basal conditions, with no apparent change in expression after treatment 
with either C12-iE-DAP or LPS (Figure 5.1). 
5.3.2 Effect of  NOD1, NOD2 and TLR4 stimulation on human pulmonary artery smooth 
muscle cells (HPASM). 
To attempt to replicate the NOD1/TLR4 effects seen in rat VSM, human vascular smooth 
muscle cells from pulmonary artery (HPASM) were treated for 24 hours with agonists to 
NOD1, NOD2 and TLR4 (Figure 5.2). The TLR4 agonist LPS (1µg/ml) induced robust CXCL8 
release at 24 hours. There was a trend to increased CXCL8 release with the NOD1 agonist 
C12-iE-DAP but no induction was seen with the NOD1 agonist FK565. In order to be sure 
that we were not missing a later response to NOD1 agonists, separate experiments were 
performed where HPASMCs were treated with the NOD1 ligands iE-DAP and C12-iE-DAP or 
the TLR4 agonist LPS for 48 hours (Table 5.3). Again, LPS induced CXCL8 release, but the 
NOD1 agonists iE-DAP and C12-iE-DAP failed to induce CXCL8 release from HPASM cells. In 
keeping with observations in rat VSM and whole aorta, the NOD2 agonist MDP failed to 
induce CXCL8 release in HPASM (Figure 5.2). 
To investigate potential interaction between NOD receptors and TLR4 for CXCL8 induction in 
HPASM, cells were stimulated with the NOD1 agonist M-Tri-DAP (10µg/ml) and the NOD2 
agonist MDP (10µg/ml) in the presence or absence of a threshold concentration of 
0.01µg/ml LPS (Figure 5.3). The combination of M-Tri-DAP and LPS led to a modest but 
significant enhancement of the CXCL8 release seen with each agonist alone (Figure 5.3A). 
MDP alone again failed to induce CXCL8 release compared to control and did not 
significantly increase CXCL8 release in combination with LPS compared to LPS alone (Figure 
5.3B). 
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To summarise, the experiments described above have demonstrated that whilst HPASM 
have a clear and reproducible response to LPS, they fail to respond to a number of NOD1 
agonists including the cell permeable NOD1 agonist C12-iE-DAP.  
5.3.3 Effect of NOD1, NOD2 and TLR4 stimulation in human endothelial cells  
Experiments in rat aorta presented in Chapter 4 suggested an important role for the 
endothelium in the sensing of PAMPs. To investigate the role of NOD1 and TLR4 in human 
endothelium a variety of endothelial cell subtypes were used. 
Stimulation of HMVEC with the specific agonists iE-DAP 0.01-10µg/ml, C12-iE-DAP 0.001-
1µg/ml (NOD1) and LPS 0.01-10µg/ml (TLR4) led to concentration dependent increases in 
CXCL8 release compared to control (Figure 5.4). LPS induced a more profound induction of 
CXCL8 than either iE-DAP or C12-iE-DAP (>10x basal as opposed to >5 fold basal). Interaction 
between NOD1 and TLR4 was then measured in HMVEC. Stimulation of HMVEC with the 
NOD1 agonists iE-DAP (10µg/ml) or C12-iE-DAP (1µg/ml) in the presence or absence of a 
threshold concentration of LPS (0.01µg/ml) failed to enhance CXCL8 release compared to 
either agonist alone (Figure 5.5). This was in contrast to the enhancement of CXCL8 by dual 
NOD1/TLR4 stimulation seen in HPASM (Figure 5.3A).  
To extend the context of these findings the effects of NOD1 agonists on two other 
endothelial cell subtypes, HUVEC and HAEC were studied. HUVEC were stimulated with the 
NOD1 agonists iE-DAP (1-10µg/ml) and C12-iE-DAP (0.1-1µg/ml), the NOD2 agonist MDP (1-
10µg/ml) and the TLR4 agonist LPS (1-10µg/ml). There was a concentration dependent 
induction of CXCL8 release with iE-DAP, C12-iE-DAP and LPS. No response was seen with 
MDP (Figure 5.6A). Again LPS was observed to induce CXCL8 release to a greater degree 
than the NOD1 agonists. HAEC were stimulated with the NOD1 agonist iE-DAP (10µg/ml), 
which induced significant CXCL8 release compared to control. LPS (TLR4) also induced CXCL8 
release, which in this particular data set, did not reach statistical significance (Figure 5.6B). 
5.3.4 NOD1 and TLR4 responses in human monocytic cells 
The experiments above suggest that in human systems, endothelial cells are important 
sensors of NOD1 agonists. However, multiple cell types are implicated in the host response 
to bacterial sepsis including ‘professional immune’ monocytic cells. Data from Chapter 3 
suggested that for rodent cells, macrophages did not respond directly to NOD1 agonists. To 
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demonstrate activity of NOD1 agonists in non-vascular human cells of the immune system, 
human donor PBMCs and the human monocytic cell line THP-1 were used. 
LPS induced CXCL8 release from human THP-1 monocytic cells but C12-iE-DAP had no effect 
(Figure 5.7A). In primary monocytes (human PBMCs), as expected, the TLR4 agonist LPS 
induced clear release of CXCL8. However the NOD1 agonist iE-DAP had no effect on CXCL8 
release by PBMCs (Table 5.4). As described previously, iE-DAP requires specific uptake 
mechanisms to enter cells. However C12-iE-DAP is more cell permeable. In separate 
experiments, C12-iE-DAP produced a variable response in PBMCs. In cells of 3 of the 5 
donors studied C12-iE-DAP induced clear release of CXCL8 (Table 5.4). However, in cells of 2 
of the 5 donors, despite LPS inducing CXCL8 release, C12-iE-DAP failed to activate the cells 
(Table 5.4). Given a high degree of variability in absolute CXCL8 release from PBMC between 
different donors, data from individual donors is given in Table 5.4 and was also expressed as 
a percentage release with C12-iE-DAP or LPS compared to unstimulated cells for each 
experiment (Figure 5.7B). The normalised data shows a modest but non-statistically 
significant induction of CXCL8 release by C12-iE-DAP and a robust induction by LPS. 
5.3.5 Investigation of the wider pro-inflammatory response in HMVEC after stimulation of 
NOD1 and TLR4 
Having established activation of HMVEC and other endothelial cell types by NOD1 or TLR4 
using CXCL8 as a marker, the wider pro-inflammatory response induced by stimulation of 
these receptors was studied using multi-cytokine and pro-inflammatory gene arrays.  
1) Mediator level 
Pro-inflammatory cytokine release was studied using the Meso Scale Discovery® human pro-
inflammatory 9-plex base kit (Meso Scale Discovery, Gaithersburg, MD, USA).  Stimulation of 
cultured HMVEC for 24 hours with the NOD1 agonist iE-DAP (10µg/ml) induced significant 
release (in order of magnitude) of CXCL8 (Figure 8A)> IL-2 (Figure 8B)> GM-CSF (Figure 8C)> 
IL12p70 (Figure 8D)> IL-1β (Figure 8E)> IFNγ (Figure 8F) and TNFα (Figure 8G). There was a 
trend for IL-6 (Figure 9H) induction by iE-DAP but this did not reach statistical significance.  
The TLR4 agonist LPS (1µg/ml) induced significant release of all measured cytokines in the 
following order CXCL8>,IL6> GM-CSF> IL-2> IL12p70> IL-1β> IFNγ> TNFα and IP-10 (Figure 
5.8A-H). 
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COX-2 is another inducible inflammatory gene in vascular tissue (Bishop-Bailey, Pepper et al. 
1997). As shown in Chapter 3 NOD1 stimulation induces COX-2 protein expression and 
activity in VSM, and PGI2 release in whole aorta. Consistent with these results, stimulation 
of HMVEC with the NOD1 agonist iE-DAP (10µg/ml) or the TLR4 agonist LPS (1µg/ml) 
induced significant PGI2 release compared to control (Figure 5.9). LPS induced PGI2 to a 
greater degree than iE-DAP (Figure 5.9). 
2) Gene level 
Pro-inflammatory gene induction following stimulation of HMVEC with the NOD1 agonist   
iE-DAP or TLR4 agonist LPS was studied using an 84 gene pro-inflammatory cytokines and 
receptors PCR array. Stimulation of HMVEC for 3 hours with either iE-DAP (10µg/ml) or LPS 
(1µg/ml) induced or repressed multiple genes involved in the inflammatory response (Figure 
5.10-13). Data was calculated from 4 separate experiments as fold change (compared to the 
respective untreated culture). Fold change was calculated from the raw cycle threshold (CT) 
values according to the manufacturer’s instructions using the ‘2 -ΔΔCT‘ method where ΔΔCT= 
(CT target gene - CT housekeeping gene) of stimulated cells - (CT target gene -  CT 
housekeeping gene) of  unstimulated cells (Livak and Schmittgen 2001). 
Raw CT values are shown in Table 5.5. The top-20 genes upregulated (>1.5 fold) by 
activation of NOD1 with iE-DAP were (in descending order) were found to be tumour 
necrosis factor alpha (TNFα), Chemokine (C-C motif) ligand 20 (CCL20), Chemokine (C-C 
motif) ligand 8 (CCL8), Chemokine (C-X-C motif) ligand 2 (CXCL2), Chemokine (C-X-C motif) 
ligand 3 (CXCL3), Lymphotoxin-beta (LTB), caspase recruitment domain family, member 18 
(CARD18), Chemokine (C-X-C motif) ligand 10 (CXCL10), Chemokine (C-C motif) ligand 4 
(CCL4), Chemokine (C-C motif) ligand 7 (CCL7), Chemokine (C-C motif) ligand 2 (CCL2), 
Interleukin-1 beta (IL-1β),  Chemokine (C-X-C motif) ligand 8 (CXCL8/IL8), Chemokine (C-C 
motif) ligand  1 (CCL1), Chemokine (C-X-C motif) ligand 6 (CXCL6), C-C chemokine receptor 
type 4 (CCR4), Chemokine (C-C motif) ligand 5 (CCL5), Chemokine (C-X-C motif) ligand 1 
(CXCL1), Interleukin-1 alpha (IL1α) and Chemokine (C-C motif) ligand 3 (CCL3) (Figure 
10.11.A). 
The top 20 genes up-regulated by activation of TLR4 with LPS were (in descending order) 
CXCL2, CXCL3, TNFα, CCL20, CCL8, CXCL1, CXCL10, IL-1β, CXCL6, LTB, CCL5, CCL4, CXCL8, 
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Interleukin 8 receptor alpha (IL8RA), Chemokine (C-C motif) 16 (CCL16), CCL7, Chemokine 
(C-X-C motif) ligand 5 (CXCL5), IL-1α, Interleukin 5 (IL-5) and CCL2 (Figure 5.11B). 
A number of genes were downregulated (>1.5 fold) by either NOD1 or TLR4 stimulation. 
Genes downregulated by iE-DAP (NOD1) (in increasing order of repression) were Toll 
interacting protein (TOLLIP), Macrophage migration inhibitory factor (MIF), secreted 
phosphoprotein 1 (SPP1), Interleukin 13 receptor, alpha 1 (IL13RA1), Interleukin 10 
receptor, beta subunit (IL10RB), Leukotriene B4 receptor 1 (LTB4R), Chemokine (C-X-C 
motif) ligand 12 (CXCL12), Interleukin-1 family member 7 (IL1F7), IL8RA, Interleukin 9 (IL9), 
Interleukin 1 receptor, type I  (IL1R1), Chemokine (C-X-C motif) ligand 13 (CXCL13), 
Chemokine (C-C motif) ligand  21 (CCL21), C-C chemokine receptor type 7 (CCR7), c-reactive 
protein (CRP), C-C chemokine receptor type 2 (CCR2), Interleukin-1 family member 10 
(IL1F10), Interleukin 13 (IL13), Chemokine (C-X-C motif) ligand 9 (CXCL9), C-C chemokine 
receptor type 8 (CCR8), Interleukin 5 receptor, alpha subunit (IL5RA), C-C chemokine 
receptor type 6 (CCR6), CD40 ligand (CD40LG) and Interleukin 10 receptor, alpha subunit 
(IL10RA) (Figure 5.12A). 
Genes downregulated by LPS (TLR4) (in increasing order of repression) were CX3C 
chemokine receptor 1 (CX3CR1), interleukin-1 receptor antagonist (IL1RN), TOLLIP, SPP1, 
MIF, Interleukin 13 receptor, alpha subunit 1 (IL13RA1), Chemokine (C-C motif) ligand  18 
(CCL18), IL1R1, IL10RB,  Interleukin-1 family member 8 (IL1F8), Complement C4-A (C4A), ), 
Interleukin-1 family member 9 (IL1F9), C-C chemokine receptor type 2 (CCR2), CXCL12, 
LTB4R, CCR6, IL13, CXCL13, IL10RA, Chemokine (C-C motif) ligand (CCL19), CRP, CCR8, 
CD40LG, C-C chemokine receptor type 7 (CCR7), CCL21, Interleukin-1 family member 10 ( 
IL1F10), Chemokine (C-C motif) ligand  15 (CCL15) and  IL5RA (Figure 5.12B). 
As demonstrated in the heatmap (Figure 5.10) there was some degree of variability of gene 
induction between different experimental days (Figure 5.10). In order to interpret the 
overall data set described above, genes were selected that were consistently up or down-
regulated by 1.5 fold or above on every experimental day. According to this analysis there 
were 14 genes in HMVEC consistently up-regulated by stimulation with iE-DAP. These were 
(in descending order of fold change) TNFα, CCL20, CXCL2, CCL5, CXCL3, LTB, CCL7, CCL2, IL-
1β, CXCL8, CCL1, CXCL6, CXCL1 and IL1-β (Table 5.6). Although upregulation of CXCL5 is 
suggested from the heat map, it was induced only 1.4 fold by iE-DAP on the 4th experimental 
day. However this gene was included in the Table for comparative purposes. Corresponding 
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fold change in response to LPS for these genes is also shown in the Table. In addition IL10RA 
was downregulated by iE-DAP and LPS according to this analysis. 
Importantly by analysing the data in this way, no differences in gene expression between 
NOD1 or TLR4 receptor stimulation could be observed. 
5.3.6 Response of HMVEC to a variety of TLR agonists 
To add context to the responses driven by NOD1 stimulation in HMVEC, the cells were 
treated with a commercial array of TLR agonists and CXCL8 release measured as an indicator 
of cell activation. Significant release of CXCL8 was observed after 24 hours treatment of 
cultured HMVEC with the TLR3 agonist High Molecular Weight Polyinosinic:polycytidylic acid 
(HMW Poly I:C), and as expected the TLR4 agonist LPS. No significant response was seen 
with agonists to TLR1/2, 2, 5, 6/2, 7, 8 and 9 (Figure 5.13).  
5.3.7 Cell viability 
Some of the agonists used had a modest effect on cell viability including Poly I:C (86.8 ± 3.9 
% versus unstimulated cells), LPS (86.9 ± 2.8 % versus unstimulated cells), FSL-1 (89.0 ± 4.0 
% versus unstimulated cells), and ODN2006 (87.3 ± 3.9 % versus unstimulated cells) (Table 
5.13). 
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5.4 Figures 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: NOD1 expression in human vascular cells. Ethidium bromide-stained agarose gels 
are shown containing RT-PCR products of NOD1 (319 bp) and GAPDH (467 bp) in HPASM 
and HMVEC from one donor each. Results are shown for NOD1 expression under basal 
conditions and after 4 hours stimulation with C12-iE-DAP 1μg/ml or LPS 1μg/ml. Lane 1: 
Negative control (H20), Lane 2: HPASM basal, Lane 3: HPASM + C12-iE-DAP 1μg/ml, Lane 4: 
HPASM + LPS 1μg/ml, Lane 5: NOD1 positive control, Lane 6: HMVEC basal, Lane 7: HMVEC + 
C12-iE-DAP 1μg/ml, Lane 8: HMVEC + LPS 1μg/ml. 
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Figure 5.2: Effects of agonists to NOD1, NOD2 and TLR4 on Human Pulmonary Artery 
Smooth Muscle Cells (HPASM). Cultured HPASM were treated for 24 hours with FK565 
100nM (NOD1), C12-iE-DAP 1μg/ml (NOD1), LPS 1μg/ml (TLR4) and MDP 10μg/ml (NOD2).  
CXCL8 was used as a marker of cell activation and measured by ELISA. Results expressed as 
mean ± SEM for n=10 (C12-iE-DAP, LPS) or n=6 (FK565, MDP). Data were analysed by one-
way ANOVA with Dunnett’s post-test; *p<0.05. 
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Figure 5.3: Effects of co-stimulation with NOD1/NOD2 agonists and LPS in HPASM. Cultured 
HPASM were treated for 24 hours with (A) M-Tri-DAP 10μg/ml (NOD1) or (B) MDP 10μg/ml 
(NOD2) with or without a threshold concentration of the TLR4 agonist LPS (0.01μg/ml). 
CXCL8 was used as a marker of cell activation and measured by ELISA. Results expressed as 
mean ± SEM for n=12. Data were analysed by two-way ANOVA with Bonferroni’s posttest; 
*p<0.05. 
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Figure 5.4: Effects of TLR4 and NOD1 stimulation in Human Lung Microvascular Endothelial 
cells (HMVEC). Cultured HMVEC were treated for 24 hours with increasing concentrations of 
(A) LPS 0.01-10μg/ml (TLR4), (B) iE-DAP 0.01-10μg/ml (NOD1) or (C) C12-iE-DAP 0.001-
1μg/ml (NOD1). CXCL8 was used as a marker of cell activation and measured by ELISA. 
Results expressed as mean ± SEM for n=12. Data were analysed by one-way ANOVA with 
Dunnett’s post-test; *p<0.05. 
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Figure 5.5: Effects of co-stimulation of NOD1 and TLR4 in HMVEC. Cultured HMVEC were 
treated for 24 hours with (A) iE-DAP 10μg/ml (NOD1) or (B) C12-iE-DAP 1μg/ml (NOD1) with 
or without a threshold concentration of the TLR4 agonist LPS (0.01μg/ml). CXCL8 was used 
as a marker of cell activation and measured by ELISA. Results expressed as mean ± SEM for 
n=9. Data were analysed by two-way ANOVA with Bonferroni’s correction; *p<0.05. 
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Figure 5.6: Effects of NOD1, NOD2 and TLR4 stimulation in various human endothelial cell 
phenotypes. (A) Cultured Human Umbilical Vein Endothelial cells (HUVEC) were treated for 
24 hours with iE-DAP 10μg/ml (NOD1), C12-iE-DAP 1μg/ml (NOD1), LPS 1μg/ml (TLR4) and 
MDP 10μg/ml (NOD2). (B) Cultured Human Aortic Endothelial cells (HAEC) were treated for 
24 hours with iE-DAP 10μg/ml (NOD1) or LPS 1μg/ml (TLR4). CXCL8 was used as a marker of 
cell activation and measured by ELISA. Results expressed as mean ± SEM for n=9 (HUVEC) or 
n=6 (HAEC). Data were analysed by one-way ANOVA with Dunnett’s post-test;*p<0.05. 
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Figure 5.7: Effects of NOD1 and TLR4 stimulation in human monocytic cells. (A) Peripheral 
Blood Mononuclear cells (PBMC) and THP-1 monocytic cells (THP-1) were treated for 24 
hours with C12-iE-DAP 1μg/ml (NOD1) or LPS 1μg/ml (TLR4). CXCL8 was used as a marker of 
cell activation and measured by ELISA. Results expressed as mean ± SEM for n=5 from 5 
donors (PBMC) or n=4 (THP-1). Data were analysed by one-way ANOVA with Dunnett’s post-
test; *p<0.05. (B) Results for PBMC normalised to control for each donor. Results expressed 
as a mean percentage of the response to media alone (CTRL) ± S.E.M. for n=5. Data were 
analysed using one sample t-test for normalized data; #p<0.05.  
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Figure 5.8: Effects of NOD1 or TLR4 stimulation on pro-inflammatory cytokine release by 
HMVEC. Cultured HMVEC were treated for 24 hours with iE-DAP 10μg/ml (NOD1) and LPS 
1μg/ml (TLR4). Inflammatory cytokine release measured using the Human Pro-Inflammatory 
9-PlexBase Kit from Meso Scale Discovery (MSD®). (A) CXCL8 (B) IL-2 (C) GM-CSF (D) IL-12p70 
(E) IL-1β (F) IFNγ (G) TNFα (H) IL-6 (I) IP10. Results expressed as mean ± SEM for n=15. Data 
were analysed by one-way ANOVA with Dunnett’s post-test;*p<0.05 or by Kruskal-Wallis 
test with Dunn’s multiple comparison test for non-parametric data; #p<0.05. 
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Figure 5.9: Effect of NOD1 or TLR4 stimulation on prostacyclin release in HMVEC. Cultured 
HMVEC were treated for 24 hours with iE-DAP 10μg/ml (NOD1) and LPS 1μg/ml (TLR4). 
Prostacyclin release was measured by the breakdown product 6-keto prostaglandin F1α by 
ELISA. Results expressed as mean ± SEM for n=15. Data were analysed by one-way ANOVA 
with Dunnett’s post test; *p<0.05. 
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Figure 5.10: Expression patterns of 84 pro-
inflammatory genes in HMVEC following 
stimulation of NOD1 or TLR4. Cultured HMVEC 
were treated for 3 hours with iE-DAP 10µg/ml 
(NOD1) or LPS 1µg/ml (TLR4). Following RNA 
extraction, inflammatory gene expression was 
measured using a focussed 84 gene Human 
Inflammatory Cytokines & Receptors RT2 
Profile PCR Array. Results are shown from 2 
donors and 4 experimental days. Green-to-red 
scale indicates expression levels from low 
(under half) to high (over 2-fold) compared to 
cells with no stimulation. 
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Figure 5.11: Expression patterns of 84 pro-inflammatory genes in HMVEC following 
stimulation of NOD1 or TLR4. (A) Top 20 genes upregulated by iE-DAP (mean fold change ± 
SEM). (B) Top 20 genes upregulated by LPS (mean fold change ± SEM).  
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Figure 5.12: Expression patterns of 84 pro-inflammatory genes in HMVEC following 
stimulation of NOD1 or TLR4. (A) Genes downregulated by iE-DAP (mean fold change ± 
SEM). (B) Genes downregulated by LPS (mean fold change ± SEM). 
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Figure 5.13: Effect of stimulation with TLR ligands in HMVEC. Cultured HMVEC were treated 
for 24 hours with PAM3 (Pam3CysSerLys4) 1µg/ml, TLR1/2 agonist; HKLM (heat killed listeria 
monocytogenes) 109 cells/ml, TLR2 agonist; Poly HMW (Poly I:C high molecular weight) 
10µg/ml, TLR3 agonist; POLY LMW (Poly I:C low molecular weight) 10µg/ml, TLR3 agonist; 
LPS (lipopolysaccharide) 1µg/ml, TLR4 agonist; Flag (flagellin) 10µg/ml,TLR5 agonist; FSL-1 
(Pam2CGDPKHPKSF) 1µg/ml, TLR6/2 agonist; Imi (imiquimod) 10µg/ml, TLR7 agonist; ssRNA 
(single stranded RNA 40) 10µg/ml, TLR8 agonist; ODN (ODN2006 type B) 5µM, TLR9 agonist. 
CXCL8 was used as a marker of cell activation and measured by ELISA. Results expressed as 
mean ± SEM for n=6. Data were analysed by one-way ANOVA with Dunnett’s multiple 
comparison test; *p<0.05. 
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5.5 Results tables 
 CXCL8 release 
ng/ml 
 CXCL8 release 
ng/ml 
 CXCL8 release 
ng/ml 
iE-DAP 
μg/ml 
 C12-iE-DAP 
μg/ml 
 LPS 
μg/ml 
 
CTRL 3.3 ± 0.7 CTRL 3.1 ± 0.1 CTRL 4.0   ± 0.5 
0.01 1.9 ± 0.1 0.01 2.1 ± 0.2 0.01 9.7   ± 1.1 
0.1 3.7 ± 0.5 0.1 2.3 ± 0.3 0.1 23.5 ± 0.4* 
1 2.0 ± 0.2 1 2.8 ± 0.1 1 32.8 ± 2.3* 
10 2.2 ± 0.5 10 2.7 ± 0.1 10 23.9 ± 1.0* 
 
Table 5.3: NOD1 and TLR4 ligand induced CXCL8 release in HPASM at 48 hours. HPASM were 
cultured for 48 hours in 96 well plates with media alone or with iE-DAP (0.01-10μg/ml), C12-
iE-DAP (0.001-1μg/ml) and LPS (0.001-1μg/ml). Results are expressed as mean ± SEM for 
n=4 from 2 experiments. Results were analysed by one-way ANOVA with Dunnett’s post-test 
(*P<0.05). 
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Agonist CXCL8 release (ng/ml) CXCL8 release (ng/ml; 
mean/#donor) 
 Mean ± S.E.M donors #1-
4 
#1 #2 #3 #4  
Control 1.1 ± 0.5 1.8 2.1 0.1 0.5  
iE-DAP 10µg/ml 1.2 ± 0.5 2.0 2.3 0.3 0.2  
LPS 1μg/ml 80.3 ± 10.7 64.7 70.6 74.1 112.0  
 Mean ± S.E.M. donors #5-
9 
#5 #6 #7 #8 #9 
Control 7.0 ± 4.8 25.7 6.4 2.4 0.3 0.2 
C12-iE-DAP 10μg/ml 19.0 ± 9.2 49.6 28.0 16.4 0.6 0.4 
LPS 1μg/ml 28.7 ± 10.8 51.0 39.3 47.8 2.6 2.9 
 
Table 5.4: Effect of NOD1 agonists, iE-DAP or C12-iE-DAP and TLR4 agonist LPS on induction 
of CXCL8 release from PBMCs at 24 hours. Results are expressed as CXCL8 release in ng/ml 
from, in the first part of the table, n=4 donors and in the second part of the table n=5 
donors. 
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Gene Mean Fold Change: 
iE-DAP (NOD1) v CTRL 
Mean Fold Change: 
LPS (TLR4) v CTRL 
ABCF1 1.2 ± 0.2 1.2 ± 0.2 
BCL6 2.1 ± 0.4 2.7 ± 0.7 
C3 1.2 ± 0.9 2.7 ± 2.1 
C4A 1.4 ± 0.4 1.4 ± 0.7 
C5 1.0 ± 0.3 1.1 ± 0.5 
CCL1 5.5 ± 2.8 6.8 ± 4.9 
CCL11 5.3 ± 4.2 10.1 ± 8.1 
CCL13 3.4 ± 1.9 6.3 ± 4.0 
CCL15 2.2 ± 1.2 0.5  ± 0.3 
CCL16 2.3 ± 0.9 9.8 ± 5.8 
CCL17 3.6 ± 2.2 5.3 ±2.1 
CCL18 2.3 ± 1.1 1.9 ± 1 
CCL19 1.7 ± 1.0 2.8 ± 2.3 
CCL2 6.8 ± 1.6 8.5 ± 1.6 
CCL20 69.6 ± 43.6 87.8 ± 33.7 
CCL21 0.7 ± 0.4 0.8 ± 0.4 
CCL23 1.3 ± 0.3 1.0 ± 0.6 
CCL24 1.0 ± 0.1 1.1 ± 0.3 
CCL25 1.5 ± 0.5 2.9 ± 1.8 
CCL26 2.2 ± 0.8 2.5 ± 1.1 
CCL3 3.7 ± 1.9 6.3 ± 3.0 
CCL4 10.7 ± 8.1 16.0 ± 8.7 
CCL5 19.8 ± 15.1 17.5 ± 3.9 
CCL7 8.3 ± 2.9 9.5 ± 2.7 
CCL8 32.0 ± 17.4 29.5 ± 13.4 
CCR1 1.7 ± 0.9 4.1 ± 3.0 
CCR2 11.7 ± 11.3 7.8 ± 7.2 
CCR3 2.2 ± 1.3 5.4 ± 3.5 
CCR4 4.9 ± 2.5 10.2 ± 8.1 
CCR5 1.2 ± 0.5 1.3 ± 0.4 
CCR6 0.7 ± 0.4 2.0 ± 1.4 
CCR7 0.7 ± 0.4 0.8 ± 0.4 
CCR8 0.6 ± 0.4 0.7 ± 0.4 
CCR9 1.7 ± 0.6 2.3 ± 1.3 
CEBPB 1.0 ± 0.2 1.7 ± 0.5 
CRP 3.2 ± 2.7 0.7 ± 0.4 
CX3CR1 1.8 ± 1.1 2.5 ± 1.6 
CXCL1 4.5 ± 1.1 27.9 ± 5.8 
CXCL10 11.9 ± 7.8 26.2 ± 10.6 
CXCL11 2.0 ± 0.9 4.8 ± 0.9 
CXCL12 0.8 ± 0.2 0.7 ±0.2 
Table 5.5: Expression patterns of 84 
pro-inflammatory genes in HMVEC 
following stimulation of NOD1 or TLR4. 
Raw data showing fold change relative 
to control for cells stimulated with iE-
DAP 10µg/ml or LPS 1µg/ml. Results are 
expressed as mean ± SEM from 2 
donors and 4 experimental days. 
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CXCL13 0.8 ± 0.4 0.8 ± 0.4 
CXCL14 1.1 ± 0.5 7.8 ± 6.8 
CXCL2 20.3 ± 6.2 192.7 ± 62.4 
CXCL3 19.6 ± 6.9 168.3 ± 43.9 
 CXCL5 2.8 ± 0.6 9.3 ± 1.7 
CXCL6 5.0 ± 1.3 18.6 ± 3.4 
CXCL9 0.8 ± 0.4 3.7 ± 2.5 
CARD18 14.0 ± 8.3 1.1 ± 0.3 
IFNA2 4.4 ± 3.4 2.6 ± 1.2 
IL10 1.7 ± 0.6 1.9 ± 0.2 
IL10RA 0.2 ± 0.1 0.6 ± 0.2 
IL10RB 0.9 ± 0.2 0.9 ± 0.2 
IL13 0.8 ± 0.4 0.7 ± 0.3 
IL13RA1 0.9 ± 0.1 0.9 ± 0.1 
IL17C 3.0 ± 2 3.2 ± 1.2 
IL1A 3.8 ± 0.9 9.2 ± 2.9 
IL1B 6.5 ± 1.8 21.6 ± 5.8 
IL1F10 0.7 ± 0.4 0.8 ± 0.5 
IL1F5 2.3 ± 1.3 4.9 ± 2.9 
IL1F6 1.5 ± 0.7 2.8 ± 1.2 
IL1F7 1.0 ± 0.4 2.9 ± 1.7 
IL1F8 1.0 ± 0.3 0.8 ± 0.2 
IL1F9 2.5 ± 1.1 3.7 ± 3 
IL1R1 0.7 ± 0.3 0.9 ± 0.3 
IL1RN 1.2 ± 0.2 1.0 ± 0.1 
IL22 1.3 ± 0.6 3.7 ± 2.5 
IL5 3.5 ± 2 8.6 ± 4.9 
IL5RA 0.9 ± 0.5 0.8 ± 0.3 
IL8 5.8 ± 1.4 14.1 ± 4 
IL8RA 2.1 ± 1.5 10.0 ± 4.5 
IL8RB 1.4 ± 0.7 4.4 ± 3.3 
IL9 1.1 ± 0.6 2.1 ± 1.2 
IL9R 1.8 ± 0.8 5.6 ± 4.3 
LTA 3.8 ± 2.2 4.1 ± 1.4 
LTB 16.5 ± 6.8 17.8 ± 5 
LTB4R 0.9 ± 0.3 0.9 ± 0.4 
MIF 0.9 ± 0.1 0.9 ± 0.1 
SCYE1 1.1 ± 0.2 1.1 ± 0.2 
SPP1 1.6 ± 0.7 0.7 ± 0.3 
TNF 132.3 ± 65.1 151.1 ± 45.6 
CD40LG 0.7± 0.5 0.7 ± 0.3 
TOLLIP 1.0 ± 0.2 1.0 ± 0.1 
XCR1 1.2 ± 0.6 6.2 ± 4.5 
Table 5.5: continued 
178 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.6: Expression patterns of 84 pro-inflammatory genes in HMVEC following 
stimulation of NOD1 or TLR4. Genes that were consistently (on each experimental day) 
increased or decreased by 1.5 fold or above following NOD1 stimulation with the equivalent 
fold change in response to TLR4 stimulation in the adjacent column. *CXCL5 was induced 
only 1.4 fold by iE-DAP on the 4th experimental day but this gene was included in the table 
for comparative purposes. 
  
 
Gene Fold Change: 
iE-DAP (NOD1) v CTRL 
Fold Change: 
LPS (TLR4) v CTRL 
TNF  132.3  151.1  
CCL20  69.6  87.8  
CXCL2  20.3  192.7  
CCL5  19.8  17.5  
CXCL3  19.6  168.3  
LTB  16.5  17.8  
CCL7  8.3  9.5  
CCL2  6.8  8.5  
IL-1β  6.5  21.6  
IL8/CXCL8  5.8  14.1  
CCL1  5.5  6.8  
CXCL6  5.0  18.6  
CXCL1  4.5  27.9  
IL-1α  3.8  9.2  
*CXCL5 2.8 9.3 
 IL10RA  -6.2  -1.6  
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Agonist MTT assay. Results expressed as % viability 
of unstimulated cells. 
FK565 10exp-7 M 115.9 ± 4.3 
C12-iE-DAP 1µg/ml 101.7 ± 2.4 
LPS 1µg/ml 104.8 ± 4.5 
 
Table 5.7: The effect of NOD1 and TLR4 agonists on HPASM cell viability at 24 hours as 
measured by the MTT assay. Data from n=6. Results are expressed as a % of the cell viability 
of unstimulated cells and are presented as mean ± S.E.M. Data were analysed using one 
sample t-test for normalized data.  
 
Agonist Alamar blue assay. Results expressed as % 
viability of unstimulated cells. 
C12-iE-DAP 1µg/ml 98.7 ± 2.5 
LPS 1µg/ml 97.1 ± 2.0 
 
Table 5.8: The effect of C12-iE-DAP (NOD1) and LPS (TLR4) on HPASM cell viability at 24 
hours as measured by the Alamar Blue assay. Data from n=4. Results are expressed as a % of 
the cell viability of unstimulated cells and are presented as mean ± S.E.M. Data were 
analysed using one sample t-test for normalized data.  
 
Agonist MTT assay. Results expressed as % viability 
of unstimulated cells. 
M-Tri-DAP 10µg/ml 105.5 ± 4.3 
M-Tri-DAP 10µg/ml + LPS 0.01µg/ml 127.7 ± 5.9 
MDP 10µg/ml 117.5 ± 5.5 
MDP 10µg/ml + LPS 0.01µg/ml 115.0 ± 4.4 
 
Table 5.9: The effect of NOD1 and TLR4 agonists, alone and in combination on HPASM cell 
viability at 24 hours as measured by the MTT assay. Data from n=6. Results are expressed as 
a % of the cell viability of unstimulated cells and are presented as mean ± S.E.M. Data were 
analysed using one sample t-test for normalized data.  
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Agonist MTT assay. Results expressed as % viability 
of unstimulated cells. 
iE-DAP (µg/ml)  
0.01 103.5 ± 4.0 
0.1 102.5 ± 4.1 
1 106.9 ± 3.4 
10 94.5   ± 3.4 
C12-iE-DAP (µg/ml)  
0.001 117.6 ± 4.3 
0.01 117.2 ± 4.7 
0.1 100.9 ± 2.3 
1 106.5 ± 5.8 
LPS (µg/ml)  
0.01 122.1 ± 5.9 
0.1 114.5 ± 5.2 
1 95.2   ± 5.6 
10 99.5   ± 6.5 
 
Table 5.10: The effect of NOD1 and TLR4 agonists on HMVEC cell viability at 24 hours as 
measured by the MTT assay. Data from n=12. Results are expressed as a % of the cell 
viability of unstimulated cells and are presented as mean ± S.E.M. Data were analysed using 
one sample t-test for normalized data.  
 
Agonist Alamar Blue assay. Results expressed as % 
viability of unstimulated cells. 
iE-DAP (µg/ml)  
1 102.8 ± 3.0 
10 105.3 ± 3.3 
C12-iE-DAP (µg/ml)  
0.1 101.1 ± 1.8 
1 105.5 ± 4.2 
LPS (µg/ml)  
1 102.6 ± 2.8 
10 101.0 ± 5.0 
MDP (µg/ml)  
1 107.2 ± 3.1 
10 100.8 ± 1.6 
 
Table 5.11: The effect of NOD1, NOD2 and TLR4 agonists on HMVEC cell viability at 24 hours 
as measured by the Alamar Blue assay. Data from n=9. Results are expressed as a % of the 
cell viability of unstimulated cells and are presented as mean ± S.E.M. Data were analysed 
using one sample t-test for normalized data.  
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Agonist Alamar Blue assay. Results expressed as % 
viability of unstimulated cells. 
iE-DAP 10µg/ml 108.5 ± 29.7 
LPS 1µg/ml 114.9 ± 23.2 
 
Table 5.12: The effect of iE-DAP (NOD1) and LPS (TLR4) on HAEC cell viability at 24 hours as 
measured by the Alamar Blue assay. Data from n=6. Results are expressed as a % of the cell 
viability of unstimulated cells and are presented as mean ± S.E.M. Data were analysed using 
one sample t-test for normalized data.  
 
Agonist Alamar Blue assay. Results expressed as % 
viability of unstimulated cells. 
PAM3 1 µg/ml 
95.0 ± 6.0 
HKLM 10exp9 cells/ml 
92.4 ± 6.8 
Poly I/C 10µg/ml 
86.8 ± 3.9* 
Poly I/C LMW 10µg/ml 
91.3 ± 4.6 
LPS 1µg/ml 
86.9 ± 2.8* 
FLG 10µg/ml 
89.7 ± 4.7 
FSL-1 1µg/ml 
89.0 ± 4.0* 
IMI 10µg/ml 
90.0 ± 4.9 
ssRNA 10µg/ml 
88.8 ± 4.6 
ODN2006 5µM 
87.3 ± 3.9* 
 
Table 5.13: Effect of stimulation with TLR ligands on HMVEC cell viability at 24 hours as 
measured by the Alamar Blue assay. Data from n=6. Results are expressed as a % of the cell 
viability of unstimulated cells and are presented as mean ± S.E.M. Data were analysed using 
one sample t-test for normalized data *P<0.05.  
PAM3 (Pam3CysSerLys4), TLR1/2 agonist; HKLM (heat killed listeria monocytogenes), TLR2 agonist; Poly HMW 
(Poly I:C high molecular weight), TLR3 agonist; POLY LMW (Poly I:C low molecular weight), TLR3 agonist; LPS 
(lipopolysaccharide), TLR4 agonist; Flag (flagellin), TLR5 agonist; FSL-1 (Pam2CGDPKHPKSF), TLR6/2 agonist; Imi 
(imiquimod), TLR7 agonist; ssRNA (single stranded RNA 40), TLR8 agonist; ODN (ODN2006 type B), TLR9 
agonist.  
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5.5 Summary 
In Chapter 4, I have demonstrated that, in rat aorta, the endothelium has a predominant 
role in the sensing of Gram negative PAMPS associated with TLR4 and NOD1 receptors, 
certainly within the first 24 hours. In addition whole human pulmonary artery was 
responsive to NOD1 agonists supporting the relevance of further study in human vascular 
cell lines. In keeping with the rat organ culture findings, in this chapter experiments using 
HPASM and HMVEC demonstrate that NOD1 agonists are more active on the human 
endothelium than smooth muscle. This observation was strengthened by demonstration of 
avid NOD1 agonist responses in other human endothelial cells including HUVEC and HAEC. 
Although HPASM did not respond directly to NOD1 agonists, there was some evidence of an 
upregulated response in protocols where cells were co-stimulated with LPS. Unlike the case 
of rat VSM versus murine macrophage in chapter 3, the difference in response between 
HMVEC and HPASM did not seem to be due to NOD1 expression, as NOD1 RNA was 
detected in both cell types, although these experiments have limitations (see below).  
In the case of human monocytes, my data was not clear cut or conclusive. Using the human 
monocytic cell line, THP-1, revealed no evidence of NOD1 responses, despite, clear 
activation by LPS. This data is in keeping with the results seen in Chapter 3 where NOD1 was 
not expressed and NOD1 agonists were inactive on murine macrophages. However, 
experiments using primary human monocytes (PBMCs) produced variable results. Cells from 
4 donors did not respond to the NOD1 agonist iE-DAP, clearly suggesting no NOD1 response. 
However, in a separate study cells of 3 of the 5 donors tested did respond to NOD1 agonist 
C12-iE-DAP. As discussed in the introduction these two agonists are both avid activators of 
the NOD1 receptor, but C12-iE-DAP is membrane permeable and able to gain easier access 
to the cytosol in some cells. Clearly, for endothelial cells there is little or no major efficacy 
difference between these two agonists for NOD1 activation, but this could be different in 
PBMCs. The reason why 2 of the 5 donors did not respond to C12-iE-DAP is not clear. 
What was very clear, however, was the finding that PBMCs did not respond to iE-DAP, 
whereas HMVEC responded well. This could suggest deficiency of uptake of the minimal 
NOD1 stimulating ligand (iE-DAP) into PBMCs. C12-iE-DAP would avoid this as it is cell 
permeable. Following this argument, HMVEC may have specific uptake pathways for Gram 
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negative peptidoglycan components, in keeping with my emerging data that the 
endothelium represents a key site of NOD1 signalling.  
In order to understand the inflammatory effects of NOD1 and TLR4 stimulation in HMVEC in 
more detail, the responses to specific agonists were measured at the gene and protein level 
for a wide variety of inflammatory agents. Overall these findings showed that for both NOD1 
and TLR4 a remarkably similar pattern of inflammatory events were induced. NOD1 and 
TLR4 agonists induced cytokines and chemokines, with no major difference at the level of 
protein release for 9 individual cytokines/chemokines and at the level of gene modulation 
for 86 related genes. In the case of cytokine/chemokine release, the major mediator was 
found to be CXCL8, although either NOD1 or TLR4 agonists similarly induced other pro-
inflammatory cytokines. This finding was particularly important in terms of validation of the 
majority of data using human systems in my thesis, where CXCL8 has been used as the 
primary readout. In the case of gene expression, CXCL8 gene was induced by either NOD1 or 
TLR4 agonists, again, this very much validates my observations using CXCL8 protein release. 
It was interesting to see that both NOD1 or TLR4 agonists down regulated some genes and, 
as with induced genes, the pattern of gene inhibition was comparable between the two. 
Finally NOD1 stimulation has been put into a wider context of pathogen mediated signalling 
by exposing HMVEC to multiple TLR agonists. This suggests that NOD1 is one of only a few 
identified PRRs that is highly active in these cells, as significant CXCL8 release was only 
observed with the TLR3 agonist Poly I:C along with LPS. 
Therefore having established that HMVEC represent a cell model where both NOD1 and 
TLR4 pathways are active, in the next chapter I have used specific pharmacological inhibitors 
to establish the validity, in HMVEC, of known NOD1/TLR4 signalling pathways whilst 
attempting to pharmacologically differentiate the activity of each receptor. Importantly I 
was able to obtain a highly novel selective NOD1 receptor antagonist, which I profiled in 
these cells. 
There are some limitations to the data presented in this chapter. The primary human cells 
used have been obtained from either pulmonary artery (HPASM) or directly from lung 
parenchyma (HMVEC), but not from systemic vessels. Therefore caution must be exercised 
in concluding any differences in NOD1 agonist responsiveness between endothelium and 
smooth muscle as vascular smooth muscle cells are heterogeneous and differences have 
been observed between vessels, particularly between the pulmonary and systemic 
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circulation. Data presented in this chapter suggests that there may be differences in NOD1 
agonist uptake between PBMCs and endothelial cells which may explain the different 
responses to the minimal NOD1 stimulating peptide iE-DAP. This hypothesis would ideally 
be investigated further, perhaps by use of drugs to block active clathryn mediated 
endocytosis or by direct imaging of agonist entry into the cell. In a similar fashion the data 
suggests that whilst HPASM are unresponsive to NOD1 agonist stimulation alone, there is 
evidence of enhanced response when co-treated with threshold concentrations of LPS. It 
would be important to consider this in more detail, perhaps at the level of agonist entry or 
NOD1 and TLR4 gene induction. Finally as is the case with data presented in Chapters 3 and 
4, I have relied on the use of selective NOD1 agonists to support a role for NOD1 specific 
effects in vascular cells. This has not yet been validated in my thesis by the use of alternative 
techniques such as specific antagonists or gene knockdown. This point is addressed in part 
in Chapter 6. 
Discussion 
The relevance of these observations is discussed in detail in Chapter 7. 
Having established that HMVEC represent a cell model where both NOD1 and TLR4 
pathways are active, in the next chapter I have used specific pharmacological inhibitors to 
establish the validity, in HMVEC, of known NOD1/TLR4 signalling pathways whilst 
attempting to pharmacologically differentiate the activity of each receptor. Importantly I 
was able to obtain a highly novel selective NOD1 receptor antagonist, which I profiled in 
these cells. 
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Chapter 6: 
Signalling pathways downstream of NOD1 and TLR4 in human 
endothelial cells 
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6.1 Rationale 
The experiments described in Chapters 4 and 5 have translated findings in rodent tissues to 
validate the activity of nucleotide oligomerisation domain-1 (NOD1) ligands in human vessel 
and cultured human endothelial cells. NOD1 and Toll-like receptor 4 (TLR4) represent two 
major receptors to detect Gram negative bacteria (Mitchell, Paul-Clark et al. 2007) and in 
reality, infection will produce multiple overlapping signals from innate immune receptors. 
Further investigation of the signalling pathways downstream of NOD1 and TLR4 may help to 
determine the relative roles played by each receptor in vascular inflammation, as well as 
offering the potential for new therapeutic targets. 
NOD1 and TLR4 signalling pathways have been well characterised in the literature as 
discussed in detail earlier in Chapter 1. However, in the vasculature these pathways remain 
to be fully explored and validated. Briefly TLR4 has been shown to signal via two adapter 
protein pathways following LPS stimulation. The MyD88 pathway leads to nuclear factor 
kappa B (NFκB) activation via recruitment of IL-1 receptor-associated kinase-1 (IRAK-1), 
IRAK-4 and TNF receptor associated factor-6 (TRAF-6). Subsequent phosphorylation of 
transforming growth factor beta activating kinase 1 (TAK1) leads to activation of the IkappaB 
kinase (IKK) complex and translocation of NFκB to the nucleus to initiate gene transcription 
(Kanayama, Seth et al. 2004). An alternative TIR domain-containing adaptor molecule-
inducing IFN-γ (TRIF) pathway signals via interferon regulatory factor 3 (IRF-3) to induce 
NFκB (Yamamoto, Takeda et al. 2004). A role for TAK1 and NFκB has also been 
demonstrated in NOD1 and NOD2 signalling (Hasegawa, Fujimoto et al. 2008). In addition 
the mitogen activated protein kinase (MAPK) family has been implicated in downstream 
signalling from NOD1 and TLR4 (Strober, Murray et al. 2006). Accordingly in this chapter the 
relative role of NFκB, TAK1, MAPK and associated signalling proteins following NOD1 and 
TLR4 stimulation in the vasculature have been investigated using specific pharmacological 
inhibitors and immunohistochemistry. 
Receptor interacting protein 2 (RIP2) has been identified as a downstream signalling protein 
specific to the NOD pathway but not TLRs (Park, Kim et al. 2007). In support of this, data in 
Chapters 3 and 4 using RIP2 inhibitors demonstrates a specific effect on NOD1 agonist 
mediated nitric oxide (NO) release by rat vascular smooth muscle (VSM) and whole aorta. 
Data in Chapter 5 clearly reveals human endothelial cells as a system that supports both 
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NOD1 and TLR4. Accordingly, in this chapter, I have used commercial as well as novel 
inhibitors to differentiate NOD1 and TLR4 signalling in human lung microvascular 
endothelial cells (HMVECs). I have used CXCL8 release and NFκB translocation to assess 
NOD1 and TLR4 responses.  In order to obtain highly novel inhibitors of RIP2 and NOD1 I 
have formed a collaboration with GSK who donated compounds that allowed me to be the 
first to pharmacologically differentiate the NOD1 and TLR4 pathways in human endothelial 
cells Unfortunately precise structural and mechanistic information on the novel RIP2 and 
NOD1 inhibitor compounds is unavailable to me at this time as this remains confidential to 
GSK under the terms of our material transfer agreement. However general details on the 
approach used to synthesize the RIP2 and NOD1 inhibitors are given in the methods section 
below and my experiments presented in this Chapter seek to address the competitive / non-
competitive relationship of the NOD1 inhibitor. 
6.2 Methods 
Methods are described in Chapter 2 in detail with brief details given below 
Cell culture: 
HMVEC were from PromoCell cultured according to manufactures recommendations as 
described in Chapter 2. Cells were cultured in 25-175cm2 sterile culture flasks with 
appropriate cell culture medium (see Table 6.1). Endothelial cells were treated in 96 well 
plates at a seeding density of 8x103 cells/well respectively.  
THP-1 cells, from a human monocytic leukaemia cell line, were obtained from the European 
collection of cell cultures (ECACC) and cultured in RPMI 1640 media supplemented with 10% 
FCS, Pen-Strep (Table 6.1) and NEAA and seeded in 96-well plates at a density of 1x105 
cells/well. 
Peripheral blood mononuclear cells (PBMCs) were isolated from human donors (Research 
Ethics Committee number 08/H0805/58) and treated at a density of 1x105 cells/well in RPMI 
supplemented with 3% autologous serum (Table 6.1) as described in Chapter 2. 
Treatments: 
Cell culture experiments data are mean ± S.E.M for separate incubations and unless 
otherwise stated protocols were repeated on at least 3 separate experimental days with 
separately prepared cells and drugs. Unless otherwise stated, all protocols using passaged 
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cells were carried out on cells from at least 2 separate donors using cells at different 
passage ranging from passage 3-9. For experiments using PBMCs cells from 5 separate 
donors were used. The primary NOD1 agonist used in this Chapter was the minimal NOD1 
stimulating peptide iE-DAP. However the NOD1 agonist C12-iE-DAP was also used in 
experiments measuring NFκB nuclear translocation at early timepoints as C12-iE-DAP is 
membrane permeable and able to rapidly induce NOD1 signalling. As previously described 
novel inhibitors of RIP2 (GSK’214) and NOD1 (GSK’217) were obtained via collaboration with 
Dr John Bertin of the Pattern Recognition Receptor DPU, GalxoSmithKline Pharmaceuticals, 
USA. RIP2 inhibitors were identified by using a RIP2 kinase ligand binding assay to screen a 
library of small molecules enriched in chemical templates that have previously been shown 
to be kinase inhibitors. Initial hits from this screen were optimized for potency, selectivity 
and other drug development properties by iterative rounds of chemical synthesis. GSK’214 
represents a significantly optimized compound that demonstrates high potency against RIP2 
in biochemical and cellular assays, along with excellent selectivity against the vast majority 
of other kinases in the kinome. Inhibitors of NOD1 were identified using a cell based assay 
measuring the blockade of IL-8 production following iE-DAP stimulation of HEK cells stably 
expressing NOD1. Selective NOD1 inhibitors were identified using a triaging strategy to 
eliminate compounds that also inhibited IL-8 production following stimulation of either the 
NOD2 or TLR2 signaling pathways. Iterative rounds of chemical synthesis led to the 
identification of GSK’217 which had increased potency relative to the initial screening hits, 
while maintaining its selectivity against the other inflammatory signaling pathways 
examined. See Table 6.2 for details of all drugs used in Chapter 6. 
Measurement of CXCL8: 
CXCL8 release was measured in cell culture supernatants by specific enzyme-linked 
immunosorbent assay (ELISA) (R&D systems, UK).  
Measurement of NF-κB translocation: 
HMVEC treated for 1h and NFκB imaged using a Cellomics VTi HTS Arrayscanner (Thermo 
Fisher, Pittsburgh, US) as described in Chapter 2 (Ding, Fischer et al. 1998). 
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Knockdown of NOD1 using small interfering RNA (siRNA): 
For NOD1 siRNA knockdown, targeting NOD1 siRNA (Hs_CARD4_1 Flexitube siRNA 
(NM_006092)) (Qiagen, Crawley, UK) was used according to manufacturer’s instructions as 
described in Chapter 2. 
 
Table 6.1: Cell culture media and supplements used for experiments in Chapter 6. 
  
Cell Media Supplements 
HMVEC (Promocell) Endothelial Cell Growth  
Medium-MV2  (Promocell) 
5%  FCS, EGF 5ng/ml, FGF 
10ng/ml, Long R3 IGF-1 
20ng/ml, VGEF 0.5ng/ml, 
Ascorbic acid 1µg/ml and 
hydrocortisone 0.2 µg/ml 
PBMC RPMI (Gibco) 3% autologous serum, NEAA, 
Pen-Strep and L-glutamine. 
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Table 6.2: Drugs used in human cell culture experiments. 
 
Agonist / Drug Mechanism of action Dose range Solvent 
iE-DAP NOD1 agonist 0.01-10µg/ml H20 
C12-iE-DAP NOD1 agonist 0.001-1µg/ml H20 
MDP  NOD2 agonist 0.01-10µg/ml H20 
LPS TLR4 agonist 0.01-1µg/ml H20 
Dexamethasone Corticosteroid 0.01-10μg/ml DMSO 
SC-514 IKK2 inhibitor 0.1-30μM DMSO 
5Z-7-oxozeaonol TAK1 inhibitor 0.001-1μM DMSO 
BIRB0796 P38 MAPK inhibitor 0.001-1μM DMSO 
PD184352 ERK inhibitor 0.001-1μM DMSO 
TI-JIP 153-163  JNK inhibitor 0.1-30µM DMSO 
SB203580 p38 MAPK/RIP2 
inhibitor 
0.001-1μM DMSO 
PP2 RIP2/src kinase 
inhibitor 
0.01-1μM DMSO 
KbNB-142-70 PKC inhibitor 0.01-10μM DMSO 
Z-VAD-fmk Caspase inhibitor 0.01-10μM DMSO 
GSK’214 RIP2 inhibitor 0.01-1μM DMSO 
GSK’217 NOD1 inhibitor 0.01-0.3µM DMSO 
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6.3 Results 
6.3.1 NOD1 and TLR4 ligand induced CXCL8 release from HMVEC 
In order to analyse the signalling pathways downstream of NOD1 and TLR4 a variety of cell 
signalling inhibitors were used prior to stimulation of cells by iE-DAP 10µg/ml (NOD1) or LPS 
1µg/ml (TLR4). As before CXCL8 was used as a marker of cell induction. As found in Chapter 
5, in experiments presented in this chapter iE-DAP or LPS induced increased release of 
CXCL8 from HMVEC (Figure 6.1) with LPS inducing greater release of CXCL8 than iE-DAP 
(again in agreement with previous experiments described in Chapter 5).  
6.3.2 Role of TAK1 and NFκB in NOD1 and TLR4 signalling in HMVEC 
To investigate the role of the signalling protein TAK1 and the ubiquitous pro-inflammatory 
transcription factor NFκB in this model, the specific TAK1 inhibitor 5Z-7-oxozeaonol (0.001-
1µM) and the IKK2 inhibitor SC-514 (0.1-30µM) were used. CXCL8 was induced with iE-DAP 
10µg/ml or LPS 1 µg/ml. Pre-treatment with 5Z-7-oxozeaonol for 30 minutes led to clear 
concentration-dependent inhibition of CXCL8 induced by either iE-DAP or LPS (Figure 6.2A). 
Conversely 30 minutes pre-treatment with the IKK2 inhibitor SC-514 failed to inhibit CXCL8 
release induced by either agonist (Figure 6.2B). NFκB driven cytokine release often shows 
sensitivity to corticosteroid treatment. In order to investigate this, the corticosteroid 
dexamethasone (0.01-1µM) was used. In keeping with the effect of SC-514, 30 minutes pre-
treatment with dexamethasone only produced a very mild inhibition of CXCL8 release by iE-
DAP or LPS (Figure 6.2C).  
In Chapter 3 I show that SC-514 inhibits NOD1 or TLR4 induced iNOS activity in rat VSM cells 
and in Chapter 4 I show the same is true for NO release by whole rat aorta in organ culture. 
The lack of effect, therefore, seen with SC-514 in CXCL8 release by HMVEC was somewhat 
surprising. To validate the lack effect of SC-514 and dexamethasone  an alternative model 
using THP-1 monocytes was used, as NFκB mediated CXCL8 release by LPS has been 
previously demonstrated in these cells (Birrell, Wong et al. 2006). In contrast to the results 
observed in HMVEC, 30 minutes pre-treatment of THP-1 cells with SC-514 (0.1-30µM) or 
dexamethasone (0.01-10µM) strongly inhibited CXCL8 release following 24 hours 
stimulation with LPS 1µg/ml (TLR4) suggesting a difference in NFκB mediated CXCL8 release 
in HMVEC following LPS (and by proxy NOD1) stimulation (Table 6.3).To further explore 
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whether NOD1 or TLR4 agonists were able to activate NFκB in HMVEC an 
immunohistochemical technique was used. One hour stimulation of cultured HMVEC with 
C12-iE-DAP 1µg/ml (NOD1), LPS 1µg/ml (TLR4) or IL-1β 1ng/ml (positive control) led to 
nuclear translocation of NFκB reflecting its activation. C12-iE-DAP and IL-1β led to profound 
NFκB nuclear translocation whereas LPS only induced modest translocation at one hour 
which did not reach statistical significance (Figure 6.3A and 6.3C). In addition the presumed 
role for TAK1 upstream of NFκB activation was strengthened in this experiment. The specific 
TAK1 inhibitor 5Z-7-oxozeaonol (1µM) profoundly inhibited the NFκB nuclear translocation 
induced after one hour by C12-iE-DAP, LPS and IL-1β (Figure 6.3A and 6.3C). The effects of 
the NOD1 and TLR4 agonists, IL-1β and TAK1 inhibitor on NFκB were mirrored at the protein 
level as reflected by paired CXCL8 release (Figure 6.3B). 
6.3.3 Role of MAPK, PKC and the inflammasome in NOD1 and TLR4 signalling in HMVEC 
To explore the role of MAPK in the induction of HMVEC specific cell signalling inhibitors 
were used. BIRB0796 and PD184352 have been described previously in Chapter 3 and are 
selective inhibitors of p38 MAPK (Kuma, Sabio et al. 2005) and extracellular signal-regulated 
kinase (ERK) (Allen, Sebolt-Leopold et al. 2003) respectively. In addition TI-JIP153-163 has been 
demonstrated to be a selective c-Jun N-terminal kinase (JNK) inhibitor (Barr, Boehm et al. 
2004).  
CXCL8 release was induced from HMVEC by iE-DAP 10µg/ml and LPS 1µg/ml. 30 minutes 
pre-treatment with the p38 MAPK inhibitor BIRB0796 (0.001-1µM) inhibited CXCL8 release 
induced by either agonist in a concentration dependent fashion (Figure 6.4A). In contrast 
the ERK inhibitor PD184352 (0.001-1µM) and JNK inhibitor TI-JIP153-163 (0.1-30µM) had no 
effect on CXCL8 release induced by either iE-DAP or LPS (Figures 6.4B and 6.4C). 
As described in Chapter 3, Protein Kinase C (PKC) has been implicated in inflammatory 
signalling downstream of LPS (Asehnoune, Strassheim et al. 2005). Previous experiments in 
the group and the results described in Chapter 3 gave contrasting results. The PKC inhibitor 
Gö6976 which inhibits all isoforms of PKC including PKD (Way, Chou et al. 2000) selectively 
blocked TLR4 signalling in J774.2 macrophages without effecting NOD1 responses in VSM 
cells (Moreno, McMaster et al. 2010). However the inhibitor KbNB-142-70, which also shows 
striking inhibition of PKD (Lavalle, Bravo-Altamirano et al. 2010) inhibited NOD1 and not 
TLR4 responses (Chapter 3, Figure 3.12). In HMVEC, pre-treatment with KbNB-142-70 
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(0.001-1µM) failed to inhibit CXCL8 release induced by either iE-DAP (NOD1) or LPS (TLR4) 
(Figure 6.5A).  
Finally NOD signalling can induce activation of the inflammasome. In agreement with the 
results obtained with VSM and macrophages in Chapter 3, the pan-caspase inhibitor Z-VAD-
fmk (0.01-10µg/ml) failed to inhibit CXCL8 release in HMVECs stimulated with either iE-DAP 
or LPS (Figure 6.5B). 
6.3.4 Role of RIP2 in NOD1 and TLR4 signalling in HMVEC 
Several pharmacological inhibitors were used in this chapter to investigate the role of RIP2 
in NOD1 and TLR4 mediated inflammation in HMVEC. The compound SB203580 has been 
extensively used as a p38 MAPK inhibitor but has also been demonstrated to potently 
inhibit RIP2 (Godl, Wissing et al. 2003). In addition the Src kinase inhibitor PP2 has been 
shown to inhibit RIP2 (Windheim, Lang et al. 2007) and indeed showed selective inhibition 
of NOD1 mediated NO release in VSM cells as described in Chapter 3. Finally a novel highly 
selective RIP2 inhibitor, GSK’214, was used to further characterise the role of RIP2 in 
activation of NFκB and subsequent CXCL8 release in HMVEC. 
Pre-incubation for 30 minutes with SB203580 (0.001-1µM) led to a concentration 
dependent inhibition of both NOD1 and TLR4 induced CXCL8 release at 24 hours in HMVEC 
(Figure 6.6A). There was significantly more inhibition of NOD1 than TLR4 responses. 
Consistent with this PP2 (0.01-10µM) significantly inhibited NOD1 mediated CXCL8 release 
at several concentrations, but only modestly inhibited TLR4 mediated CXCL8 release at the 
highest concentration used (Figure 6.6B). 
The novel RIP2 inhibitor GSK’214 (0.01-1µM) selectively inhibited NOD1 mediated CXCL8 
release from HMVEC at 24 hours when given 30 minutes prior to stimulation with iE-DAP 
(10µg/ml) (Figure 6.7A). No significant effect on TLR4 responses was observed (Figure 6.7B).  
RIP2 is described as a signalling protein upstream of NFκB in the transduction of NOD1 
responses (Hasegawa, Fujimoto et al. 2008). GSK’214 (1µm) and to a lesser extent PP2, 
significantly inhibited NFκB nuclear translocation at 1 hour in HMVEC (Figures 6.8A and 
6.8C) with associated inhibition of CXCL8 release at 24 hours (Figure 6.8B). No significant 
inhibition of basal NFκB translocation was demonstrated and there was no inhibition of 
TLR4 or positive control (IL1β) responses (Figure 6.8A). 
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6.3.5 Profile of novel NOD1 antagonist in endothelial cells and monocytes. 
There are no commercially available pharmacological NOD antagonists, however a novel 
inhibitor of NOD1, GSK’217 was obtained through the collaboration with Dr John Bertin at 
GlaxoSmithKline pharmaceuticals. 
GSK’217 (0.001-0.3µM) selectively inhibited NOD1 mediated CXCL8 release from HMVEC at 
24 hours when given 30 minutes prior to stimulation with iE-DAP (10µg/ml). The IC50 of 
GSK’217 was 0.042µM. No significant effect on TLR4 responses was observed (Figure 6.9).  
As demonstrated in Chapter 5, HMVEC do not respond to the NOD2 agonist MDP, however 
PBMCs are known to respond to NOD2 stimulation (Yu, Wong et al. 2011) therefore these 
cells were used to profile GSK’217 against NOD2 and TLR4 ligands. MDP induced at least a 
doubling of CXCL8 release relative to control in PBMCs from 4 donors (Figure 6.10A) In 
keeping with the development of GSK’217 as a specific NOD1 inhibitor, it had no effect on 
CXCL8 release induced by the NOD2 ligand MDP or LPS (Figure 6.10A + B).  
The exact mechanism of action of the novel NOD1 inhibitor GSK’217 has not been revealed 
by GSK. To assess the nature of the pharmacological inhibition, a competitive antagonism 
protocol was used where inhibition of CXCL8 release from HMVEC by increasing 
concentrations of GSK’217 (0.03-10µM) was measured at different concentrations of iE-DAP 
(1-100µg/ml). There was a ten-fold shift in IC50 from 0.01µM to 0.12µM to inhibit 
concentrations of iE-DAP from 1µg/ml to 100µg/ml (Figure 6.11). However my data does not 
conclusively prove that GSK’217 acts as a classical competitive antagonist to NOD1 ligand 
binding.  
6.3.6 Effect of NOD1 small interfering RNA (NOD1 siRNA) on NOD1, TLR4 and IL-1β 
mediated CXCL8 release in HMVEC-comparison to the novel NOD1 inhibitor GSK’217. 
In the absence of commercial inhibitors, previous researchers have used molecular 
techniques to assess the specificity of NOD1 responses. Small interfering RNA (siRNA) to 
NOD1 is one such technique which, for example, has been previously reported in the 
literature as a method of determining the role of NOD1 in responses to Chlamydia 
Pneumoniae and Listeria Monocytogenes (Opitz, Forster et al. 2005; Opitz, Puschel et al. 
2006). In order to profile GSK’217 against an siRNA technique, HMVEC were incubated with 
NOD1 siRNA or non-targeting (NT) control for 24 hours prior to stimulation with iE-DAP 
10µg/ml, LPS 1µg/ml and IL-1β (1ng/ml). HMVEC were treated in parallel with GSK’217 
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(1µM) for 30 minutes prior to addition of the same agonists. NOD1 siRNA reduced iE-DAP 
induced CXCL8 release compared to NT control, but had a similar effect on LPS, IL-1β and 
basal responses (Figure 6.12a). In contrast GSK’217 had no effect on basal CXCL8 release but 
instead specifically inhibited the response to iE-DAP, with no effect on LPS and IL-1β 
responses (Figure 6.12b). Quantities of RNA extracted from paired HMVEC were too low to 
confirm acceptable NOD1 knockdown in this experiment, this limitation is highlighted in the 
summary below. 
6.3.7 Cell viability. 
The majority of drugs used had no effect on cell viability however the JNK inhibitor              
TI-JIP153-163 exerted a modest reduction in viability (viability 82.9 ± 1.9% versus unstimulated 
cells) when cells were co-treated with LPS (Table 6.4). In addition GSK’214 induced a modest 
reduction in cell viability (viability 65.7 ± 7.9% versus unstimulated cells) with LPS co-
treatment (Table 6.5) and GSK’217 induced a very mild reduction in cell viability when co-
treated with iE-DAP (viability 95.0 ± 1.1% versus unstimulated cells) or LPS (viability 96.0 ± 
0.6% versus unstimulated cells) (Table 6.5). 
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6.4 Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Basal, NOD1 and TLR4 driven CXCL8 release in Human Lung Microvascular 
Endothelial cells (HMVEC). Cultured HMVEC were treated for 24 hours with iE-DAP 10µg/ml 
(NOD1) or LPS 1µg/ml (TLR4). CXCL8 release was measured by ELISA. Results expressed as 
mean ± SEM for n=36. Data were analysed by one-way ANOVA with Bonferroni’s multiple 
comparison test; *p<0.05, +p<0.05. 
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Figure 6.2: Role of transforming growth factor β-activated kinase 1 (TAK1), NFκB and 
corticosteroids on NOD1 and TLR4-induced CXCL8 release in HMVEC. Cultured HMVEC were 
treated with increasing concentrations of (A) the TAK1 inhibitor 5Z-7-oxozeaenol (0.001-
1µM) or (B) the I-κB kinase (IKK) 2 inhibitor SC-514 (0.1-30 μM) or (C) the corticosteroid 
dexamethasone (0.01-10µM). CXCL8 release was induced in HMVEC with iE-DAP 10μg/ml 
(NOD1) or LPS 1μg/ml (TLR4). ). Results are expressed as a percentage of response to the 
agonist alone (mean ± SEM; n=4).  Results were analysed by 1-sample t-test; *p<0.05 and by 
2-way ANOVA; ns=non-significant iE-DAP vs LPS. 
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Figure 6.3: Nuclear factor kappa B (NFκB) activation in HMVEC.  (A) NFκB nuclear intensity 
following stimulation with C12-iE-DAP 10µg/ml (NOD1), LPS 10µg/ml (TLR4), or IL-1β 1ng/ml 
for 1 hour in the presence or absence of the transforming growth factor β activating kinase 
1 (TAK1) inhibitor 5Z-7-oxozeaonol. (B) Paired CXCL8 release after 24 hours. Results are 
expressed as mean ± SEM of n=6. Data was analysed by one-way ANOVA followed by 
Bonferroni's Multiple Comparison Test; *p<0.05, +p<0.05. (C) Representative images of 
NFκB nuclear translocation under the different experimental conditions. 
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Figure 6.4: Role of mitogen activated protein kinases (MAPK) on NOD1 and TLR4-induced 
CXCL8 release in HMVEC. Cultured HMVEC were treated with increasing concentrations of 
(A) the p38 MAPK inhibitor BIRB0796 (0.001-1µM) or (B) the mixed extracellular signal-
regulated ERK inhibitor PD184352 (0.001-1µM) or (C) the c-Jun N-terminal kinase (JNK) 
inhibitor TI-JIP153-163 (0.1-30µM). CXCL8 release was induced in HMVEC with iE-DAP 
10μg/ml (NOD1) or LPS 1μg/ml (TLR4). Results are expressed as a percentage of response to 
the agonist alone (mean ± SEM; n=4). Results were analysed by 1-sample t-test; *p<0.05 and 
by 2-way ANOVA. 
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Figure 6.5: Role of the protein kinase C (PKC) and inflammasome on NOD1 and TLR4-
induced CXCL8 release by HMVEC. Cultured HMVEC were treated with increasing 
concentrations of (A) the PKC inhibitor KbNB-142-70 (0.001-1µM) or (B) the pan-caspase 
inhibitor Z-VAD-fmk (0.01-10µM). CXCL8 release was induced in HMVEC with iE-DAP 
10μg/ml (NOD1) or LPS 1μg/ml (TLR4). Results are expressed as a percentage of response to 
the agonist alone (mean ± SEM; n=4). Results were analysed by 1-sample t-test; *p<0.05 and 
by 2-way ANOVA. 
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Figure 6.6: Role of receptor interacting protein-2 (RIP2) on NOD1 and TLR4-induced CXCL8 
release in HMVEC. Cultured HMVEC were treated with increasing concentrations of (A) the 
mixed RIP2/p38 MAPK inhibitor SB203580 (0.01-10µM) or (B) the mixed RIP2/src kinase 
inhibitor PP2 (0.01-10µM). CXCL8 release was induced in HMVEC with iE-DAP 10μg/ml 
(NOD1) or LPS 1μg/ml (TLR4). Results are expressed as a percentage of response to the 
agonist alone (mean ± SEM; n=4). Results were analysed by 1-sample t-test; *p<0.05 and by 
2-way ANOVA; #p<0.05 vs. LPS. 
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Figure 6.7: Effect of a novel RIP2 inhibitor GSK’214 on NOD1 and TLR4-induced CXCL8 
release by HMVEC. Cultured HMVEC were treated with increasing concentrations of 
GSK’214 (0.01-1μM). CXCL8 release was induced in HMVEC with iE-DAP 10μg/ml (NOD1) or 
LPS 1μg/ml (TLR4). Results are expressed as a percentage of response to the agonist alone 
(mean ± SEM; n=6). Results were analysed by 1-sample t-test; *p<0.05 and by 2-way 
ANOVA; #p<0.05 vs. LPS. 
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Figure 6.8: Effect of the novel RIP2 inhibitor GSK’214 on Nuclear factor kappa B (NFκB) 
activation in HMVEC.  (A) NFκB nuclear intensity following stimulation with C12-iE-DAP 
10µg/ml (NOD1), LPS 10µg/ml (TLR4), or IL-1β 1ng/ml for 1 hour in the presence or absence 
of GSK’214 300nM. Results are expressed as mean ± SEM for n=3 from one experimental 
day (B) Representative images of NFκB nuclear translocation under the different 
experimental conditions.  
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Figure 6.9: Effect of a novel NOD1 inhibitor GSK’217 on NOD1 and TLR4-induced CXCL8 
release by HMVEC. Cultured HMVEC were treated with increasing concentrations of 
GSK’214 (0.001-0.3μM). CXCL8 release was induced in HMVEC with iE-DAP 10μg/ml (NOD1) 
or LPS 1μg/ml (TLR4). Results are expressed as a percentage of response to the agonist 
alone (mean ± SEM; n=6). Results were analysed by 1-sample t-test; *p<0.05 and by 2-way 
ANOVA; #p<0.05 vs. LPS. 
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Figure 6.10: Effect of the novel NOD1 inhibitor GSK’217 on NOD2 and TLR4 induced CXCL8 
release by PBMC. (A) Plated PBMC were treated with increasing concentrations of GSK’217 
(0.01-01μM). CXCL8 release was induced with MDP 10μg/ml (NOD2) or LPS 1μg/ml (TLR4). 
Results are expressed as mean ± S.E.M from n=4 from 4 donors. (B) Normalised data for 
MDP and LPS responses. Results are expressed as a percentage of response to the agonist 
alone (mean ± SEM; n=4 from 4 donors). Results were analysed by 1-sample t-test. 
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Figure 6.11: Effect of the novel NOD1 inhibitor GSK’217 on NOD1 induced CXCL8 release by 
HMVEC at increasing doses of iE-DAP.  Results are expressed as a percentage of response to 
the agonist alone minus the basal response (mean ± SEM; n=6).  
 
  
-3 -2 -1 0 1 2
0
50
100
iE-DAP 1g/ml     (IC50 0.010M)
iE-DAP 3g/ml     (IC50 0.019M)
iE-DAP 10g/ml   (IC50 0.028M)
iE-DAP 30g/ml   (IC50 0.047M)
iE-DAP 100g/ml (IC50 0.117M)
log[GSK'217]M

[C
X
C
L
8
] 
%
 p
o
s
it
iv
e
 c
o
n
tr
o
l
 
208 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12: Effect of small interfering RNA (siRNA) to NOD1 on CXCL8 release from HMVEC.  
(A) CXCL8 release following stimulation with iE-DAP 10µg/ml (NOD1), LPS 1µg/ml (TLR4), or 
IL-1β 0.1ng/ml for 24 hours in the presence or absence of non-targeting siRNA (NT) or NOD1 
siRNA. (B) Paired data from the same experiment demonstrating CXCL8 release following 
stimulation with iE-DAP 10µg/ml (NOD1), LPS 1µg/ml (TLR4), or IL-1β 0.1ng/ml for 24 hours 
in the presence or absence of the novel NOD1 inhibitor GSK’217 (1µM). Results are 
expressed as mean ± SEM of n=6.  
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6.5 Results tables 
 
 % CXCL8 release vs  
CTRL 
% CXCL8 release vs  
LPS 1µg/ml 
Dexamethasone (µM)   
CTRL 100.0 ± 0 100 ± 0 
0.001 111.5 ± 14.3 34.4 ± 3.9* 
0.01 126.6 ± 13.3 23.6 ± 3.4* 
0.1 118.2 ± 17.3 18.0 ± 2.1* 
1 126.6 ± 13.3 17.6 ± 1.8* 
SC-514 (µM)   
CTRL 100 ± 0 100 ± 0 
0.1 93.4 ± 15.2 76.6 ± 19.5 
1 111.6 ± 5.8 73.8 ± 18.8 
10 98.9 ± 9.2 32.4 ± 8.4* 
30 111.6 ± 5.8 13.6 ± 4.0* 
 
Table 6.3: Effects of the corticosteroid dexamethasone and the IKK2 inhibitor SC-514 on 
CXCL8 release by THP-1 monocytes. THP-1 cells were activated by LPS 1µg/ml following 
30mins pre-treatment with dexamethasone (0.001-1µM) or SC-514 (0.1-30µM). Results are 
expressed as a percentage of response to media alone (CTRL) or LPS (mean ± SEM; n=9). 
Results were analysed by 1-sample t-test; *p<0.05. 
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Drug HMVEC. Alamar Blue assay. Results expressed as % viability of 
unstimulated cells. 
Basal + iE-DAP 10µg/ml + LPS 1µg/ml 
5Z-7-oxozeaonol 
1µM 
147.2 ± 49.8 143.9 ± 70.8 213.8  ± 118.9 
SC-514                  
30µM 
103.2 ± 27.8 75.5 ± 6.1 89.0 ± 7.3 
Dexamethasone 
10µM 
227.7 ± 70.0 115.8 ± 24.1 128.9 ± 24.4 
BIRB0796             
1µM 
174.1 ± 63.8 87.5 ± 36.3 141.6 ± 48.1 
PD184352            
1µM 
113.0 ± 32.3 129.0 ± 36.4 118.5 ± 11.4 
TI-JIP153-163  
30µM 
87.8 ± 30.4 62.3 ± 23.6 82.9 ± 1.9* 
KbNB-142-70 
1µM 
72.2 ± 26.6 67.8 ± 15.8 113.4 ± 9.0 
Z-VAD-fmk 
10µM 
62.4 ± 32.7 69.2 ± 34.8 961.1 ± 806.5 
SB203580 10µM 115.5 ± 10.3 119.6 ± 10.8 103.0 ± 38.3 
PP2 10µM 101.9 ± 10.5 112.2 ± 3.2 107.5 ± 4.5 
 
Table 6.4: The effects of various cell signalling inhibitors on cell viability in HMVEC as 
measured by the Alamar Blue test. Results are shown for the highest concentration of 
inhibitor used in unstimulated cells (basal) and after stimulation with iE-DAP 10µg/ml 
(NOD1) or LPS 1µg/ml (TLR4). Data from n=4. Results are expressed as a % of the cell 
viability of unstimulated cells and are presented as mean ± S.E.M. Data were analysed using 
one sample t-test for normalized data; *p<0.05. 
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Drug HMVEC. Alamar Blue assay. Results expressed as % viability of 
unstimulated cells. 
Basal + iE-DAP 10µg/ml + LPS 1µg/ml 
GSK’214 1µM 103.1 ± 20.8 111.8 ± 9.3 65.7 ± 7.9* 
GSK’217 0.3µM 95.7 ± 8.3 95.0 ± 1.1* 96.0 ± 0.6* 
 
Table 6.5: The effects of the RIP2 inhibitor GSK’214 and the NOD1 inhibitor GSK’217 on cell 
viability in HMVEC as measured by the Alamar Blue test. Results are shown for the highest 
concentration of inhibitor used in unstimulated cells (basal) and after stimulation with iE-
DAP 10µg/ml (NOD1) or LPS 1µg/ml (TLR4). Data from n=6. Results are expressed as a % of 
the cell viability of unstimulated cells and are presented as mean ± S.E.M. Data were 
analysed using one sample t-test for normalized data; *p<0.05. 
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6.6 Summary 
 
In this, the final results chapter of my thesis, pharmacological inhibitors have been used to 
explore similarities and differences in NOD1 and TLR4 signalling in HMVEC. In true Gram 
negative infection, the endothelium would be exposed to multiple PAMPs including NOD1 
and TLR4 agonists. By studying the signalling of each receptor in a cell system where each is 
active (as demonstrated in Chapter 5) it raises the potential of validating pharmacological 
targets which could be used to determine the relative importance of NOD1 in subsequent 
models of inflammation, or indeed suggest new therapies. 
The first set of experiments in this chapter set out to validate the role of NFκB in NOD1 and 
TLR4 agonist induced CXCL8 release in HMVEC, following on from the evidence of its role in 
iNOS induction in rodent VSM. Inhibition of TAK1 (implicated as a mediator in NFκB 
induction by both TLRs and NODs) did indeed significantly inhibit CXCL8 release induced by 
either iE-DAP or LPS. In addition early nuclear localisation of NFκB by C12-iE-DAP and LPS 
was demonstrated by immunohistochemistry, a process that was again blocked by TAK1 
inhibition. Conversely treatment with dexamethasone and the IKK2 inhibitor SC-514 (both 
inhibitors of NFκB activation) failed to dramatically reduce iE-DAP or LPS mediated CXCL8 
release in HMVEC despite potent inhibition of LPS mediated release of the same chemokine 
in a reference human monocytic cell line. This might suggest that PRR mediated CXCL8 
release in endothelial cells is more dependent on NFκB independent pathways despite 
evidence that NOD1 and TLR4 do activate NFκB in these cells. One such pathway is the 
MAPK family. In keeping with this the p38 MAPK antagonist BIRB0796 potently inhibited     
iE-DAP and LPS mediated CXCL8 release in HMVEC, although no significant effect was seen 
with inhibition of ERK or JNK. 
RIP2 is clearly identified in the literature as a signalling protein specific to the NOD pathway, 
although there is relatively little published work using pharmacological inhibitors to 
demonstrate this. In this chapter, two non-selective inhibitors of RIP2, SB203580 and PP2, 
showed a greater degree of inhibition to NOD1 pathway responses than TLR4. Subsequent 
use of a highly novel RIP2 antagonist GSK’214 confirmed profound inhibition of NOD1 
agonist mediated NFκB activation and CXCL8 release in HMVEC with no apparent effect on 
LPS responses. This agrees with the highly specific inhibition of NOD1 signalling achieved by 
GSK’214 in rat aorta (Chapter 4).  
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In the last set of experiments, GSK’217, a putative NOD1 antagonist was profiled in HMVEC 
and PBMCs. Like the RIP2 antagonist GSK’214, GSK’217 inhibited iE-DAP responses in 
HMVEC with no effect on the response to LPS. This specificity of GSK’217 for NOD1 
responses was confirmed in PBMCs in which it had no effect on the response to the NOD2 
ligand MDP. Finally in a pilot experiment, GSK’217 was demonstrated to be superior to 
siRNA knockdown of NOD1, in selectively inhibiting responses to iE-DAP compared to LPS 
thus confirming the utility of the novel inhibitor as a tool to study the relative roles of NOD1 
versus TLR4 in more complicated inflammatory models. Suggested signalling pathways 
downstream of NOD1 and TLR4 in HMVEC are shown in the schematic (Figure 6.13). 
 
 
 
Figure 6.13: Suggested parallel signalling pathways for NOD1 and TLR4 in HMVEC with 
putative sites of action of selected pharmacological inhibitors. 
  
The data presented in this chapter using HMVEC have confirmed discrete signalling 
pathways for NOD1 and TLR4 within a single cell type. This novel data is relevant to our 
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understanding of how gram negative bacteria might affect the vasculature in disease 
including for example septic shock and ARDS, however there are limitations in this chapter 
which leave opportunities for further research. The signalling data presented in this chapter 
is from cells stimulated with specific NOD1 and TLR4 agonists with the assumption that this 
represents stimulation from the natural ligands present on Gram negative bacteria. In 
reality host cells would be exposed to multiple PAMPs from invading pathogens which might 
dramatically alter the response seen to just one specific PRR agonist in vitro. In addition the 
specific RIP2 and NOD1 receptor antagonists cannot be assumed to work selectively in the 
case of whole pathogen stimulation. Future protocols could answer this by controlled 
infection of endothelial cells with gram negative pathogens in vitro and analysis of 
downstream signalling pathways from NOD1 and TLR4 with special consideration to the use 
of the novel RIP2 and NOD1 inhibitors. Whilst the principle aim of my PhD was to translate 
rodent models of NOD1 mediated inflammation into human tissue I have not been able to 
provide evidence of functional consequences of NOD1 stimulation. This could be addressed 
by translating my findings back into animal models of vascular inflammation. Unfortunately 
the novel NOD1 inhibitor GSK’217 is not active in rodent cells (Appendix 1) but the novel 
RIP2 inhibitor GSK’214 shows avid activity in rodent vascular cells (Appendix 1) and remains 
a powerful tool to differentiate NOD1/2 from TLR4 signalling. As with the data in Chapters 3 
and 4, inflammatory mediator release (e.g. CXCL8) has been used to establish key signalling 
events. It is a relative weakness that I have not validated this by demonstrating activation of 
the pathways directly, by, for example measurement of phosphorylated signalling 
intermediates. An attempt was made to answer this point by using a commercial ELISA kit 
(InstantOne™ ELISA, eBioscience, UK) in HMVEC stimulated by NOD1 and TLR4 agonists. 
Unfortunately there were technical issues with the plate including very high absorbance in 
the negative control wells. Due to time constraints it was not possible to repeat these 
experiments but it would remain useful in future experiments to validate the signalling 
pathways described in this chapter with the use of either ELISA or western blotting 
techniques for key signalling intermediates including pTAK1 and pp38 MAPK. Finally data in 
this chapter has validated the use of specific NOD1 agonists as representing NOD1 mediated 
cell activation as the specific NOD1 inhibitor GSK’217 is highly specific against these agonists 
versus LPS. In pilot experiments I was able to parallel these observations with those where 
NOD1 was putatively knocked down using siRNA. Interestingly the NOD1 knockdown 
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approach reduced responses to LPS and IL-1β in addition to that of the NOD1 agonist iE-DAP 
whereas GSK’217’s effect was specific to iE-DAP. This is potentially interesting and might 
suggest that NOD1 co-operates with other proteins away from the active site affected by 
GSK217. This idea could be pursued by performing pull-down experiments where NOD1 is 
immunoprecipitated with associated proteins and the complex probed for known signalling 
partners. However, in the siRNA experiments, due to lack of RNA recovered, I was not able 
to confirm effective gene knock down. These experiments would need to be repeated 
before firm conclusions can be made. 
Discussion 
The relevance of these observations is discussed in detail in Chapter 7. 
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Chapter 7 
General Discussion 
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Since the seminal papers describing Toll and the role of Toll like receptor (TLR)4 as the 
lipopolysaccharide (LPS) receptor (Lemaitre, Nicolas et al. 1996; Poltorak, He et al. 1998), 
there has been much interest around pattern recognition receptor (PRR) responses in 
human infectious and inflammatory disease. At the beginning of my PhD thesis in 2009, a 
considerable literature had amassed concerning TLR4 but relatively little with respect to 
nucleotide oligomerisation domain-1 (NOD1). This is illustrated by searching the online 
pubmed library with the search terms ‘TLR4’ and ‘NOD1’. For TLR4, 3796 papers were listed 
prior to 2009, with only 250 for NOD1. Thus in my thesis I have explored NOD1 mediated 
vascular dysfunction at a time where this receptor’s functions remain relatively unknown. A 
key development during the course of my research has been the pharmaceutical 
development of novel NOD1 pathway antagonists. This has been an incredibly well timed 
event in terms of use in my vascular models but also highlights the importance that the 
pharmaceutical industry places in PRR and NOD biology for the development of new 
therapeutic targets for human disease. 
The vasculature plays a prominent role in the inflammatory response, through vasodilation 
and the trafficking of leucocytes to sites of infection. However excessive vascular 
inflammation may result in deleterious effects on the host exemplified by septic shock, 
acute lung injury and in a more chronic setting, atherosclerosis. Whilst specialised immune 
cells such as the macrophage have predominantly been used to study PRR responses, it is 
clear that blood vessels themselves can sense pathogen associated molecular patterns 
(PAMPs) to upregulate pro-inflammatory genes. This was demonstrated early in LPS 
stimulated rat aorta, with induction of inducible nitric oxide synthase (iNOS) and 
hyporesponsiveness to adrenergic stimulation (Beasley, Cohen et al. 1990; Rees, Cellek et al. 
1990). Following on from this, work in our group had characterised vessel responses to 
Gram positive bacteria and Gram negative bacteria as being through separate TLR pathways 
(TLR2 vs TLR4), whilst establishing that, in rats, the NOD1 ligand FK565 is sensed by vascular 
smooth muscle (VSM) and induces profound vascular shock in vivo (Cartwright, McMaster et 
al. 2007; Cartwright, Murch et al. 2007). In the latter in vivo study, the effect of NOD1 
stimulation appeared to be predominantly vascular as there was a minimal effect on 
neutrophil ingress into the lung compared to LPS. This suggested the possibility that NOD1 is 
a key receptor mediating pathogen associated vascular inflammation and that therapeutic 
targeting of NOD1 might be helpful to control vascular dysfunction in sepsis without 
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creating overt immune compromise. In my thesis, I have investigated in more detail the 
signalling pathways downstream of NOD1 in vascular cells, with comparison to that of TLR4 
as an alternative ‘sensor’ of Gram negative bacteria. In addition I have established an 
important role for the endothelium in early whole vessel responses to PAMPs whilst also 
translating experiments in rodents into man, establishing that NOD1 ligands directly induce 
human inflammatory genes and proteins in vascular tissue. Finally I have profiled novel 
signalling inhibitors of the NOD1 pathway, demonstrating that they are highly specific versus 
the TLR4 pathway in both vascular and immune cells.  
In the initial part of my thesis I extended previous work in the group on a rat VSM cell line 
known to respond to the NOD1 ligand FK565. In keeping with the idea that NOD1 functions 
predominantly as a vascular PRR, iNOS and cyclooxygenase-2 (COX-2) were induced in VSM 
by heat killed E Coli, LPS and FK565 whereas only E Coli and LPS were able to induce these 
enzymes in a murine macrophage cell line. Further analysis suggested this was due to lack of 
NOD1 expression in the macrophages as evidenced at the gene and protein level. This is 
somewhat in contradiction to the literature on human NOD expression which suggests that 
NOD1 is fairly ubiquitously expressed.  My data therefore suggests there might be 
differences in the pattern of NOD1 expression between rodents and humans.  
Whilst earlier experiments in the group had used FK565 as the sole NOD1 ligand, by the 
time I started experimental work several commercial NOD1 ligands were available including 
the minimal NOD1 stimulating peptide iE-DAP and its cell permeable derivative C12-iE-DAP. 
It was therefore important to profile these new agonists in the rodent VSM and 
macrophages compared to FK565 as previous reports have suggested inter-species 
differences in response to NOD1 ligands with a tetrapeptide structure (FK156) or tri-peptide 
(e.g. M-Tri-DAP) structure (Magalhaes, Philpott et al. 2005). In the VSM cells, iE-DAP, C12-iE-
DAP, and FK565 were all capable of inducing nitric oxide (NO) release in VSM, whilst being 
equally incapable of activating macrophages. C12-iE-DAP and FK565 appear to be more 
potent than iE-DAP in the VSM. Whilst this may be expected with C12-iE-DAP given its 
permeability and ability to access intracellular NOD1 easily, the greater effect with FK565 
may well represent a greater affinity of rodent cells for the tetrapeptide structure of FK565. 
In keeping with an important role for NOD1 in the vasculature, the NOD2 ligand muramyl 
dipeptide (MDP) failed to induce NO release in VSM. However there was equally no 
response in macrophages despite the reported demonstration of NOD2 expression in the 
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human monocyte (Ogura, Inohara et al. 2001). Again this may suggest caution in the 
interpretation of NOD responses in rodent cells. There is ample evidence in the literature for 
cooperation between TLR4 and NOD responses in a variety of cell types. This was duly 
investigated in Chapter 3 in VSM cells. Although there was a trend to enhanced NO release 
after co-treatment of C12-iE-DAP and iE-DAP with LPS this did not amount to a significant 
synergistic response. This may lead to the conclusion that interaction between NOD1 and 
TLR4 pathways may be cell and/or agonist specific, and indeed I go on to show enhanced 
cell activation with NOD1 agonist and LPS co-stimulation in Human pulmonary artery 
smooth muscle cells (HPASMs) in Chapter 5. However, as discussed in the summary for 
Chapter 3, caution must be taken in extrapolating data obtained in clonal cell lines due to 
the inherent risk of altered gene expression as a result of repeated cell passage. For 
example the VSM clone used is hyporesponsive to LPS but this is certainly not the case with 
primary VSM cells.  
Having established the relative activity of the NOD ligands in VSM and macrophage, I then 
wanted to investigate the signalling pathways downstream of the respective receptors using 
each cell type as a model system. In keeping with the known literature on signalling via 
NODs and TLR4, the use of specific pharmacological inhibitors demonstrated a role for 
nuclear factor kappa B (NFκB) activation via transforming growth factor β activating kinase 
(TAK1) in both NOD1 agonist induced responses in VSM and LPS induced responses in 
macrophages. A point of relative weakness in this data is that NO release alone was used as 
a readout for the effect of the TAK1 inhibitor. This data would have been strengthened by 
use of an alternative technique (e.g. immunohistochemical) to demonstrate NFκB nuclear 
localisation following NOD1 or TLR4 agonist treatment, and the inhibition of this response 
by the TAK1 inhibitor.  
The mitogen activated protein kinase (MAPK) family of signalling proteins have been 
implicated in iNOS induction and were duly investigated in VSM and macrophages in 
Chapter 3. Interestingly inhibition of the p38MAPK pathway appeared to predominantly 
abrogate NO release induced by the NOD1 agonist iE-DAP, whilst inhibition of extracellular 
regulated kinase (ERK) was shown to inhibit NO release by both iE-DAP and LPS, and 
inhibition of c-jun N terminal kinase (JNK) had no convincing effect on responses to either 
PAMP. This seems consistent with the observed literature in which the role of MAPK family 
members in iNOS induction is extremely variable between different cell types. In support of 
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my findings, iNOS induction by INFγ plus LPS in a specific mouse macrophage clone was 
shown to be reduced by ERK inhibition but actually enhanced by p38MAPK inhibition, 
although JNK signalling was also implicated in this paper (Chan and Riches 2001). 
Phosphorylated MAPK proteins may directly promote gene transcription via transcription 
factors including AP-1 but have also been implicated in post-translational modification of 
inflammatory mediators (Lee, Laydon et al. 1994). Again a relative weakness of my data is 
the reliance on NO production alone as a guide to downstream signalling events. The 
signalling data presented in Chapter 3 could perhaps be strengthened by measurement of 
changes in iNOS mRNA expression relative to NO release to gain insight into the relative 
roles of the signalling intermediates (e.g. p38MAPK) on transcriptional and/or post-
translational events. In addition direct demonstration of relevant protein phosphorylation 
(e.g. p38MAPK to pp38MAPK) following agonist stimulation would strengthen the data 
obtained with pharmacological inhibitors alone, particularly given the notorious lack of 
specificity of kinase inhibitors (Cohen 2010).    As expected from the literature, inhibition of 
receptor interacting protein-2 (RIP2) (with, in Chapter 3, relatively non-selective 
pharmacological tools) specifically inhibited NO release induced by the NOD1 ligand iE-DAP. 
I have conceded in the summary for Chapter 3 that the use of specific NOD1 agonists has 
been assumed to demonstrate NOD1 specific signalling but I have not backed this up by 
alternative techniques such as gene knockdown. In defence of this, iE-DAP (used to induce 
NO release in the signalling experiments) has a depth of literature to support its use as a 
specific NOD1 stimulating peptide. In addition experiments in Chapter 6 have attempted, in 
part, to address this issue, albeit with their own limitations which are discussed later in this 
chapter. 
So to briefly summarise, the early experiments of my thesis in rat tissue supported the 
hypothesis that NOD1 activity is particularly important in vascular cells and introduced the 
idea that specific pharmacological inhibitors could be useful in separating NOD1 and TLR4 
signalling in the vasculature. However isolated responses in VSM do not necessarily predict 
NOD1 responses in whole vessel or provide insight into any role of the endothelium.  
To address this, a whole vessel organ culture model was used. Although previous work in 
the group had established hypocontractility in rat aorta ex vivo after stimulation with the 
NOD1 ligand FK565 (Cartwright, Murch et al. 2007), my experiments extended this by 
considering the relative role of the endothelium as well as downstream signalling events in 
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the responses to either NOD1 or TLR4 ligands. In keeping with previous findings, the aortic 
rings produced a sustained basal release of NO over 96 hours. In addition stimulation of the 
rings with C12-iE-DAP or LPS resulted in enhanced release of NO into the culture 
supernatant. This effect was maintained over 96 hours although the greatest relative 
release over basal was seen at 24 and 48 hours. Aortic rings also demonstrated basal release 
of PGI2 although this markedly decreased after day 2. This is likely to be explained by loss of 
constitutively expressed PGI2 synthetase in the vessels in culture as has been previously 
described (Bishop-Bailey, Larkin et al. 1997). Whilst LPS enhanced PGI2 release over basal 
conditions, the NOD1 agonist C12-iE-DAP failed to do so. This contrasts to findings described 
in Chapter 3 where the NOD1 agonist FK565 induced PGI2 release in cultured rat VSM via 
induction of COX-2. Indeed NOD1 agonist induced PGI2 release is also demonstrated in 
human endothelial cells in Chapter 5. As with the decline of basal PGI2 release from the 
vessels, the most likely explanation for the lack of C12-iE-DAP effect is lack of adequate PGI2 
synthetase in the cultured vessels and its decline over time, such that responses have only 
been seen with the relatively more potent TLR4 ligand LPS. Measurement of COX-2 
induction by C12-iE-DAP, either at the gene or protein level would be an alternative way to 
confirm a role for NOD1 in this vasoactive pathway. Whilst NO release from healthy vessels 
is predominantly by endothelial NOS (eNOS), in inflammatory conditions iNOS is induced. In 
confirmation of this NO release by either C12-iE-DAP or LPS was inhibited by the specific 
iNOS antagonist 1400W. As already discussed earlier in this chapter, NFκB is an important 
transcription factor involved in the expression of iNOS. Accordingly and in keeping with 
results seen previously in cultured VSM, suppression of NFκB activation by the IKK2 inhibitor 
SC-514 prevented enhancement of NO release by either NOD1 or TLR4 stimulation. In 
support of this pharmacological data, immunohistochemistry and imaging of NFκB nuclear 
translocation confirmed early activation by both receptor agonists. In Chapter 3, 
pharmacological inhibitors were used to try and tease apart the NOD1 and TLR4 signalling 
pathways. As predicted by the literature, RIP2 emerged as a specific downstream mediator 
of NOD1 agonist driven NO release. These findings are further validated in Chapter 4 by 
demonstration of specific inhibition of C12-iE-DAP induced NO release in whole aorta by the 
novel and highly specific RIP2 inhibitor GSK’214. This data not only strengthens my model of 
NOD1 induced inflammation in vascular tissue but is the first to my knowledge to use this 
novel (or indeed any other) small molecule inhibitor of the NOD1 signalling pathway in an 
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organ culture set up as opposed to experiments in cultured cells. Indeed the potency and 
specificity of effect seen with GSK’214 on whole vessel is encouraging if this drug is to 
eventually be applied to human disease. 
Perhaps the most important finding from the whole aorta experiments was the relative 
importance of the endothelium in whole vessel responses to C12-iE-DAP and LPS at 24 
hours. Mechanical disruption of the endothelium by very gentle rolling of the aortic ring on 
sterile forceps significantly inhibited the NO release induced by either agonist. This was in 
contrast to previous findings that suggested that the VSM is the predominant source of 
vasoactive mediators from LPS stimulated vessels (Bishop-Bailey, Larkin et al. 1997). It 
should be noted that at the 48 hour time point, the relative importance of the endothelium 
is diminished in my experiments. This suggests that the VSM component of the vessel 
assumes a greater role for NO release at longer periods of PAMP stimulation. However, 
these findings do strengthen my observation of endothelial predominance in the first 24 
hours as the disrupted vessel is clearly still metabolically active at the 48 hour time point i.e. 
the removal of the endothelium has not fatally damaged the rest of the vessel.  
The experiments up to this point had established the validity of the rodent vasculature as a 
model for NOD1 induced vascular inflammation, with the additional novel observation that 
the endothelium has a predominant role in the initial sensing of bacterial ligands by vessels. 
Existing literature at the time of these experiments did refer to a role for NOD1 in human 
endothelial cells in response to whole bacteria (Opitz, Forster et al. 2005; Opitz, Puschel et 
al. 2006), but there was no published material confirming direct NOD1 ligand induction of 
human vessels, endothelial cells, or smooth muscle cells. Given the reported differences in 
human versus mouse responses to NOD1 ligands it was therefore crucial to validate my 
findings in human tissue. 
In the first instance, translation to human tissue was performed in whole ex vivo blood 
vessel bioassay. Freshly excised rings of pulmonary artery, surplus to surgical requirements 
were exposed to C12-iE-DAP and LPS for up to 48 hours. Given the invasive nature of the 
surgery and dissection and the time taken to transport, and process the piece of tissue, 
basal levels of CXCL8 release (used as a surrogate measure of vessel activation) were high 
and variable. Despite this, stimulation with either the NOD1 or TLR4 ligand induced 
significant CXCL8 release compared to basal levels at 48 hours. This important novel 
observation validates the idea of inducible NOD1 signalling in the human vasculature, 
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without a requirement for co-induction with LPS. In contrast a degree of literature exists 
describing poor responses to NOD1 ligands in human cells without synergistic enhancement 
by TLRs (Tada, Aiba et al. 2005; van Heel, Ghosh et al. 2005). Due to relative scarcity of 
human tissue I was unable to perform organ culture experiments on the pulmonary artery 
segments with and without endothelium. Having established a clear response to NOD1 
agonists in human vessel it would be desirable to further explore the role of the 
endothelium using mechanical disruption in the same way as performed with the rat aorta 
and perhaps also by imaging the expression of vasoactive enzymes in the endothelial and 
smooth muscle layers by confocal microscopy. This was beyond the scope of my thesis but is 
of ongoing interest in the group. 
The data presented in Chapter 4 certainly supports a role for NOD1 in vessel responses to 
Gram negative bacteria. A weakness however is the lack of demonstration of functional 
responses to NOD1 stimulation. Septic shock is characterised by vasoplegia and insensitivity 
to vasopressor agents. It would therefore be useful to expand on my organ culture work by 
examining the effect of NOD1 stimulation on vessel tone and vasopressor sensitivity by 
using relevant organ bath myography techniques. Our group has extensive experience with 
this in rat and mouse vessels and is currently adapting protocols for use in human tissue.  
Given the limitations of the human vessel data already discussed, an in vitro model was used 
to explore the relative importance of endothelial versus smooth muscle cell sensing of 
NOD1 ligands by the human vasculature. In keeping with the use of whole pulmonary artery, 
human lung microvascular endothelial cells (HMVEC) and HPASM were cultured and 
stimulated for up to 48 hours with NOD1 or TLR4 ligands. LPS induced CXCL8 in both cell 
types. Crucially whilst a robust release of CXCL8 relative to control was seen in response to 
NOD1 stimulation in HMVEC, there was no significant induction in HPASM at either 24 or 48 
hours. This is an important observation and a clear difference in NOD1 mediated vascular 
signalling between rodents and man, for, as discussed earlier, I have demonstrated avid 
rodent VSM responses to a variety of NOD1 ligands. However, the relative importance of 
the endothelium in the rodent organ culture model is supported by this translational data. 
Unlike the case of rodent VSM and macrophage, the differences in NOD1 ligand activity 
between HMVEC and HPASM do not seem to be due to variation in NOD1 expression as RNA 
for NOD1 was obtained for both cell types. In addition stimulation with NOD1 or TLR4 
ligands did not obviously change the degree of NOD1 expression. In support of this, there 
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was a minor degree of synergistic interaction between NOD1 and TLR4 ligands when HPASM 
were co-stimulated suggesting (though not proving) the existence of viable NOD1 signalling 
components in these cells. It is similarly unlikely that the absence of NOD1 ligand response 
in the HPASM is due to ligand access as even the cell permeable C12-iE-DAP failed to induce 
significant CXCL8 release. It is however possible that non-specific entry of NOD1 ligand into 
the cell (as one might expect with C12-iE-DAP) is not the optimal mode of NOD1 activation. 
This is suggested by research describing active uptake of NOD1 ligands and specific 
processing in endosomes (Lee, Tattoli et al. 2009). The physiological relevance of this may 
precise ligand delivery to clustered intracellular NOD1 at  areas of the cell membrane where 
there is active pathogen invasion in order to maximise the inflammatory response (Kufer, 
Kremmer et al. 2008).  
So, in humans, endothelial cells appear to be the predominant sensor for NOD1 agonists in 
the vasculature, with the caveat that the majority of my experiments were conducted in 
cells of the pulmonary vasculature and that validation with cells (particularly VSM) from 
systemic vessels would be useful. What about ‘professional’ immune cells? To explore this, 
responses to NOD agonists and LPS were measured in peripheral blood mononuclear cells 
(PBMCs) from healthy donors and the human monocytic cell line THP-1. In PBMCs a variable 
degree of CXCL8 induction by C12-iE-DAP was seen between donors, however this induction 
was not as significant as that seen in endothelial cells. Unlike endothelium, the non cell 
permeable NOD1 ligand iE-DAP was unable to stimulate CXCL8 release. No NOD1 response 
could be elicited in THP-1 cells. Thus in a similar way to HPASMC, PBMCs appear relatively 
deficient in functional NOD1 signalling compared to endothelial cells. This is despite 
evidence of intact signalling components as shown by the variable response to C12-iE-DAP 
and the reports in the literature of synergistic activity with TLRs described above. Again, like 
HPASM it could be hypothesised that whilst PBMCs express NOD1 they lack a specific 
uptake pathway for natural or extracellular NOD1 ligand thus limiting functional activity. 
This is worthy of further study beyond my thesis, perhaps by including imaging techniques 
for NOD1 agonist entry into the cell as well as NOD1 receptor localisation on the endosome. 
Having established endothelial cells as an important target for both NOD1 and TLR4 ligands, 
I next wanted to characterise the inflammatory response in these cells in more detail. At the 
protein level, iE-DAP and LPS induced multiple inflammatory cytokines and chemokines 
consistent with the acute inflammatory response. Importantly of 9 measured 
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chemokine/cytokines, CXCL8 was the most abundantly released by stimulation with both 
NOD1 and TLR4 agonists thus validating the choice of CXCL8 as the predominant read out 
for human cell and vessel activation by these PRRs in the majority of the experiments 
presented.  At the gene level both iE-DAP and LPS induce upregulation of multiple 
inflammatory genes. Indeed over the course of four experiments, no definitive differences 
in induced expression could be seen between the two receptors in a focussed panel of 84 
inflammatory genes. This interesting observation suggests considerable redundancy in the 
immune response to Gram negative pathogens which is wholly understandable given the 
vital importance of innate immune responses throughout evolution. Again in validation of 
the use of CXCL8 as a marker of cell activation elsewhere in the thesis, the CXCL8 gene was 
highly upregulated by both NOD1 and TLR4. Other consistently  upregulated genes over the 
course of four experiments included CCL and CXCL chemokines such as CCL20 and 2 and 
CXCL1,2,5 and 6. This illustrates the potential importance of NOD1 and TLR4 signalling in the 
endothelium as a powerful signal for leukocyte migration. Given the potentially deleterious 
effects of over abundant inflammatory cell activity in tissues (for example acute lung injury) 
the powerful induction of chemokine genes by these PRRs gives weight to the concept of 
them being valid targets for drug therapy. This is strengthened by the  profound 
upregulation of interleukin-1β and tumour necrosis factor-α genes by both iE-DAP and LPS 
in HMVEC as both of these cytokines are implicated in the pathogenesis of septic shock. 
NOD1 and TLR4 agonists did also down-regulate genes in HMVEC although only the 
interleukin-10 receptor alpha-subunit (IL-10RA) was consistently downregulated. Given that 
IL10-RA mediates the anti-inflammatory effect of IL-10 and the suppression of pro-
inflammatory cytokines, it’s downregulation by NOD1 or TLR4 stimulation is consistent with 
the overall pro-inflammatory effect of stimulating these PRRs. This does also suggest that 
signalling via NOD1 and TLR4 may evade some of the negative feedback steps designed to 
limit inflammation which may have consequences in human disease. 
Whilst the protein and gene expression data supports a broadly similar cellular activation by 
NOD1 and TLR4 it does appear that HMVEC only respond to a narrow range of PAMPs. 
When stimulated with a broad range of TLR agonists, only the viral PAMP Poly I:C 
(stimulating TLR3) was able to induce CXCL8 release in addition to LPS. Thus NOD1 and a 
restricted number of TLRs appear important in inflammatory activation in HMVEC validating 
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their further study. It does however raise interesting questions on the role of the 
endothelium in sensing Gram positive PAMPs, by for example TLR2.  
Given the broad and similar induction of inflammation by NOD1 and TLR4 ligand stimulation 
in endothelial cells, obvious questions remain about the relative importance of these 
receptors in human disease including responses to whole pathogens. To be able to 
investigate these questions in the future it would be desirable to pharmacologically 
differentiate the downstream signalling pathways. This of course could also offer the 
potential for new therapeutic targets. Accordingly for the final section of my research I used 
a variety of pharmacological inhibitors to attempt to characterise and separate NOD1 and 
TLR4 signalling. Again HMVEC were used as a model system where NOD1 and TLR4 
pathways are both active. In keeping with the data seen in rodent VSM and macrophages, 
both iE-DAP and LPS were shown to induce nuclear translocation of NFκB in HMVEC 
(although this effect was much more robust for iE-DAP at the time point of 1 hour). Again 
TAK1 appears important for NFκB induction as the specific antagonist 5Z-7-oxozeaonol 
strongly inhibited nuclear translocation. Interestingly there is conflicting data from these 
experiments regarding the role of NFκB in CXCL8 release by HMVEC. Although antagonism 
of TAK1 abrogated CXCL8 release at 24 hours, this effect could not be reproduced by 
inhibition of NFκB activity with a corticosteroid or the specific IKK2 inhibitor SC-514. In 
parallel experiments in monocytes, SC-514 and dexamethasone profoundly inhibited LPS 
induced CXCL8 release suggesting that the lack of effect in HMVEC was indeed specific to 
these cells. This data suggests that although NOD1 and TLR4 ligands activate NFκB in 
HMVEC, this is not the predominant pathway for CXCL8 release in these cells. Another 
possibility is signalling through the MAPK family. In support of this, a highly specific p38 
MAPK inhibitor abrogated both LPS and iE-DAP mediated CXCL8 release.  
The literature on NLR signalling has clearly identified RIP2 as a specific downstream 
signalling protein for NOD1 and NOD2 but not TLRs (Park, Kim et al. 2007). I therefore 
concentrated my efforts on targeting RIP2 in order to validate the importance and 
specificity of this protein in human endothelium as well as to enable separation of the 
signalling pathways for future models of vascular inflammation. The relatively non-specific 
RIP2 inhibitors SB203580 and PP2 showed a greater degree of inhibition of iE-DAP than LPS 
induced CXCL8 release but there was still significant inhibition of the LPS response at higher 
concentrations of the antagonists. At this point I was very fortunate to be able to 
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collaborate with Dr John Bertin of GSK. Dr Bertin and his colleagues in the Pattern 
Recognition Receptor DPU have developed highly novel inhibitors of the NOD1 pathway 
which are in an advanced stage of pre-clinical development for trial in human inflammatory 
disease including inflammatory bowel disease. It should be noted that specific inhibitors to 
PRR pathways are rare. TLR4 inhibitors have been developed including analogues of Lipid-A 
but these have been of variable efficacy. The opportunity to profile novel NOD pathway 
inhibitors was therefore extremely interesting for my project and also provided important 
validation for my other experiments which had relied on the specificity of  iE-DAP and C12-
iE-DAP towards the NOD1 receptor. In HMVEC, the putative RIP2 antagonist GSK’214 acted 
as a highly specific inhibitor of NOD1 agonist mediated CXCL8 release with no effect on LPS 
mediated CXCL8 release. In keeping with the reported action of RIP2 upstream of NFκB, 
pilot results revealed that GSK’214 selectively antagonises C12-iE-DAP mediated nuclear 
translocation of NFκB with no effect on the LPS response or that of IL-1β. As discussed 
earlier GSK’214 also acts in rodent systems as was demonstrated by selective inhibition of 
C12-iE-DAP mediated NO release by whole aorta. 
Whilst RIP2 proves highly specific in differentiating NOD1 agonist from TLR4 agonist induced 
cytokine release it would not differentiate NOD1 signalling from that of NOD2 as both 
receptors utilise RIP2. GSK have also developed a novel NOD1 (GSK’217) inhibitor. GSK’217 
proved to be a highly specific inhibitor of iE-DAP versus LPS mediated CXCL8 release in 
HMVEC. Given the lack of NOD2 activity demonstrated in HMVEC by lack of response to 
MDP, the specificity of GSK’217 to the NOD1 rather than NOD2 pathway was demonstrated 
in PBMCs. Finally whilst GSK have not yet provided me with detailed structural information 
on their compounds, the mechanism of action of GSK’217 is suggested though not proved 
by my data to be one of direct competitive antagonism. I did attempt to validate my results 
with the NOD1 inhibitor using a small interfering RNA technique to knockdown NOD1 in 
HMVEC. Interestingly whilst the NOD1 siRNA did impair iE-DAP mediated CXCL8 release it 
also had a clear effect on LPS and IL-1β mediated release, whereas GSK’217 specifically 
inhibited responses to iE-DAP. Although this might represent a toxic effect on the cells it 
could also imply interaction between NOD1 and IL-1R pathways at a site remote from the 
binding site for GSK’217. This could be further investigated by co-immunoprecipitation 
techniques as discussed in Chapter 6 however the siRNA data discussed is only presumptive 
as not enough RNA was extracted to confirm efficient NOD1 knockdown.  This does also 
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illustrate the potential advantage of a specific small molecule inhibitor to investigate NOD 
signalling as opposed to techniques such as gene knockdown where off target effects are 
common. 
Overall this last set of results demonstrate highly specific effects of the putative NOD1 
signalling pathway inhibitors in vascular tissue. These inhibitors will therefore be very useful 
tools to develop more complex models of vascular inflammation and may themselves 
represent novel therapeutic agents. It is a relative weakness that the effects of the various 
cell signalling inhibitors used in HMVEC (including GSK’214 and GSK’217) were not validated 
with demonstration of the effects on their specific targets. This was attempted in the case of 
the MAPK family with a commercial phospho-ELISA but technical difficulties prevented the 
acquisition of reliable data. Also given the lack of structural and functional information for 
the GSK compounds it would be difficult to know how to best validate their function. 
Certainly further validation of the signalling pathway intermediates would be helpful either 
by western blot or specific binding assays. 
 Collectively my results have answered my hypothesis that NOD1 is an important 
inflammatory pathway in the vasculature. I have demonstrated that a broad range of NOD1 
ligands are most active in stromal cells of the vasculature, compared to myeloid cells, in 
both rodent and human systems. I have translated NOD1 mediated activation of whole 
vessels into human tissue and demonstrated that the endothelium is the predominant 
NOD1 ligand sensing cell in the human vasculature. Endothelial responses to both NOD1 
ligand and LPS results in the induction of multiple inflammatory genes and proteins. 
Crucially I have finished by demonstrating that novel NOD1 pathway inhibitors are indeed 
highly selective in vascular tissue opening up future research directions in terms of 
understanding the relative role of these Gram negative PRRs in more complex models of 
vascular disease. 
How might the findings described in my PhD be relevant to human disease? An immediately 
relevant field is that of sepsis itself, where a large number of cases are due to Gram negative 
bacteria. Eritoran is a TLR4 antagonist that has reached Phase III trials for sepsis. Despite 
initial promise the latest trial data is disappointing with lack of evidence for survival benefit. 
It could be hypothesised that alternative PRR pathways to TLR4 such as NOD1 are equally 
important in sepsis. For example the endothelium is crucial to the pathophysiology of sepsis 
mediated organ damage such as acute lung injury and my data suggests the endothelium 
229 
 
appears to be a key site for NOD1 ligand sensing. It will now be important to profile the 
relative importance of NOD1 versus TLR4 signalling in live bacterial models of septic vascular 
inflammation, something that will be greatly aided by the use of the novel receptor 
antagonists. As discussed in Chapter 6 it would be interesting, now that the paradigm of 
NOD1 responsiveness in human tissue is secure, to re-evaluate this PRR in more complex 
animal models of vascular disease. This might include models of sepsis similar to that 
already published within the group (Cartwright, Murch et al. 2007).  Before embarking on 
such research it will be important to fully characterise the NOD pathway signalling inhibitors 
in different animals. Data presented in Chapter 4 and Appendix 1 demonstrates that whilst 
GSK’214 is active in rodent cells, GSK’217 is not. This would set constraints on any planned 
animal models. 
The NOD pathway may also be of growing importance in more chronic forms of 
cardiovascular disease. During the course of my experiments, research was published from a 
group in Japan demonstrating direct induction of inflammatory chemokines in human 
coronary artery endothelial cells by NOD1 ligands (Nishio, Kanno et al. 2011). The authors 
went on to demonstrate focal NOD1 ligand induced coronary arteritis in vivo after oral 
administration of the ligand. Also, given the suggestion that NLRP3 may be involved at the 
very earliest stages of plaque formation (Duewell, Kono et al. 2010) there is certainly a 
precedent for the role of NLRs in atherosclerosis. Meanwhile, the wider research field of 
NOD biology will be watching with interest to see if novel therapeutics emerge in the field of 
inflammatory bowel disease where the role of NOD2 and NOD1 are relatively well 
characterised. This also has implications for other pathologies where there is a dysregulated 
microbiome, such as supporative lung disease including cystic fibrosis (CF), adult non-CF 
bronchiectasis, and perhaps chronic obstructive lung disease itself. In all these conditions 
there will be a need to accurately determine the relative importance of alternative PRR 
pathways in driving pathology. Approaches such as mine utilising specific pharmacological 
blockade of NOD and TLR pathways will therefore be highly relevant for the further 
investigation and treatment of human disease. My discussion concludes with a schematic 
summarising the main findings described in this thesis. 
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Figure 7.1: Working model of Gram-negative bacteria induced vascular inflammation via 
TLR4 and NOD1.  
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Appendix 1 
Activity of GSK’214 and GSK’217 in rodent tissue. 
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Figure A1: Effect of the novel RIP2 inhibitor GSK’214 (A) and the NOD1 inhibitor GSK’217 (B) 
on NOD1 and TLR4 agonist induced NO release by rat VSM. Cultured VSM were treated with 
increasing concentrations of GSK’217 (0.01-01μM). NO release was induced with C12-iE-DAP 
1µg/ml (NOD1) or LPS 1μg/ml (TLR4) and measured as nitrite by the Griess assay. Results 
are expressed as mean ± S.E.M from n=6. Results were analysed by by one-way ANOVA 
followed by Dunnett's post test; *p<0.05. This data was obtained in collaboration with Mr 
Ali Hosin and is also presented in his Pharmacology BSc project. 
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